US20110024307A1 - Analyte sensor - Google Patents

Analyte sensor Download PDF

Info

Publication number
US20110024307A1
US20110024307A1 US12/829,264 US82926410A US2011024307A1 US 20110024307 A1 US20110024307 A1 US 20110024307A1 US 82926410 A US82926410 A US 82926410A US 2011024307 A1 US2011024307 A1 US 2011024307A1
Authority
US
United States
Prior art keywords
sensor
sensor element
membrane
signal
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/829,264
Inventor
Peter C. Simpson
Robert Boock
Apurv Ullas Kamath
Matthew Wightlin
Michael J. Estes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexcom Inc
Original Assignee
Dexcom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dexcom Inc filed Critical Dexcom Inc
Priority to US12/829,264 priority Critical patent/US20110024307A1/en
Assigned to DEXCOM, INC. reassignment DEXCOM, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOOCK, ROBERT, KAMATH, APURV ULLAS, ESTES, MICHAEL J., WIGHTLIN, MATTHEW, SIMPSON, PETER C.
Publication of US20110024307A1 publication Critical patent/US20110024307A1/en
Priority to US14/057,720 priority patent/US9907497B2/en
Priority to US14/058,091 priority patent/US9320466B2/en
Priority to US15/877,682 priority patent/US10420494B2/en
Priority to US16/537,419 priority patent/US11559229B2/en
Priority to US18/145,220 priority patent/US20230129853A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14503Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/14517Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for sweat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05CAPPARATUS FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05C3/00Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material
    • B05C3/02Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05CAPPARATUS FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05C3/00Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material
    • B05C3/02Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material
    • B05C3/09Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material for treating separate articles
    • B05C3/10Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material for treating separate articles the articles being moved through the liquid or other fluent material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05CAPPARATUS FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05C3/00Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material
    • B05C3/02Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material
    • B05C3/12Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material for treating work of indefinite length
    • B05C3/125Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material for treating work of indefinite length the work being a web, band, strip or the like
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B23MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23KSOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
    • B23K26/00Working by laser beam, e.g. welding, cutting or boring
    • B23K26/36Removing material
    • B23K26/362Laser etching
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0223Operational features of calibration, e.g. protocols for calibrating sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0209Special features of electrodes classified in A61B5/24, A61B5/25, A61B5/283, A61B5/291, A61B5/296, A61B5/053
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/04Arrangements of multiple sensors of the same type
    • A61B2562/043Arrangements of multiple sensors of the same type in a linear array
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/12Manufacturing methods specially adapted for producing sensors for in-vivo measurements
    • A61B2562/125Manufacturing methods specially adapted for producing sensors for in-vivo measurements characterised by the manufacture of electrodes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05CAPPARATUS FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05C5/00Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work
    • B05C5/02Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work the liquid or other fluent material being discharged through an outlet orifice by pressure, e.g. from an outlet device in contact or almost in contact, with the work
    • B05C5/0241Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work the liquid or other fluent material being discharged through an outlet orifice by pressure, e.g. from an outlet device in contact or almost in contact, with the work for applying liquid or other fluent material to elongated work, e.g. wires, cables, tubes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05DPROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00Processes for applying liquids or other fluent materials
    • B05D1/18Processes for applying liquids or other fluent materials performed by dipping
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05DPROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D3/00Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
    • B05D3/06Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to radiation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B23MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23KSOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
    • B23K26/00Working by laser beam, e.g. welding, cutting or boring
    • B23K26/08Devices involving relative movement between laser beam and workpiece
    • B23K26/0823Devices involving rotation of the workpiece
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C2791/00Shaping characteristics in general
    • B29C2791/004Shaping under special conditions
    • B29C2791/009Using laser
    • CCHEMISTRY; METALLURGY
    • C23COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23CCOATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C2/00Hot-dipping or immersion processes for applying the coating material in the molten state without affecting the shape; Apparatus therefor

Definitions

  • the embodiments described herein relate generally to devices, systems, and methods for measuring an analyte in a host.
  • Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events.
  • a variety of intravascular, transcutaneous and implantable sensors have been developed for continuously detecting and quantifying blood glucose values. Many conventional implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate sensing of blood glucose. Additionally, many conventional transcutaneous and intravascular sensors have problems in accurately sensing and reporting back analyte values continuously over extended periods of time due to non-analyte-related signals caused by interfering species or unknown noise-causing events.
  • a sensor system for measurement of an analyte concentration in a host comprising: a first sensor element configured to measure an analyte concentration in a host over a first range of analyte concentrations; and a second sensor element configured to measure analyte concentration in the host over a second range of analyte concentrations, wherein the first range of analyte concentrations and the second range of analyte concentrations are different.
  • the first range of analyte concentrations and the second range of analyte concentrations are both within a physiologically relevant range.
  • the first range of analyte concentrations and the second range of analyte concentrations each comprise only a portion of the physiologically relevant range.
  • the first range of analyte concentrations and the second range of analyte concentrations overlap partially, but not completely.
  • the analyte is glucose
  • the first range of analyte concentrations is from about 30 mg/dL to about 120 mg/dL and the second range of analyte concentrations is from about 80 mg/dL to about 400 mg/dL.
  • a lowest value of the second range of analyte concentrations is greater than a lowest value of the first range of analyte concentrations.
  • the first sensor element and the second sensor element have different sensitivities.
  • the sensitivity of the first sensor element is greater than the sensitivity of the second sensor element.
  • the analyte is glucose
  • the first sensor element has a sensitivity of from about 1 pA/mg/dL to about 100 pA/mg/dL.
  • the analyte is glucose
  • the second sensor element has a sensitivity of from about 20 pA/mg/dL to about 300 pA/mg/dL.
  • the first sensor element and the second sensor element have different current densities.
  • the analyte is glucose
  • the first sensor element has a current density of from about 3 pA/mg/dL/mm 2 to about 325 pA/mg/dL/mm 2 .
  • the analyte is glucose
  • the second sensor element has a current density of from about 65 pA/mg/dL/mm 2 to about 1,000 pA/mg/dL/mm 2 .
  • a lowest value of the first range of analyte concentrations is less than a lowest value of the second range of analyte concentrations.
  • the first sensor element and the second sensor element have different analyte-related to non-analyte-related signal ratios.
  • the analyte-related to non-analyte-related signal ratio of the first sensor element is greater than the analyte-related to non-analyte-related signal ratio of the second sensor element.
  • the analyte is glucose
  • the sensor system is capable of achieving an accuracy of analyte concentration measurements wherein the measurements are within +/ ⁇ 20% of a true analyte concentration value 80% of the time during a time period greater than about 7 days.
  • the first sensor element comprises a first membrane and the second sensor element comprises a second membrane, wherein the first membrane is different from the second membrane
  • the first membrane and the second membrane have different membrane properties.
  • the first membrane comprises a resistance domain different from a resistance domain of the second membrane.
  • the first membrane comprises an interference domain different from an interference domain of the second membrane.
  • the first membrane and the second membrane have a different number of domains.
  • the first membrane and the second membrane each comprise glucose oxidase configured to generate hydrogen peroxide by reaction of glucose and oxygen with the glucose oxidase
  • the first sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the first membrane
  • the second sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the second membrane
  • the first membrane is configured to consume more hydrogen peroxide than the second membrane.
  • the first membrane is configured to direct more hydrogen peroxide to the first electrode than the second membrane system directs to the second electrode.
  • At least one membrane selected from the group consisting of the first membrane and the second membrane is configured to recycle and/or reuse the hydrogen peroxide for a purpose other than for measurement.
  • the sensor system further comprises sensor electronics operably connected to the first sensor element and the second sensor elements wherein the sensor electronics comprise at least one potentiostat.
  • the at least one potentiostat is configured to apply a first bias potential to the first sensor element and a second bias potential to the second sensor element, wherein the first bias potential is different from the second bias potential.
  • the first bias potential is less than the second bias potential.
  • a highest concentration of the first range of analyte concentrations is less than the lowest concentration of the second range of analyte concentrations.
  • the sensor system is configured for implantation wholly in a tissue of a host.
  • the sensor system is configured for transcutaneous placement through a skin of a host.
  • the sensor system is configured for non-invasive measurement through a skin of a host.
  • the sensor system is configured for fluid communication with a vascular system of a host.
  • the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a sensor system for measurement of an analyte concentration in a host comprising: a first sensor element configured to measure analyte concentrations over a first range at a first current density; and a second sensor element configured to measure analyte concentrations over a second range at a second current density, wherein the first current density and the second current density are different.
  • the first current density is greater than the second current density.
  • the highest concentration of the first range is less than the lowest concentration of the second range.
  • the analyte is glucose
  • the first sensor element has a sensitivity of from about 1 pA/mg/dL to about 100 pA/mg/dL.
  • the analyte is glucose
  • the second sensor element has a sensitivity of from about 20 pA/mg/dL to about 300 pA/mg/dL.
  • the analyte is glucose
  • the first second element has a current density of from about 3 pA/mg/dL/mm 2 to about 325 pA/mg/dL/mm 2
  • the analyte is glucose
  • the second sensor element has a current density of from about 65 pA/mg/dL/mm 2 to about 1,000 pA/mg/dL/mm 2 .
  • the system is configured to measure at least one of a current selected from the group consisting of a current produced by the first sensor element and a current produced by the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a sensor system for measurement of an analyte concentration in a host comprising: a plurality of sensor elements, each wherein each sensor element is configured for measurement over a different range of analyte concentrations, wherein the plurality of sensor elements comprise: a first sensor element comprising a first membrane; and a second sensor element comprising a second membrane; wherein the first sensor membrane and the second sensor membrane have different membrane properties.
  • the first membrane comprises a resistance domain different from a resistance domain of the second membrane.
  • the first membrane comprises an interference domain different from an interference domain of the second membrane.
  • a number of domains of the first membrane and a number of domains of the second membrane are different.
  • the first membrane and the second membrane each comprise glucose oxidase configured to generate hydrogen peroxide by reaction of glucose and oxygen with the glucose oxidase
  • the first sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the first membrane
  • the second sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the second membrane.
  • the first membrane is configured to consume more hydrogen peroxide than the second membrane.
  • the first membrane is configured to direct more hydrogen peroxide to the first electrode than the second membrane directs to the second electrode.
  • At least one membrane selected from the group consisting of the first membrane and the second membrane is configured to recycle and/or reuse the hydrogen peroxide for a purpose other than for measurement.
  • the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a sensor system for measurement of an analyte concentration in a host comprising: a plurality of sensor elements, each configured to measure analyte concentrations over different time periods of in vivo implantation, wherein the plurality of sensor elements comprises a first sensor element configured to measure analyte concentrations over a first time period of in vivo implantation and a second sensor element configured to measure analyte concentrations over a second time period of in vivo implantation.
  • the first time period is during an initial period of in vivo implantation, wherein the second time period is during a second time period of in vivo implantation, and wherein the second period begins after the initial period has begun.
  • the first time period and the second time period overlap partially, but not completely.
  • the first time period is from about day 1 post-implantation to about day 3 post-implantation and the second time period is from about day 2 post-implantation to about day 10 post-implantation.
  • the first time period is from about day 1 post-implantation to about day 21 post-implantation and the second time period is from about day 10 post-implantation to about year 1 post-implantation.
  • the first sensor element comprises a first biointerface membrane and the second sensor element comprises a second biointerface membrane, and wherein the first biointerface membrane has at least one property different from that of the second biointerface membrane.
  • the first biointerface membrane comprises a three dimensional architecture.
  • the second biointerface membrane comprises a three dimensional architecture that is different from the three dimensional architecture of the first biointerface membrane.
  • the three dimensional architecture of the first biointerface membrane comprises pores within a first range of sizes and the three dimensional architecture of the second biointerface membranes comprises pores within a second range of sizes, wherein the largest size of the first range of sizes is smaller than the smallest size of the second range of sizes.
  • the sensor system is configured for implantation wholly in a tissue of a host.
  • the sensor system is configured for transcutaneous placement through a skin of a host.
  • the sensor system is configured for fluid communication with a vascular system of a host.
  • the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a method for processing data from a sensor system configured for measurement of an analyte concentration in a host comprising: calibrating a first sensor element, wherein the first sensor element is configured to measure an analyte concentration within a first range of analyte concentrations; and calibrating a second sensor element, wherein the second sensor element is configured to measure an analyte concentration within a second range of analyte concentrations, wherein the second range is different from the first range.
  • calibrating the first sensor element comprises receiving an external reference value.
  • calibrating the first sensor element comprises receiving a calibration value provided by a manufacturer.
  • calibrating the first sensor element comprises performing a first algorithm.
  • calibrating the first sensor element further comprises performing a second algorithm, and wherein the second algorithm is different from the first algorithm.
  • the first range and second range partially, but not completely, overlap within an overlapping range.
  • calibrating the first sensor element comprises receiving an external reference value within the overlapping range.
  • calibrating the second sensor element comprises receiving a value obtained from the first sensor element.
  • the first sensor element and the second sensor element each have different current densities, and wherein calibrating the second sensor element utilizes a known relationship between the current density of the first sensor element and the current density of the second sensor elements.
  • the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a method for processing data from a sensor system configured for measurement of an analyte concentration in a host comprising: processing a first signal from a first sensor element, wherein the first sensor element is configured to measure an analyte concentration in a first range, and wherein the first signal is associated with the analyte concentration; and processing a second signal from a second sensor element, wherein the second sensor element is configured to measure an analyte concentration in a second range, wherein the second signal is associated with the analyte concentration, and wherein the first range is different from the second range.
  • At least one of processing the first signal or processing the second signal comprises comparing the first signal to the second signal.
  • At least one of processing the first signal or processing the second signal comprises averaging and/or integrating the first signal to the second signal.
  • At least one of processing the first signal or processing the second signal comprises polling the first signal to the second signal.
  • At least one of processing the first signal or processing the second signal comprises evaluating an accuracy of the first signal.
  • the method further comprises: calibrating the first signal to generate a first calibrated signal; and calibrating the second signal to generate a second calibrated signal.
  • At least one of processing the first signal or processing the second signal comprises evaluating an accuracy of the first calibrated signal and an accuracy of the second calibrated signal.
  • the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a method for manufacturing a sensor system configured for measurement of an analyte concentration in a host, the method comprising: manufacturing a first sensor element configured to measure an analyte concentration in a first range; and manufacturing a second sensor element configured to measure an analyte concentration in a second range, wherein the second range is different from the first range.
  • manufacturing the first sensor element comprises forming a first electrode, and wherein manufacturing the second sensor element comprises forming a second electrode.
  • manufacturing the first sensor element further comprises forming a first membrane on the first electrode, and wherein manufacturing the second sensor element further comprises forming a second membrane on the second electrode.
  • the first membrane is configured to provide a first current density and the second membrane is configured to provide a second current density, and wherein the first current density is different from the second current density.
  • forming the first membrane and forming the second membrane comprise optically curing the first membrane and the second membrane so as to provide a different sensitivity for the first membrane and the second membrane.
  • optically curing the first membrane and the second membrane comprise using selective photolithography so as to provide a different current density for the first membrane and the second membrane.
  • using selective photolithography comprises masking the first membrane during at least a portion of the photolithographic exposure of the second membrane.
  • curing the first membrane and the second membrane comprises at least one method selected from the group consisting of drop coating, masking for spray coating, and dip coating to multiple depths.
  • the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • a sensor system for continuous measurement of an analyte concentration in a host, the sensor system comprising a first sensor element configured to measure an analyte concentration and generate a first signal; a second sensor element configured to measure the analyte concentration and generate a second signal, the second sensor element having at least one characteristic different from the first sensor element; and sensor electronics configured to determine an analyte concentration value based on at least one of the first signal or the second signal.
  • the sensor electronics are configured to estimate an analyte concentration value based on at least one of the first signal or the second signal and based on an estimation of a parameter.
  • the sensor electronics are further configured to average or integrate the first signal and the second signal.
  • the sensor electronics are further configured to assign a first weight to the first signal and assign a second weight to the second signal, wherein a magnitude of the first weight and a magnitude of the second weight are dependent on the estimation of the parameter.
  • the parameter is associated with the analyte concentration.
  • the parameter is associated with a time period of a sensor session.
  • the parameter is associated with a presence of a level of an interferent.
  • the parameter is associated with a concentration of oxygen.
  • the first sensor element comprises a first membrane having a first hydrophilic component and a first hydrophobic component
  • the second sensor element comprises a second membrane having a second hydrophilic component and a second hydrophobic component
  • the first sensor membrane and the second sensor membrane have a different hydrophilic to hydrophobic ratio
  • the first membrane comprises a first domain configured to reduce a flux of the analyte therethrough
  • the second membrane comprises a second domain configured to reduce a flux of the analyte therethrough, and wherein the first domain and the second domain are different.
  • system further comprises a potentiostat configured to apply a first bias potential to the first sensor element and to apply a second bias potential to the second sensor element, wherein the first bias potential and the second bias potential are different.
  • the first sensor element comprises a first membrane configured to reduce a flux of interferents therethrough
  • the second sensor element comprises a second membrane configured to reduce a flux of interferents therethrough, and wherein interferent blocking characteristics of the first membrane and the second membrane are different.
  • the first sensor element is further configured to monitor at least one levels of an interferent.
  • a method for processing data from a sensor system configured for continuous measurement of an analyte concentration in a host, the method comprising receiving a first signal, associated with an analyte concentration in a host, from a first sensor element; receiving a second signal, associated with the analyte concentration in the host, from a second sensor element, wherein the second sensor element hays at least one characteristic different from the first sensor element; and determining, using sensor electronics, an analyte concentration value based on at least one of the first signal or the second signal.
  • determining the analyte concentration value is further based on an estimation of a parameter.
  • determining the analyte concentration value comprises averaging or integrating the first signal and the second signal.
  • averaging or integrating the first signal and the second signal comprises assigning a first weight to the first signal and assigning a second weight to the second signal, wherein a magnitude of the first weight and a magnitude of the second weight are dependent on the estimation of the parameter.
  • the parameter is associated with the analyte concentration.
  • the parameter is associated with a time period of a sensor session.
  • the parameter is associated with a presence of a level of an interferent.
  • the parameter is associated with a concentration of oxygen.
  • the method further comprises applying a first bias potential to the first sensor element and a second bias potential to the second sensor element, wherein the first bias potential and the second bias potential are different.
  • a sensor system for continuous measurement of an analyte concentration in a host, the sensor system comprising a first sensor element configured to measure analyte concentrations over a first time period of in vivo implantation; and a second sensor element configured to measure analyte concentrations over a second time period of in vivo implantation, wherein the first time period and the second time period are different.
  • the first time period is associated with an initial period of in vivo implantation
  • the second time period is associated with a second time period of in vivo implantation
  • the second period begins after the initial period of in vivo implantation has begun.
  • the first time period and the second time period overlap partially, but not completely.
  • the first time period and the second time period do not overlap.
  • the first time period is from about day 1 post-implantation to about day 3 post-implantation, and wherein the second time period is from about day 2 post-implantation to about day 10 post-implantation.
  • the first time period is from about day 1 post-implantation to about day 21 post-implantation, and wherein the second time period is from about day 10 post-implantation to about year 1 post-implantation.
  • the sensor system is configured for implantation wholly in a tissue of a host.
  • the sensor system is configured for transcutaneous placement through a skin of a host.
  • the senor system is configured for fluid communication with a vascular system of a host.
  • FIG. 1A is perspective view of one embodiment of a continuous analyte sensor.
  • FIG. 1B is a perspective view of another embodiment of a continuous analyte sensor.
  • FIG. 2A is a cross-sectional view through the analyte sensor of FIG. 1A on line 2 A- 2 A, illustrating one embodiment of the membrane system.
  • FIG. 2B is a cross-sectional view through the analyte sensor of FIG. 1A on line 2 B- 2 B, illustrating one embodiment of the membrane system.
  • FIG. 2C is a cross-sectional view through the analyte sensor of FIG. 1A on line 2 C- 2 C, illustrating one embodiment of the membrane system.
  • FIG. 3 is a block diagram illustrating continuous glucose sensor electronics, in one embodiment.
  • FIG. 4 is a flowchart illustrating the measuring and processing of sensor data, in one embodiment.
  • FIG. 5 is a flowchart illustrating the measuring and processing of sensor data, in another embodiment.
  • FIG. 6A is a flowchart illustrating one embodiment for manufacturing of a sensor system.
  • FIG. 6B is a flowchart illustrating another embodiment for manufacturing of a sensor system.
  • analyte is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological sample (e.g., bodily fluids, including, blood, serum, plasma, interstitial fluid, cerebral spinal fluid, lymph fluid, ocular fluid, saliva, oral fluid, urine, excretions or exudates).
  • a biological sample e.g., bodily fluids, including, blood, serum, plasma, interstitial fluid, cerebral spinal fluid, lymph fluid, ocular fluid, saliva, oral fluid, urine, excretions or exudates.
  • Analytes can include naturally occurring substances, artificial substances, metabolites, or reaction products.
  • the analyte for measurement by the sensing elements, devices, and methods is albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO 2 , chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, metabolic markers, and drugs.
  • analytes are contemplated as well, including but not limited to acetaminophen, dopamine, ephedrine, terbutaline, ascorbate, uric acid, oxygen, d-amino acid oxidase, plasma amine oxidase, xanthine oxidase, NADPH oxidase, alcohol oxidase, alcohol dehydrogenase, pyruvate dehydrogenase, diols, Ros, NO, bilirubin, cholesterol, triglycerides, gentisic acid, ibuprophen, L-Dopa, methyl dopa, salicylates, tetracycline, tolazamide, tolbutamide, acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles
  • Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments.
  • the analyte can be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like.
  • the analyte can be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, p
  • Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), histamine, Advanced Glycation End Products (AGEs) and 5-hydroxyindoleacetic acid (FHIAA).
  • ascorbic acid uric acid
  • dopamine dopamine
  • noradrenaline 3-methoxytyramine (3MT)
  • 3-methoxytyramine (3MT) 3,4-dihydroxyphenylacetic acid
  • DOPAC 3,4-dihydroxyphenylacetic acid
  • HVA homovanillic acid
  • 5HT 5-hydroxytryptamine
  • histamine histamine
  • AGEs Advanced Glycation End Products
  • FHIAA 5-hydroxyindoleacetic acid
  • continuous and “continuously,” as used herein in reference to analyte sensing are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to the continuous, continual, or intermittent (e.g., regular) monitoring of analyte concentration, such as, for example, performing a measurement about every 1 to 10 minutes.
  • operably connected is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to one or more components linked to another component(s) in a manner that allows transmission of signals between the components.
  • one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit.
  • the electrode is “operably connected” to the electronic circuitry.
  • host as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to animals (e.g., humans) and plants.
  • electrochemically reactive surface and “electroactive surface,” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to the surface of an electrode where an electrochemical reaction takes place.
  • H 2 O 2 hydrogen peroxide
  • glucose oxidase produces H 2 O 2 as a byproduct.
  • the H 2 O 2 reacts with the surface of the working electrode to produce two protons (2H + ), two electrons (2e ⁇ ), and one molecule of oxygen (O 2 ), which produces the electric current being detected.
  • a reducible species for example, O 2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
  • sensor element is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the region or mechanism of a monitoring device responsible for the detection of a particular analyte.
  • raw data stream and “data stream,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an analog or digital signal directly related to the measured glucose concentration from the glucose sensor.
  • the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a glucose concentration.
  • the terms broadly encompass a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
  • counts is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of a digital signal.
  • a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode.
  • counter electrode voltage measured in counts is directly related to a voltage.
  • a sensor includes an electrode covered by a membrane system having a diffusion resistance domain and an enzyme domain. If the electrode is deemed to be the point of reference and the diffusion resistance domain is positioned farther from the electrode than the enzyme domain, then the diffusion resistance domain is more distal to the electrode than the enzyme domain.
  • proximal to is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship between various elements in comparison to a particular point of reference.
  • some embodiments of a sensor include an electrode covered by a membrane system having a diffusion resistance domain and an enzyme domain. If the electrode is deemed to be the point of reference and the enzyme domain is positioned nearer to the electrode than the diffusion resistance domain, then the enzyme domain is more proximal to the sensor than the diffusion resistance domain.
  • domain is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to regions of a membrane that can be layers, uniform or non-uniform gradients (i.e., anisotropic) or provided as portions of the membrane.
  • baseline is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the component of an analyte sensor signal that is not related to the analyte concentration.
  • the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide).
  • sensitivity is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an amount of electrical current produced by a predetermined amount (unit) of the measured analyte.
  • a sensor has a sensitivity (or slope) of about 1 to about 300 picoAmps of current for every 1 mg/dL of glucose analyte.
  • a sensor has a sensitivity (or slope) of about 3 to about 1,000 picoAmps of current per mm 2 of electroactive surface, for every 1 mg/dL of glucose analyte.
  • Described herein is an improved sensor system with a plurality of sensor elements, in which each sensor element is designed to measure analyte concentration and to have a different characteristic, attribute, or configuration than the other sensor element(s) of the system.
  • sensor data from each of the plurality of different sensor elements is selectively used when a certain predetermined condition is present.
  • the predetermined condition can relate to any of a variety of parameters, such as, oxygen concentration, time since initiation of the sensor session, presence of a certain level of interference activity, for example.
  • the predetermined condition can also relate to analyte concentration.
  • the continuous analyte sensor system comprises a plurality of sensor elements that are each configured to provide a preselected level of accuracy in two or more physiologically relevant ranges, so that the system can accurately measure an analyte concentration across a physiologically relevant range.
  • the plurality of sensor elements may provide the system with the capability of performing highly accurate measurements of glucose concentration in both hyperglycemic and hypoglycemic ranges.
  • Various methods for confirming accuracy of a sensor include, but are not limited to, the Clarke Error Grid, Parkes Error Grid, Continuous Glucose Error grid, Mean Absolute Relative Difference (MARD) analysis, and YSI (Yellow Springs Instrument) analysis. Some or all of these methods can be used to verify the accuracy of the sensor's measurements.
  • the sensor's level of accuracy is verified by confirming that a high percentage (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98%) of its paired data points within zone A of the Clarke Error Grid.
  • the sensor's level of accuracy is verified by using a MARD analysis, such that the sensor's accuracy is confirmed with an MARD of about 30% or less, or about 25% or less, or about 20% or less, or about 15% or less, or about 10% or less, or about 5% or less.
  • the sensor's level of accuracy is verified by using YSI analysis, such that a large percentage of readings (e.g., about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or more) are within about 20 mg/dL of a YSI reading.
  • the plurality of sensor elements are housed within the same body, but in alternative embodiments the sensor elements are housed in different bodies. With embodiments in which a plurality of sensor elements are housed in the same body, in some of these embodiments, the sensor elements are physiologically connected or separated by a spacing.
  • FIG. 1A provides a perspective view of one embodiment of a sensor system 180 and illustrates an in vivo portion of a working electrode 100 comprising two analyte sensor elements 102 and 104 and a reference electrode 108 .
  • the reference electrode 108 is used to provide a reference value for measuring the working electrode potential of the sensor elements 102 , 104 .
  • an insulator 106 is disposed between the two sensor elements 102 and 104 , and between the sensor element 104 and the reference electrode 108 , to provide necessary electrical insulation therebetween.
  • the insulator spacing separating the two sensor elements 102 and 104 may be minimized, so that the sensor elements 102 and 104 may both function under almost identical physiological conditions.
  • FIG. 1B provides a perspective view of another embodiment comprising a sensor system 180 having a first working electrode 150 comprising a first sensor element 102 and a second working electrode 160 comprising a second sensor element 104 . Similar to the embodiment shown in FIG. 1A , the sensor system 180 also includes a reference electrode 108 for providing a reference value for measuring the working electrode potential of the sensor elements 102 , 104 . Both the first working electrode 150 and the second working electrode 160 comprise an insulator 106 that separates the sensor elements 102 and 104 from the reference electrode 108 .
  • Sensor element 102 is associated with a membrane 142
  • sensor element 104 is associated with another membrane 152 .
  • the thickness, composition, and/or structure of one or more layers (e.g., electrode, interference, or enzyme domains) of membrane system 142 differs from that of membrane system 152 , but in other embodiments membranes 142 , 152 may be substantially the same. Additional sensor systems and configuration are described in U.S. Provisional Application No. 61/222,751 filed Jul. 2, 2009 and U.S. patent application Ser. No. ______, filed Jul. 1, 2010, and entitled “ANALYTE SENSORS AND METHODS FOR MANUFACTURING SAME,” each of which is incorporated by reference herein in its entirety.
  • the senor is configured for transdermal (e.g., transcutaneous) placement, but in other embodiments the sensor is configured for intravascular placement, subcutaneous placement, intramuscular placement, or intraosseous placement.
  • the sensor may use any method to provide an output signal indicative of the concentration of the analyte of interest; these methods may include, for example, invasive, minimally invasive, or non-invasive sensing techniques.
  • the output signal associated with the analyte concentration of the host is typically a raw signal used to provide a useful value of the analyte of interest to a user (e.g., a patient or physician) using the device. Accordingly, appropriate smoothing, calibration, or evaluation methods can be applied to the signal or system as a whole to provide relevant and acceptable estimated analyte data to the user.
  • the senor may use any of a wide variety of known suitable detection methods. These methods may include, but are not limited to, enzymatic, chemical, physical, electrochemical, immunochemical, optical, radiometric, calorimetric, protein binding, microscale methods of detection, and the like. Additional description of analyte sensor configurations and detection methods can be found, e.g., in U.S. Patent Publication No. US-2007-0213611-A1, U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2005-0143635-A1, U.S. Patent Publication No. US-2007-0020641-A1, U.S. Patent Publication No.
  • the sensor system comprises a plurality of sensor elements, each or some of which are configured to measure different ranges of analyte concentration.
  • the sensor system may include a first sensor element configured to accurately measure analyte concentration in a first range of analyte concentrations and a second sensor element configured to accurately measure analyte concentration in a second range of analyte concentrations.
  • the sensor system is configured to measure glucose concentration over a range of from about 30, 40, 50, 60, 70, or 80 mg/dL to about 200, 250, 300, 350, 400, 450, 500, 550 or 600 mg/dL.
  • the sensor system includes a plurality of sensor elements configured to measure different analyte concentration ranges, each of which comprises a portion of the physiologically relevant range.
  • the different ranges do not overlap, but in other embodiments, the ranges overlap, either partially or entirely.
  • the sensor system comprises a first sensor element configured to measure a glucose concentration of from about 30 mg/dL to about 120 mg/dL and a second sensor element configured to measure a glucose concentration of from about 80 mg/dL to about 400 mg/dL.
  • the first sensor element is configured to measure a glucose concentration of from about 30 mg/dL to about 120 mg/dL, or from about 40 mg/dL to about 100 mg/dL
  • the second sensor element is configured to measure a glucose concentration of from about 60 mg/dL to about 500 mg/dL, or from about 90 mg/dL to about 450 mg/dL.
  • the sensor system can comprise any number of sensor elements.
  • the plurality of sensor elements may each be tuned to measure at a particular analyte concentration range, tuned to measure at a particular time period during a sensor session, and/or to tuned to measure at any particular range of any of a variety of parameters (e.g., parameters relating to concentration of oxygen, concentration of a interferent, etc.).
  • the sensor system comprises three sensor elements configured to measure a first range, a second range, and a third range, e.g., with a first sensor element associated with a range of about 30-90 mg/dL, a second sensor element associated with a range of about 80-160 mg/dL, and a third sensor element associated with a range of about 140-400 mg/dL.
  • the sensor system is provided with 4, 5, 6, 7, 8, 9, 10, 20, 40, or more sensor elements.
  • language associating sensor measurement or output of analyte concentration to a particular range of analyte concentrations, particular range of time, or any other range corresponding to a parameter or condition should not be construed as precluding the sensor element from measuring outside the particular range described or from having its signal used to form an estimation of an analyte concentration value (e.g., estimation by using a weighted average or weighted sum of a plurality of signals). Rather, such language should be construed to mean that the sensor element is configured to be tuned (with respect to measurement accuracy) to a particular range, such that all or a weighted portion of the sensor output of analyte concentrations in that particular range comes from the sensor element particularly tuned thereto.
  • each sensor element may have a different configuration and be tuned to measure analyte concentration within a preselected analyte concentration range (e.g., high glucose concentration range vs. low glucose concentration range).
  • a preselected analyte concentration range e.g., high glucose concentration range vs. low glucose concentration range.
  • the exemplary sensor system is configured to provide output to a user from the first sensor element, second sensor element, or both, based, at least in part, on the analyte concentration range that the first or second sensor element is particularly tuned for.
  • the phrase “accurately measure,” or the like should be construed as referring to a level of accuracy that provides clinically useful analyte measurements.
  • the sensitivity or current density (i.e., sensitivity divided by surface area of the electroactive surface) of one or more of the sensor elements is substantially higher than the sensitivities or current densities of other sensor elements, but in other embodiments, the sensitivities or current densities of the sensor elements are substantially equal.
  • the sensor system includes a first sensor element having a first sensitivity and a second sensor element having a second sensitivity, wherein the first sensitivity is higher than the second sensitivity.
  • the first sensitivity is from about 1 pA/mg/dL to about 100 pA/mg/dL, or from about 1 pA/mg/dL to about 25 pA/mg/dL
  • the second sensitivity is from about 20 pA/mg/dL to about 300 pA/mg/dL, or from about 50 pA/mg/dL to about 100 pA/mg/dL.
  • the sensor system includes a first sensor element having a first current density and a second sensor element having a second current density, wherein the first current density is higher than the second current density.
  • the current density of the first element is from about 3 pA/mg/dL/mm 2 to about 325 pA/mg/dL/mm 2 , or from about 3 pA/mg/dL/mm 2 to about 85 pA/mg/dL/mm 2
  • the current density of the second element is from about 65 pA/mg/dL/mm 2 to about 1,000 pA/mg/dL/mm 2 , or from about 165 pA/mg/dL/mm 2 to about 1,700 pA/mg/dL/mm 2 .
  • the sensor element with the higher sensitivity or higher current density is used to measure or provide output at low glucose concentration ranges, while the sensor element with the lower sensitivity or lower current density is used to measure or provide output at high glucose concentration ranges.
  • improved glucose concentration measurement accuracy at both low and high glucose levels is achieved by configuring the first sensor element to have a higher sensitivity or higher current density and the second to have a lower sensitivity or lower current density.
  • the sensor elements each have a different bias potential applied against it by a potentiostat.
  • An increased bias potential applied against a sensor element may not only facilitate the oxidization and measurement of H 2 O 2 , but may also facilitate the oxidization of water or other electroactive species.
  • the bias setting is increased by about 0.05 V to about 0.4 V above what is necessary for sufficient H 2 O 2 measurements.
  • the sensor system comprises a first sensor element configured with a first bias setting (for example, +0.6V) for measuring a signal only from the product of the enzyme reaction, and a second sensor element configured with a second bias setting (for example, +1.0V) that oxidizes and measures water or other electroactive species.
  • the first sensor element is configured to measure at low analyte ranges, where the oxygen-to-glucose molar ratio is high
  • the second element is configured to measure at high analyte ranges, where the oxygen-to-glucose molar ratio is low and where additional oxygen can be helpful for preventing a molar excess of glucose relative to oxygen.
  • the sensor elements each have different analyte-related to non-analyte-related signal ratios.
  • the sensor system includes first and second sensor elements, and wherein the first sensor element has a higher sensitivity or higher current density than the second sensor element, the first sensor element also has higher analyte-related to non-analyte-related signal ratio than the second sensor element.
  • the combination of a higher sensitivity or higher current density and a higher analyte-related to non-analyte-related signal ratio further improves measurement accuracy at low analyte levels.
  • An increase or decrease of the analyte-related to non-analyte-related signal ratio may be obtained by modifying membrane properties (e.g., composition, thickness, etc.).
  • the sensor system has a plurality of sensor elements, in which one or more of the sensor elements are configured to have a different membrane system (i.e., with different membrane properties) than the other sensor element(s).
  • the plurality of sensor elements each comprises a membrane with a hydrophilic component and a hydrophobic component, with the membrane of each sensor element having a different hydrophilic component to hydrophobic component ratio than the ratio(s) of the membrane(s) of other sensor element(s).
  • membrane property changes can include changes to, for example, permeability of analyte, sensitivity to analyte, permeability of interferents, sensitivity to interferents, permeability to oxygen, expected sensor life, accuracy at certain periods during a sensor session, etc.
  • changing the hydrophilic component to hydrophobic component ratio can also change the sensor run-in-time (i.e., the time between the insertion of the sensor subcutaneously and stabilization of the sensor). It has been found that an increase in this ratio (i.e., larger amounts of the hydrophilic component than the hydrophobic component) can substantially reduce run-in time. While not wishing to be bound by theory, it is believed that this phenomenon may be attributed at least in part to faster hydration of membranes having a greater proportion of hydrophilic components, when the sensor is inserted into the patient and contacts a biological sample.
  • the sensor system may comprise one sensor element with a reduced run-in-time (e.g., about 0.1 hour, 0.2 hour, 0.3 hour, 0.4 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 4, hours, or 6 hours) that is tuned to an early portion of the sensor session and other sensor element(s) that are tuned to other portions of the sensor session.
  • the sensor element configured with the reduced run-in-time may be used to calibrate the other sensor elements.
  • sensor elements can be formed with a membrane that permits a greater flux of glucose molecules into the enzyme layer (which may comprise glucose oxidase) of the membrane, than sensor elements designed for low sensitivity or low current density.
  • the sensor system is designed to comprise a plurality of sensor elements, each of which is configured to have different membrane characteristics, with respect to oxygen permeability and/or glucose permeability.
  • each of the plurality of sensor elements may have a different sensitivity or current density.
  • the sensor system comprises a first sensor element configured with a high sensitivity or high current density and a second sensor element configured with a low sensitivity or low current density. It has been found that high glucose sensitivity sensor elements typically perform worse in lower oxygen environments than the low glucose sensitivity sensor element.
  • the sensor system can be configured to accept data from the low sensitivity or low current density sensor element, instead of the high sensitivity or high current density sensor element.
  • data from the high sensitivity or high current density sensor element may still be accepted, but accorded less weight than data from the low sensitivity or low current density sensor element.
  • comparison and analysis is performed on signals.
  • the comparison and analysis can include integrating or averaging signals from a plurality of sensor elements.
  • the sensor electronics may be configured to accord less (or no) weight to a high sensitivity sensor element, as compared to a low sensitivity sensor element, in environments associated with low oxygen and high glucose concentration. Conversely, the sensor electronics may be configured to accord more weight to the high sensitivity sensor element in environments associated with high oxygen and low glucose concentration. As an alternative to weighting, the sensor electronics may be configured to poll sensor data from the low glucose sensitivity sensor only when an environment associated with a low oxygen environment is detected.
  • signals received from the two sensor elements can be compared and analyzed to provide information not only about glucose concentration, but information about other parameters that can affect sensor performance. For example, during a sensor session, if the oxygen level near the sensor elements diminishes below a certain level, the high sensitivity sensor element may no longer be accurate. Under these conditions, the high sensitivity sensor may become noisy and thus become less accurate, while the low sensitivity sensor element can continue to measure accurately. Accordingly, in some embodiments in which comparison and analysis of signals is made by integrating or averaging signals from a plurality of sensor elements, the sensor electronics may be configured to accord less (or no) weight to a high sensitivity sensor element, as compared to a low sensitivity sensor element, in environments associated with low oxygen and high glucose concentration.
  • the sensor electronics may be configured to accord more weight to the high sensitivity sensor element in environments associated with high oxygen and low glucose concentration.
  • the sensor electronics may be configured to poll sensor data from the low glucose sensitivity sensor only when an environment associated with a low oxygen environment is detected.
  • the noise that may be present in data from a high sensitivity sensor element may provide an indication that a low glucose sensitivity sensor is approaching an environment in which it may also become inaccurate as well.
  • the sensor electronics may be configured to monitor, on the high sensitivity sensor element, a noise pattern that corresponds to a low oxygen environment. Following detection of the noise pattern, the sensor electronics can be instructed to poll data from the low sensitivity only, or alternatively adjust the weight accorded to the high sensitivity sensor with respect to the low sensitivity sensor.
  • oxygen availability typically decreases with time during the age of a sensor, as the amount of oxygen that can be transported across the membrane of a sensor element diminishes. While not wishing to be bound by theory, it is believed that this phenomenon may be attributed at least in part to the body's response to a foreign object (e.g., a continuous glucose sensor), whereby barrier cells are formed surrounding the sensor elements. In turn, the barrier cells reduce or completely block the transport of oxygen across the membrane of the sensor elements.
  • a foreign object e.g., a continuous glucose sensor
  • the sensor system is formed with a high sensitivity or high current density sensor element that provides greater accuracy during a large duration of the sensor system's life, and a low sensitivity or low current density sensor element that provides better low oxygen performance, and thus can be used near the end of the sensor system's life.
  • the sensor system comprises a plurality of sensor elements used to continuously provide sensor data after insertion of the sensor, even during time periods which may be problematic for conventional sensors.
  • the sensor system comprises a first sensor element and a second sensor element, each with different membrane properties.
  • the first sensor element is tuned to measure analyte concentration during a first period, such as an initial time period after sensor implantation (e.g., during about the first 0.1 hour, 0.2 hour, 0.5 hour. 0.75 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days post-insertion).
  • the first sensor element is designed with a particular membrane (e.g., a membrane that hydrates quickly after insertion into interstitial fluid) that is tuned for accuracy during the initial period after sensor insertion.
  • the second sensor element is tuned to measure analyte concentration during a second time period (e.g., after about 0.2 hour, 0.5 hour, 0.75 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4, days, 5 days, 7 days, 2 weeks, or 1 year post-insertion), where the second period begins after the initial period begins.
  • the time periods of the different sensor elements overlap.
  • sensor elements can be tuned to measure accurately over a specific time period.
  • the time periods overlap partially, but in other embodiments, there is no overlap of time periods.
  • the first time period is from about hour 0.2 to about day 3 post-insertion
  • the second time period is from about hour 6 to about day 10 post-insertion.
  • there is partial overlap between hour 6 and day 3 post-insertion include, but are not limited to, a sensor system having the first time period of from about day 1 to about day 21, and a second time period of from about day 10 to about year one.
  • the time period of one sensor may completely overlap the time period of another sensor.
  • the first time period is from about hour 0.5 to about day 2
  • the second time period is from about hour 6 to about day 10
  • the third time period is from about day 3 to about day 10.
  • the second time period completely overlaps the third time period.
  • the second sensor element tuned to measure at a later time period may be formed with a robust biointerface to create strong vascularized tissue ingrowth, thereby providing more durability, but also a longer break in time. By having a plurality of sensor elements tuned to different time periods, the sensor system is capable of continuously and accurately measuring analyte concentrations across a wide range of time periods.
  • the senor includes a membrane system comprising a single layer deposited onto the electroactive surfaces of the sensor, wherein the single layer includes one or more functional domains (e.g., distinct portions).
  • the membrane system includes two or more deposited layers, each of which is configured to perform different functions.
  • FIG. 2A is a cross-sectional view through one embodiment of the sensor element 102 of FIG. 1A on line 2 A- 2 A, illustrating one exemplary embodiment of a membrane system 132 covering an elongated conductive body 200 .
  • elongated conductive body as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an elongated body formed at least in part of a conductive material and includes any number of coatings formed thereon.
  • an “elongated conductive body” may be in the form of a bare elongated core (e.g., a metal wire, a wire formed of a conductive polymer, a planar substrate formed of a non-conductive material) or an elongated core covered (e.g., coated, plated, cladded, etc.) with one, two, three, four, five, or more layers or domains of material that may be conductive or non-conductive.
  • a bare elongated core e.g., a metal wire, a wire formed of a conductive polymer, a planar substrate formed of a non-conductive material
  • an elongated core covered e.g., coated, plated, cladded, etc.
  • the membrane system 132 comprises a plurality of domains, including an electrode domain 202 , an interference domain 204 , an enzyme domain 206 , and a diffusion resistance domain 208 .
  • FIG. 2B is a cross-sectional view through one embodiment of the sensor element 104 of FIG. 1A on line 2 B- 2 B, illustrating one exemplary embodiment of a membrane system 122 covering an elongated conductive body 200 covered by an insulating domain 212 and a conductive domain 214 . As illustrated in FIG.
  • the membrane system 122 associated with sensor element 104 also comprises an electrode domain 202 , an interference domain 204 , an enzyme domain 206 , and a diffusion resistance domain 208 .
  • FIG. 2C illustrates a cross-sectional view through line 2 C- 2 C of FIG. 1A .
  • the thickness, composition, and/or structure of one or more layers (e.g., electrode, interference, or enzyme domains) of membrane system 132 differs from that of membrane system 122 .
  • this particular embodiment can also include a high oxygen solubility domain, a biointerface domain, or a bioprotective domain, such as is described in more detail in U.S. Patent Application Publication No. US-2005-0245799-A1, U.S. Patent Application Publication No. US-2009-0247856-A1, and U.S. Patent Application Publication No. US-2009-0247855-A1, and such as are described in more detail below.
  • the membrane system can be deposited on the exposed electroactive surfaces using known thin film techniques including, but not limited to, conventional vapor deposition, spraying, electro-depositing, dipping, and the like.
  • the domains are deposited by dipping the sensor into a solution and drawing out the sensor at a speed that provides the desired domain thickness.
  • the domains are deposited by spraying a solution onto the sensor for a period of time which provides the desired domain thickness.
  • a combination of different deposition techniques is used for the different domains being deposited. For example, in one embodiment, dipping processes are used to deposit the electrode and enzyme domains onto the electrode, whereas a spraying process is used to deposit the diffusion resistance domain.
  • vapor deposition processes e.g., physical or chemical vapor deposition processes
  • processes include, but are not limited to, ultrasonic vapor deposition, electrostatic deposition, evaporative deposition, deposition by sputtering, pulsed laser deposition, high velocity oxygen fuel deposition, thermal evaporator deposition, electron beam evaporator deposition, deposition by reactive sputtering molecular beam epitaxy, atmospheric pressure chemical vapor deposition (CVD), atomic layer CVD, hot wire CVD, low-pressure CVD, microwave plasma-assisted CVD, plasma-enhanced CVD, rapid thermal CVD, remote plasma-enhanced CVD, and ultra-high vacuum CVD, for example.
  • the membrane system can be disposed over (or deposited on) the electroactive surfaces using any known method.
  • one or more domains of the membrane system is formed from one or more materials such as silicone, polytetrafluoroethylene, polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, polyamides, polyimides, polystyrenes, cellulosic polymers, polysulfones and block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers.
  • silicone polytetrafluoroethylene
  • polyethylene-co-tetrafluoroethylene polyolefin
  • the membrane system comprises an electrode domain.
  • Providing the electrode domain 202 ensures that an electrochemical reaction occurs between the electroactive surfaces of the working electrode and the reference electrode, and thus the electrode domain may be situated more proximal to the electroactive surfaces than the interference or enzyme domain.
  • the electrode domain includes a coating that maintains a layer of water at the electrochemically reactive surfaces of the sensor.
  • the presence of the electrode domain provides an environment between the surfaces of the working electrode and the reference electrode which facilitates an electrochemical reaction between the electrodes.
  • a humectant in a binder material can be employed as an electrode domain; this allows for the full transport of ions in the aqueous environment.
  • the electrode domain can also assist in stabilizing the operation of the sensor by accelerating electrode start-up and drifting problems caused by inadequate electrolyte.
  • the material that forms the electrode domain can also provide an environment that protects against pH-mediated damage that can result from the formation of a large pH gradient due to the electrochemical activity of the electrodes.
  • the electrode domain includes a hydrophilic polymer film (e.g., a flexible, water-swellable, hydrogel) having a “dry film” thickness of from about 0.05 microns or less to about 20 microns or more, or from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, or from about 3, 2.5, 2, or 1 microns, or less, to about 3.5, 4, 4.5, or 5 microns or more.
  • “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation by standard coating techniques.
  • the electrode domain is formed of a curable mixture of a urethane polymer and a hydrophilic polymer.
  • coatings are formed of a polyurethane polymer having carboxylate or hydroxyl functional groups and non-ionic hydrophilic polyether segments, wherein the polyurethane polymer undergoes aggregation with a water-soluble carbodiimide (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)) in the presence of polyvinylpyrrolidone and cured at a moderate temperature of, e.g., about 50° C.
  • a water-soluble carbodiimide e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
  • the electrode domain is formed from one or more hydrophilic polymers (e.g., a polylactone, a polyimide, a polylactam, a functionalized polyamide, a functionalized polylactone, a functionalized polyimide, a functionalized polylactam or a combination thereof) that renders the electrode domain substantially more hydrophilic than an overlying domain, (e.g., interference domain, enzyme domain).
  • the electrode domain is formed substantially entirely or primarily from a hydrophilic polymer.
  • the electrode domain is formed substantially entirely from poly-N-vinylpyrrolidone (PVP).
  • PVP poly-N-vinylpyrrolidone
  • the electrode domain is formed entirely from a hydrophilic polymer.
  • Useful hydrophilic polymers include but are not limited to poly-N-vinylpyrrolidone, poly-N-vinyl-2-piperidone, poly-N-vinyl-2-caprolactam, poly-N-vinyl-3-methyl-2-caprolactam, poly-N-vinyl-3-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-caprolactam, poly-N-vinyl-3-ethyl-2-pyrrolidone, poly-N-vinyl-4,5-dimethyl-2-pyrrolidone, polyvinylimidazole, poly-N,N-dimethylacrylamide, polyvinyl alcohol, polyacrylic acid, polyethylene oxide, poly-2-ethyl-oxazoline, copolymers thereof and mixtures thereof.
  • a blend of two or more hydrophilic polymers may be desirable in some embodiments.
  • the hydrophilic polymer(s) is not crosslinked, but in other embodiments, crosslinking is performed.
  • crosslinking can be promoted by, e.g., adding a crosslinking agent, such as but not limited to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, or by irradiation at a wavelength sufficient to promote crosslinking between the hydrophilic polymer molecules. While not wishing to be bound by theory, it is believed that crosslinking creates a more tortuous diffusion path through the domain.
  • an independent electrode domain is described herein, in some embodiments sufficient hydrophilicity is provided in the interference domain or enzyme domain (the domain adjacent to the electroactive surfaces) so as to provide for the full transport of ions in the aqueous environment (e.g., without a distinct electrode domain). In these embodiments, an electrode domain may not be necessary.
  • the sensor system comprises a plurality of sensor elements, each with different electrode domain properties.
  • one of the plurality of sensor elements may be designed to allow for quick hydration of the electrode domain following insertion of the sensor into the body. It has been found that fast hydration of the electrode domain may lead to a reduction in run-in time of the sensor.
  • the membrane system is provided with an optional interference domain, also referred to as an interference layer.
  • the interference domain substantially reduces the flux of one or more interferents into the electrochemically reactive surfaces.
  • the interference domain may be configured to be much less permeable to one or more of the interferents than to the measured species, e.g., the product of an enzymatic reaction that is measured at the electroactive surface(s), such as H 2 O 2 , for example.
  • the reduction of interferent permeability corresponds to a reduction or a blocking of artificial signals.
  • Some known interferents for a glucose sensor include acetaminophen, lidocaine, ascorbic acid, bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen, L-dopa, methyl dopa, salicylate, tetracycline, tolazamide, tolbutamide, triglycerides, and uric acid, for example.
  • the interference domain contemplated in certain embodiments is configured to improve interferent blocking in certain key ranges (e.g., a hypoglycemic range), where a flux of interferents substantially exaggerates the response signal, thereby leading to false or misleading results.
  • Use of an interference domain in the membrane may result in longer membrane diffusion times (e.g., 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes or more) for the measured species, because of the interference layer's additional thickness to the membrane.
  • Use of the interference domain may also result in increased startup times (e.g., 30 minutes, 1 hour, 3 hours, 6 hours, 9 hours, or 12 hours), due to the additional time required for the sensor to hydrate and break in.
  • the sensor system can be tuned or adjusted with respect to measurement accuracy across a physiological relevant range of glucose concentrations, start up time, diffusional time lags, and the like.
  • the sensor system comprises a first sensor element and a second sensor element, each with different interference domain properties.
  • the first sensor element is configured to measure glucose concentrations in hypoglycemic ranges by being formed with an interference layer with an increased thickness to substantially reduce or block the flux of interferents.
  • the second sensor element is configured to measure glucose concentrations in hyperglycemic ranges by being formed without an interference layer, or alternatively by being formed with an interference layer with decreased thickness.
  • the interference domain is formed from one or more cellulosic derivatives.
  • Cellulosic derivatives include, but are not limited to, cellulose esters and cellulose ethers.
  • cellulosic derivatives include polymers such as cellulose acetate, cellulose acetate butyrate, 2-hydroxyethyl cellulose, cellulose acetate phthalate, cellulose acetate propionate, cellulose acetate trimellitate, and the like, as well as their copolymers and terpolymers with other cellulosic or non-cellulosic monomers.
  • Cellulose is a polysaccharide polymer of ⁇ -D-glucose.
  • cellulosic derivatives are used in some embodiments, other polymeric polysaccharides having similar properties to cellulosic derivatives can also be employed.
  • Descriptions of cellulosic interference domains can be found in U.S. Patent Application Publication No. US-2006-0229512-A1, U.S. Patent Application Publication No. US-2007-0173709-A1, U.S. Patent Application Publication No. US-2006-0253012-A1 and U.S. Patent Application Publication No. US-2007-0213611-A1.
  • the interference domain includes a thin, hydrophobic membrane that is non-swellable and restricts diffusion of high molecular weight species.
  • the interference domain in certain embodiments is permeable to relatively low molecular weight substances, such as hydrogen peroxide, but also restricts the passage of higher molecular weight substances, including glucose and ascorbic acid.
  • Other systems and methods for reducing or eliminating interference species that can be applied to the membrane system are described in U.S. Pat. No. 7,074,307, U.S. Patent Application Publication No.
  • a distinct interference domain is not included in the membrane system or is functionally combined with another layer.
  • the interference domain is deposited either directly onto the electroactive surfaces of the sensor or onto the distal surface of the electrode domain. It is contemplated that in some embodiments the thickness of the interference domain is from about 0.01 microns or less to about 20 microns or more.
  • the thickness of the interference domain is from about 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns. In some of these embodiments, the thickness of the interference domain is from about 0.2, 0.4, 0.5, or 0.6, microns to about 0.8, 0.9, 1, 1.5, 2, 3, or 4 microns.
  • the sensor system comprises a plurality of sensor elements, each with different interference domain properties. It has been found that certain interference domains lack completely precise specificity with respect to interferents. In other words, with certain interference domains, the membrane not only reduces the flux of interferents, but also reduces the flux of glucose or measured species such as hydrogen peroxide generated from an enzyme-catalyzed reaction. In these embodiments, having an interference domain that substantially reduces the flux of an interferent may result in a sensor element with decreased sensitivity and a lower signal level than an equivalent sensor element without the interference domain.
  • the sensor system may comprise a plurality of sensor elements, with each having different levels of interference blocking capabilities and/or having specificity for different interferents.
  • the plurality of sensor elements may each have different specificity for different interferents.
  • the sensor system may comprise a first sensor element that has an interference domain specifically designed to substantially reduce (or block) the flux of a certain interferent (e.g., acetaminophen), a second sensor element that has a different interference domain specifically designed to substantially reduce (or block) the flux of another interferent (e.g., uric acid), a third sensor element that has yet another different interference domain specifically designed to substantially reduce (or block) the flux of yet another interferent (e.g., ascorbic acid), and a fourth sensor element that has no interference domain.
  • a certain interferent e.g., acetaminophen
  • a third sensor element that has yet another different interference domain specifically designed to substantially reduce (or block) the flux of yet another interferent (e.g., ascorbic acid)
  • a fourth sensor element that has no interference domain
  • Detection of an elevated level of one or more interferents may be obtained by comparing signals associated with the different sensor elements.
  • the processor module may be programmed to identify the presence of interferents by comparing sensor data with certain data patterns known to correspond to the presence of interferents.
  • processing of the plurality of data streams associated with their respective plurality of sensor elements may be adjusted.
  • sensor data associated with the sensor element configured with a higher interferent blocking ability may be accorded more weight, and sensor data associated with the sensor element(s) without or with minimal interferent blocking ability may be accorded less (or no) weight.
  • a different filtering algorithm may be used on the sensor data, the sensor system may stop displaying data to the user if the interference level exceeds a certain threshold, and/or an alert or alarm may be triggered to prompt the user to take certain actions (e.g., to perform additional calibrations).
  • the membrane system further includes an enzyme domain 206 disposed more distally from the electroactive surfaces than the interference domain; however other configurations are also contemplated.
  • the enzyme domain provides an enzyme to catalyze the reaction of the analyte and its co-reactant, as described in more detail below.
  • the enzyme domain includes glucose oxidase (GOX); however other enzymes, for example, alcohol dehydrogenase, galactose oxidase or uricase oxidase, can also be used.
  • the enzyme domain is configured and arranged for detection of at least one of substance such as albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO 2 , chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, a drug, various minerals, various metabolites, and the like.
  • substance such as albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO 2 , chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium,
  • the senor is configured and arranged to detect two or more of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO 2 , chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, a drug, various minerals, various metabolites, and the like.
  • the sensor's response may be limited by neither enzyme activity nor co-reactant concentration. Because enzymes, including glucose oxidase, are subject to deactivation as a function of time even in ambient conditions, this behavior can be compensated for in forming the enzyme domain.
  • the enzyme domain is constructed of aqueous dispersions of colloidal polyurethane polymers including the enzyme. However, in alternative embodiments the enzyme domain is constructed from an oxygen enhancing material, such as silicone, or fluorocarbon, for example, in order to provide a supply of excess oxygen during transient ischemia. In some embodiments, the enzyme is immobilized within the domain. See, e.g., U.S. Patent Application Publication No. US-2005-0054909-A1.
  • the enzyme domain is deposited onto the interference domain for a domain thickness of from about 0.05 micron or less to about 20 microns or more, or from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, or from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns.
  • the enzyme domain is deposited directly onto the electroactive surfaces.
  • the enzyme domain is formed by dip coating or spray coating one or more layers at a predetermined concentration of the coating solution, insertion rate, dwell time, withdrawal rate, or desired thickness.
  • the sensor system comprises a plurality of sensor elements, each with different enzyme domain properties.
  • the sensor system comprises a plurality of sensor elements each designed to have a different sensitivity or current sensitivity than the other sensor element(s).
  • the differences in sensor sensitivity or current density may be achieved by modifying each sensor element to have a different amount of enzyme.
  • one of the plurality of sensor elements may have an enzyme domain which comprises polymers that contain mediators and enzymes that chemically attach to the polymers. The mediator used may oxidize at lower potentials than hydrogen peroxide, and thus fewer oxidizable interferents are oxidized at these low potentials.
  • one of the sensor elements may have a very low baseline (i.e., a baseline that approaches a zero baseline and that does not receive substantial signal contribution from non-glucose-related noise), such that the signal generated therefrom can be used to compare with the signal from another sensor element operating at a higher bias potential.
  • the baseline present in the signal from the sensor element operating at a higher bias potential may be calculated (from the signal generated from the sensor element operating with a baseline of about zero) by comparing the signals from the two sensor elements (e.g., by subtracting one signal from another signal after accounting for scaling).
  • one of the plurality of sensor elements may have an enzyme domain which uses a mediator that may reduce or eliminate the need for oxygen, as the mediator take the place of oxygen in the enzyme reaction.
  • a mediator may reduce or eliminate the need for oxygen, as the mediator take the place of oxygen in the enzyme reaction.
  • Such a sensor element may be tuned for (and configured to detect) low oxygen environments, while other sensor elements are used in normal or high in vivo oxygen environments.
  • the membrane system is provided with a diffusion resistance domain, also referred to as a diffusion resistance layer, a resistance domain, or a resistance layer.
  • the membrane system is situated more distal to the electrode relative to the enzyme, electrode, and interference domains.
  • the diffusion resistance domain serves to control the flux of oxygen and other analytes (for example, glucose) to the underlying enzyme domain.
  • oxygen and other analytes for example, glucose
  • an immobilized enzyme-based sensor employing oxygen as cofactor is supplied with oxygen in non-rate-limiting excess in order to respond linearly to changes in glucose concentration, while not responding to changes in oxygen tension. More specifically, when a glucose-monitoring reaction is oxygen-limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels may be obtained only up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 500 mg/dL.
  • the diffusion resistance domain of certain embodiments includes a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme domain, thereby rendering oxygen in non-rate-limiting excess.
  • the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the diffusion resistance domain.
  • the diffusion resistance domain exhibits an oxygen-to-glucose permeability ratio of approximately 200:1, but in other embodiments the oxygen-to-glucose permeability ratio is approximately 100:1, 125:1, 130:1, 135:1, 150:1, 175:1, 225:1, 250:1, 275:1, 300:1, or 500:1.
  • one-dimensional reactant diffusion may provide sufficient excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes et al., Anal. Chem., 66:1520-1529 (1994)).
  • a lower ratio of oxygen-to-glucose is sufficient to provide excess oxygen by using a high oxygen soluble domain (for example, a silicone material) to enhance the supply/transport of oxygen to the enzyme membrane or electroactive surfaces.
  • a high oxygen soluble domain for example, a silicone material
  • the resistance domain can be modified for other analytes and co-reactants as well.
  • the resistance domain includes a polyurethane membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to an analyte sensor, the membrane being fabricated from commercially available materials.
  • Suitable hydrophobic polymer components include polyurethane and polyetherurethaneurea.
  • Polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material.
  • a polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material.
  • Diisocyanates that may be used include, but are not limited to, aliphatic diisocyanates containing from about 4 to about 8 methylene units.
  • Diisocyanates containing cycloaliphatic moieties can also be useful in the preparation of the polymer and copolymer components of the membranes, in accordance with some embodiments.
  • the material that forms the basis of the hydrophobic matrix of the resistance domain can be any of those known in the art as appropriate for use as membranes in sensor devices and as having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes.
  • non-polyurethane type membranes examples include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials, and mixtures or combinations thereof.
  • a suitable hydrophilic polymer component as employed in certain embodiments is polyethylene oxide.
  • one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethylene oxide.
  • the polyethylene oxide portions of the copolymer are thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic polymer component.
  • the 20% polyethylene oxide-based soft segment portion of the copolymer used to form the final blend affects the water pick-up and subsequent glucose permeability of the membrane.
  • a lower ratio of oxygen-to-glucose is sufficient to provide excess oxygen by using a high oxygen solubility domain (for example, a silicone or fluorocarbon-based material or domain) to enhance the supply/transport of oxygen to the enzyme domain. If more oxygen is supplied to the enzyme, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess.
  • the resistance domain is formed from a silicone composition, such as is described in U.S. Patent Application Publication No. US-2005-0090607-A1.
  • an oxygen conduit for example, a high oxygen solubility domain formed from silicone or fluorochemicals
  • the oxygen conduit can be formed as a part of the coating (insulating) material or can be a separate conduit associated with the assembly of wires that forms the sensor.
  • the resistance domain deposited onto the enzyme domain yields a domain thickness of from about 0.05 microns or less to about 20 microns or more, or from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, or from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns.
  • the resistance domain can be deposited onto the enzyme domain using any of a variety of known deposition techniques, such as, but not limited to, vapor deposition, spray coating, or dip coating. In some embodiments, spray coating is desired. The spraying process atomizes and mists the solution, and therefore most or all of the solvent is evaporated prior to the coating material settling on the underlying domain, thereby minimizing contact of the solvent with the enzyme.
  • the sensor system comprises a plurality of sensor elements, each with different diffusion resistance domain properties, such that each sensor element is configured to control the flux of the analyte or a co-analyte differently than the other sensor elements.
  • each or some of the diffusion resistance domains of certain sensor element(s) can have sensitivities or current densities different from the other sensor elements, which allows for accuracy to be tuned or designed at low and high values, for example.
  • Differences in diffusion resistance domain properties can be achieved by modifying the diffusion resistance domain, e.g., by modifying the thickness or composition of the diffusion resistance domain.
  • membranes are configured to provide, to generate, or to consume hydrogen peroxide molecules, depending upon the relevant physiological range that the sensor is configured to measure. This arrangement, in turn provides for more accurate measurements.
  • Membranes configured to consume hydrogen peroxide molecules include superoxide dismutase, catalase, horseradish, and/or like compounds.
  • first and second membranes each comprise an enzyme (e.g., glucose oxidase) configured to generate hydrogen peroxide by reaction of glucose and oxygen with the enzyme, wherein the first and second sensor elements each comprise an electrode configured to measure at least some of the hydrogen peroxide generated within the first and second membranes.
  • the first membrane is configured to consume more hydrogen peroxide than the second membrane system, for example, by providing in one of the membranes a hydrogen peroxide-consuming enzyme configured to reduce exogenous hydrogen peroxide originating from a source outside the sensor.
  • any of a variety of systems and methods for consuming hydrogen peroxide in a membrane can alternatively or additionally be used.
  • the glucose-related to non-glucose-related signal ratio of one of the sensors element or its sensor sensitivity or current density can be adjusted (e.g., relative to the other sensor element).
  • one of the membranes is configured to direct more hydrogen peroxide to its associated electrode than the other membrane, which can be accomplished by a membrane configured to block at least some of the hydrogen peroxide from escaping from the sensor element, for example.
  • any of a variety of systems and methods for directing hydrogen peroxide in a membrane can alternatively or additionally be used.
  • the glucose-related to non-glucose-related signal ratio of one of the sensor element or its sensor sensitivity or current density can be adjusted (e.g., relative to the other sensor element).
  • sensor elements comprising the membrane system have been found to provide sustained function (at least 90% signal strength), even at low oxygen levels (for example, at about 0.6 mg/L O 2 ). While not wishing to be bound by theory, it is believed that the diffusion resistance domain provides sufficient diffusion resistivity, such that oxygen limitations of the sensor occur at a substantially lower oxygen concentration than with conventional sensors.
  • one or more of the sensor elements of a sensor system exhibits a 100 ⁇ 10% functionality, or about 100% functionality over physiological glucose concentrations (from about 40 mg/dL to about 400 mg/dL) at oxygen concentrations as low as about 0.6 mg/L or less, or about 0.3 mg/L or less, or about 0.25 mg/L or less, or about 0.15 mg/L or less, or about 0.1 mg/L or less, or about 0.05 mg/L or less.
  • the glucose sensors of some embodiments consume 1 ⁇ g or less of enzyme over their operational lifetimes (e.g., 7 days or less).
  • the sensors described herein of certain embodiments can include a biointerface membrane that encases the entire sensor or encases a portion of the sensor, to minimize migration or growth of host inflammatory cells, immune cells, or soluble factors to sensitive regions of the device.
  • the biointerface membrane promotes vascularization of the device and facilitates transport of solutes across the device-tissue interface to enhance the device's performance.
  • a sensor with a biointerface domain has an initial sleep period (e.g., the first few hours, days, or weeks after implant), during which the sensor does not provide accurate measurements, as vascularization of the sensor progresses.
  • initial sleep period e.g., the first few hours, days, or weeks after implant
  • Other embodiments of the biointerface are described in more detail in U.S. Patent Application Publication No. US-2007-0027370-A1.
  • the first and second biointerface membranes comprise three dimensional architectures that are different from each other.
  • the three dimensional architecture of the first biointerface membrane can comprise pores defined by a first range of sizes
  • the three dimensional architecture of the second biointerface membranes can comprise pores defined by a second range of sizes.
  • the first range of sizes e.g., less than about 20 microns
  • the second range of sizes e.g., greater than about 20 microns).
  • the three dimensional architecture of the first or second sensor element is porous while that of the other sensor element is nonporous.
  • Other embodiments of the three dimensional architecture are described in more detail in U.S. Patent Application Publication No. US-2005-0251083-A1.
  • FIG. 3 is a block diagram illustrating one embodiment of the sensor electronics 300 .
  • the ASIC 305 is coupled to a communication port 338 and a battery 334 .
  • the illustrated embodiment includes an Application Specific Integrated Circuit (ASIC) 305 that includes much of the electronic circuitry, in other embodiments, the ASIC 305 is replaced with one or more of any suitable logic device, such as, for example, field programmable gate arrays (FPGA), microprocessors, analog circuitry, or other digital or analog circuitry.
  • FPGA field programmable gate arrays
  • a potentiostat 310 is coupled to a glucose sensor in order to receive sensor data from the glucose sensor. Any of a variety of mechanisms can be used to couple the potentiostat 310 to the glucose sensor. For example, in one embodiment, the one or more ends of the working electrode(s) is exposed to provide electrical connection between the potentiostat and the first and second sensor elements. In one embodiment, the potentiostat 310 provides a voltage to the glucose sensor in order to bias the sensor to enable measurement of a current value indicative of the analyte concentration in the host (also referred to as the analog portion). The potentiostat can have one channel or multiple channels, depending on the number of working electrodes, for example.
  • the potentiostat 310 includes a resistor (not shown) that translates the current into voltage.
  • a current to frequency converter is provided that is configured to continuously integrate the measured current, for example, using a charge counting device.
  • an A/D converter digitizes the analog signal into “counts” for processing. Accordingly, the resulting raw data stream in counts is directly related to the current measured by the potentiostat 310 .
  • a processor module 314 is the central control unit that controls the processing of the sensor electronics.
  • the processor module 314 is formed as part of a custom chip, such as an ASIC, however a computer system other than an ASIC can be used to process data as described herein, for example a microprocessor can be used for some or all of the sensor electronics module processing.
  • the processor module 314 typically provides a program memory 316 , which provides semi-permanent storage of data, for example, storing data such as sensor identifier (ID) and programming to process data streams (for example, filtering, calibration, fail-safe checking, and the like).
  • the processor additionally can be used for the system's cache memory, for example for temporarily storing recent sensor data.
  • the processor module comprises memory storage components such as ROM, RAM, dynamic-RAM, static-RAM, non-static RAM, EEPROM, rewritable ROMs, flash memory, and the like.
  • RAM 318 can be used for the system's cache memory, for example for temporarily storing recent sensor data.
  • the processor module 314 comprises a digital filter, for example, an IIR or FIR filter, configured to smooth the raw data stream from the A/D converter.
  • digital filters are programmed to filter data sampled at a predetermined time interval (also referred to as a sample rate). In some embodiments, such as when the potentiostat 310 is configured to measure the analyte at discrete time intervals, these time intervals determine the sample rate of the digital filter.
  • the processor module 314 can be programmed to request a digital value from the integrator at a predetermined time interval, also referred to as the acquisition time.
  • the values obtained by the processor module 314 are advantageously averaged over the acquisition time due the continuity of the current measurement. Accordingly, the acquisition time determines the sample rate of the digital filter.
  • the processor module 314 is further configured to generate data packages for transmission to one or more display devices. Furthermore, the processor module 314 generates data packets for transmission to these outside sources, e.g., via telemetry.
  • the data packages can be customizable for each display device, for example, and may include any available data, such as displayable sensor information having customized sensor data or transformed sensor data, sensor/sensor electronics module ID code, raw data, filtered data, calibrated data, rate of change information, trend information, error detection or correction, or the like.
  • a data storage memory 320 is operably connected to the processor module 314 and is configured to store a variety of sensor information.
  • the data storage memory stores 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30 or more days of continuous analyte sensor data.
  • the data storage memory 220 stores sensor information such as raw sensor data (one or more raw analyte concentration values), transformed sensor data, or any other displayable sensor information.
  • the sensor electronics are configured to receive and store contact information in the data storage memory (or program memory), including a phone number or email address for the sensor's host or health care providers for the host (e.g., family member(s), nurse(s), doctor(s), or other health care provider(s)), which enables communication with a contact person (e.g., via phone, pager or text messaging in response to an alarm (e.g., a hypoglycemic alarm that has not been responded to by the host)).
  • user parameters can be programmed into (or modified in) the data storage memory (or program memory) of the sensor electronics module, via a display device such as a personal computer, personal digital assistant, or the like.
  • User parameters can include contact information, alert/alarms settings (e.g., thresholds, sounds, volume, or the like), calibration information, font size, display preferences, defaults (e.g., screens), or the like.
  • alert/alarms settings e.g., thresholds, sounds, volume, or the like
  • calibration information e.g., font size, display preferences, defaults (e.g., screens), or the like.
  • the sensor electronics module can be configured for direct programming of certain user parameters.
  • clinical data of a medical practitioner is uploaded to the sensor electronics and stored on the data storage memory 320 , for example.
  • information regarding the host's condition, treatments, medications, etc. can be stored on the sensor electronics and can be viewable by the host or other authorized user.
  • certain of the clinical data are included in a data package that is transmitted to a display device in response to triggering of an alert.
  • the clinical data can be uploaded to the sensor electronics via any available communication protocol, such as direct transmission via a wireless Bluetooth, infrared, or RF connection, or via a wired USB connection, for example.
  • the clinical data can be uploaded to the sensor electronics via indirect transmission, such as via one or more networks (e.g., local area, personal area, or wide area networks, or the Internet) or via a repeater device that receives the clinical data from a device of the medical practitioner and retransmits the clinical data to the sensor electronics module.
  • networks e.g., local area, personal area, or wide area networks, or the Internet
  • a repeater device that receives the clinical data from a device of the medical practitioner and retransmits the clinical data to the sensor electronics module.
  • any of a variety of configurations of separate data storage and program memories can be used, including one or multiple memories that provide the necessary storage space to support the sensor electronic data processing and storage requirements. Accordingly, the described location of storage of any particular information or programming is not meant to be limiting, but rather exemplary.
  • the sensor electronics is configured to perform smoothing or filtering algorithms on the sensor data (e.g., raw data stream or other sensor information), wherein the smoothed or filtered data is stored in the data storage memory as transformed data.
  • the sensor data e.g., raw data stream or other sensor information
  • the smoothed or filtered data is stored in the data storage memory as transformed data.
  • U.S. Patent Application Publication No. US-2005-0043598-A1 U.S. Patent Application Publication No. US-2007-0032706-A1
  • U.S. Patent Application Publication No. US-2007-0016381-A1 and U.S. Patent Application Publication No. US-2008-0033254-A1 describe some algorithms useful in performing data smoothing or filtering herein (including signal artifacts replacement).
  • the sensor electronics are configured to calibrate the sensor data, and the data storage memory 320 stores the calibrated sensor data points as transformed sensor data. In some further embodiments, the sensor electronics are configured to wirelessly receive calibration information from a display device, from which the sensor electronics module is configured to calibrate the sensor data.
  • U.S. Pat. No. 7,310,544 and U.S. Pat. No. 6,931,327 describe some algorithms useful in sensor calibration herein.
  • the sensor electronics are configured to perform additional algorithmic processing on the sensor data (e.g., raw data stream or other sensor information) and the data storage memory 320 is configured to store the transformed sensor data or sensor diagnostic information associated with the algorithms.
  • the data storage memory 320 is configured to store the transformed sensor data or sensor diagnostic information associated with the algorithms.
  • a user interface 322 can include any of a variety of interfaces, such as one or more buttons 324 , a liquid crystal display (LCD) 326 , a vibrator 328 , an audio transducer (e.g., speaker) 330 , backlight, or the like.
  • a backlight can be provided, for example, to aid the user in reading the LCD in low light conditions.
  • the components that comprise the user interface 322 provide controls to interact with the user (e.g., the host).
  • buttons 324 can allow, for example, toggle, menu selection, option selection, status selection, yes/no response to on-screen questions, a “turn off” function (e.g., for an alarm), a “snooze” function (e.g., for an alarm), a reset, or the like.
  • the LCD 326 can be provided, for example, to provide the user with visual data output.
  • the audio transducer 330 e.g., speaker
  • audible signals are differentiated by tone, volume, duty cycle, pattern, duration, or the like.
  • the audible signal is configured to be silenced (e.g., snoozed or turned off) by pressing one or more buttons 324 on the sensor electronics module or by signaling the sensor electronics module using a button or selection on a display device (e.g., key fob, cell phone, or the like).
  • a display device e.g., key fob, cell phone, or the like.
  • the audio transducer 330 is mounted to the circuit board or the sensor electronics module housing. In some embodiments, the sound produced by the audio transducer 330 exits the device from a sound port in the sensor electronics, such as a hole on the sensor electronics.
  • the hole may be waterproofed or otherwise protected from moisture by a waterproof material that easily allows sound waves there through.
  • the hole is protected from moisture by an acoustically transparent venting material (wherein the material allows at least about 60%, 70%, 80%, 90%, 95%, or more of the transmitted sound waves therethrough), such as a screw-in vent, a press-fit vent, a snap-in vent, an o-ring vent, and adhesive vent, or the like.
  • acoustically transparent venting material is W.L. Gore & Associates (Elkton, Md.) under the trade name Protective Vents (Acoustic Vents).
  • the vibrator 328 can include a motor that provides, for example, tactile signals or alerts for reasons such as described with reference to the audio transducer, above.
  • the vibrator motor 328 provides a signal in response to triggering of one or more alerts, which can be triggered by the processor module 314 that processes algorithms useful in determining whether alert conditions associated with one or more alerts have been met, for example, present or predicted hyper- and hypoglycemic conditions.
  • one or more different alerts are differentiated by intensity, quantity, pattern, duration, or the like.
  • the alarm is configured to be silenced (e.g., snoozed or turned off) by pressing one or more buttons 324 on the sensor electronics or by signaling the sensor electronics using a button or selection on a display device (e.g., key fob, cell phone, or the like).
  • a display device e.g., key fob, cell phone, or the like.
  • the vibrator motor 328 is mounted to the circuit board or the sensor electronics housing.
  • the diameter of the motor may be less than or equal to about 6 mm, 5 mm, 4 mm, 3.5 mm, 3 mm, 2.5 mm, or 2 mm.
  • the overall length of the vibrator motor may be less than or equal to about 18 mm, 16 mm, 14 mm, 12 mm, or 10 mm.
  • the vibrator motor 328 is used to provide a vibratory alarm that creates vibration or movement of the sensor within the host.
  • a concentration increase of non-analyte-signal-causing electroactive species can interfere with sensor function and cause noise observed during host start-up or sedentary periods.
  • local lymph pooling which can occur when a part of the body is compressed or when the body is inactive, can cause, in part, this local build up of interferents (e.g., electroactive metabolites).
  • a local accumulation of wound healing metabolic products likely causes noise on the sensor during the first few hours to days after sensor insertion. Accordingly, it is believed vibration or movement of the sensor at the insertion site, after sensor insertion, can reduce or eliminate pooling of local interfering species caused by the wound healing process described above.
  • the sensor is vibrated or moved at predetermined intervals or in response to noise artifacts detected on the sensor signal.
  • U.S. Patent Application Publication No. US-2005-0043598-A1 U.S. Patent Application Publication No. US-2007-0032706-A1
  • U.S. Patent Application Publication No. US-2007-0016381-A1 and U.S. Patent Application Publication No. US-2008-0033254-A1 describe systems and methods for detection of noise artifacts, noise episodes or classification of noise, which can be useful with the embodiments described herein.
  • the sensor electronics are configured to transmit sound waves into the host's body (e.g., abdomen or other body part) that are felt by the host, thereby alerting the host without calling attention to the host, or allowing a hearing-impaired visually-impaired, or tactilely-impaired host to be alerted.
  • the sound waves are transmitted into the host's body using the electrodes of the sensor itself.
  • one or more transcutaneous electrodes are provided for transmitting sound waves.
  • electrodes are provided in the adhesive patch that holds the sensor/sensor electronics module onto the host's body, which can be used to transmit the sound waves.
  • different sound waves are used to transmit different alarm conditions to the host.
  • the sound waves can be differentiated by any sound characteristic, such as but not limited to amplitude, frequency and pattern.
  • mild electric shock can be used to transmit one or more alarms to the host.
  • the level of shock can be designed such that the shock is not overly uncomfortable to the host; however, the intensity of the level of shock can be configured to increase when a host does not respond to (e.g., snooze or turn off) an alert within an amount of time.
  • the shock is delivered to the host's body using the electrodes of the sensor itself.
  • the sensor system includes one or more additional electrodes configured for delivering the shock to the host (alone or in combination with the electrodes related to analyte measurement).
  • the one or more electrodes are disposed on the host's skin, such as in the adhesive patch, for delivering the shock.
  • one or more additional patches, each including an electrode are provided, for delivering the shock. The additional patches can be in wired or wireless communication with the sensor electronics module.
  • a telemetry module 332 is operably connected to the processor module 314 and provides the hardware, firmware, and/or software that enable wireless communication between the sensor electronics and one or more display devices.
  • wireless communication technologies that can be implemented in the telemetry module 332 include radio frequency (RF), infrared (IR), Bluetooth, spread spectrum communication, frequency hopping communication, ZigBee, IEEE 802.11/802.16, wireless (e.g., cellular) telecommunication, paging network communication, magnetic induction, satellite data communication, GPRS, ANT, or the like.
  • the telemetry module comprises a Bluetooth chip.
  • Bluetooth technology is implemented in a combination of the telemetry module 332 and the processor module 314 .
  • a battery 334 is operatively connected to the processor module 314 (and possibly other components of the sensor electronics) and provides the necessary power for the sensor electronics.
  • the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used (e.g., AAA, Nickel-cadmium, Zinc-carbon, Alkaline, Lithium, Nickel-metal hydride, Lithium-ion, Zinc-air, Zinc-mercury oxide, Silver-zinc, or hermetically-sealed).
  • the battery is rechargeable.
  • a plurality of batteries is used to power the system.
  • the receiver is transcutaneously powered via an inductive coupling, for example.
  • a battery charger or regulator 336 can be configured to receive energy from an internal or external charger.
  • a battery regulator (or balancer) 336 regulates the recharging process by bleeding off excess charge current to allow all cells or batteries in the sensor electronics module to be fully charged without overcharging other cells or batteries.
  • the battery 334 (or batteries) is configured to be charged via an inductive or wireless charging pad. Any of a variety of known methods of charging batteries can be employed, which can be implemented with the system described herein, including wired (cable/plug) and wireless methods.
  • One or more communication ports 338 can be provided to allow communication with other devices, for example a PC communication (com) port can be provided to enable communication with systems that are separate from, or integral with, the sensor electronics module.
  • the communication port for example, can comprise a serial (e.g., universal serial bus or “USB”) communication port, allows for communicating with another computer system (e.g., PC, personal digital assistant or “PDA,” server, or the like).
  • the sensor electronics is able to transmit historical data to a PC or other computing device for retrospective analysis by a patient or physician.
  • the processor module of the sensor electronics and/or another computer system is configured to execute prospective algorithms used to generate transformed sensor data or displayable sensor information, including, for example, algorithms that: evaluate a clinical acceptability of reference or sensor data, evaluate calibration data for best calibration based on inclusion criteria, evaluate a quality of the calibration, compare estimated analyte values with time corresponding measured analyte values, analyze a variation of estimated analyte values, evaluate a stability of the sensor or sensor data, detect signal artifacts (noise), replace signal artifacts, determine a rate of change or trend of the sensor data, perform dynamic and intelligent analyte value estimation, perform diagnostics on the sensor or sensor data, set modes of operation, evaluate the data for aberrancies, or the like, which are described in more detail in U.S.
  • the sensor electronics can be configured to store the transformed sensor data (e.g., values, trend information) and to communicate the displayable sensor information to a plurality of different display devices.
  • the display devices are “dummy” devices, namely, they are configured to display the displayable sensor information as received from the sensor electronics, without any additional sensor data processing.
  • the sensor electronics is operatively connected to at least one sensor element configured to measure an analyte concentration in a first predetermined range and a second sensor element configured to measure an analyte concentration in a second predetermined range.
  • the first range is for the most part different from the second range.
  • the first range can be used to measures glucose concentration values from about 0 mg/dL to about 100 mg/dL and the second range can be used to measure glucose concentration values from about 80 mg/dL to about 400 mg/dL.
  • continuous glucose sensors A variety of conventional continuous glucose sensors have been developed for detecting and quantifying glucose concentration in a host. These sensors typically require one or more blood glucose measurements, or the like, from which calibration of the continuous glucose sensor is performed to calculate the relationship between the current output of the sensor and blood glucose measurements, so that meaningful glucose concentration values can be accurately calculated and communicated to a patient or doctor.
  • continuous glucose sensors can be sensitive to changes in the baseline current or sensitivity over time, for example, due to changes in a host's metabolism, maturation of the tissue at the biointerface of the sensor, presence of interfering species which cause a measurable increase or decrease in the signal, or the like. Therefore, in addition to initial calibration, continuous glucose sensors may be responsive to baseline or sensitivity changes over time.
  • recalibration of the sensor may be required periodically. Consequently, users of conventional continuous glucose sensors may be required to obtain numerous blood glucose measurements daily or weekly, in order to maintain accurate calibration of the sensor over time.
  • Some of the embodiments provide improved calibration techniques that utilize calibration and matched data points of one sensor element to further calibrate the second sensor element.
  • a known reference value can be used to calibrate a plurality of sensor elements accurately.
  • FIG. 4 is a flowchart 400 illustrating calibration and output of sensor data, in one embodiment.
  • Some of the embodiments provide a method for processing data from a sensor system configured for measurement of an analyte concentration in a host, where the sensor system includes a plurality of sensor elements, each or some of which measure different ranges of analyte concentration within the host and/or different time periods of implantation with a predetermined level of accuracy.
  • the processor module receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from one or more of the plurality of sensor elements, each or some of which can be in wired or wireless communication with the sensor.
  • sensor data e.g., a data stream
  • the sensor system has two or more sensors elements configured and arranged to provide values in different analyte concentration ranges
  • the sensor data from the two or more sensor elements is received substantially simultaneously, such as within the same or serially received data transmissions.
  • sensor data from each of the sensor elements is received serially, for example.
  • the processor module calibrates the first and/or second sensor elements.
  • calibrating the first sensor element includes processing an external reference value and/or one or more values provided by a manufacturer.
  • the user can administer a self-monitored blood analyte test to obtain an analyte value (e.g., a point) using any suitable analyte sensor, and then enter the numeric analyte value into the computer system.
  • analyte value e.g., a point
  • the two sensor elements when the received sensor data is within an overlapping range of the predetermined measurement range of two sensor elements, the two sensor elements can be calibrated with the same calibration information. In some of these embodiments, a first sensor element is calibrated first, and then one or more calibrated sensor values from the first sensor element are then used to calibrate a second and/or another sensor element.
  • a known relationship is defined between the first and second sensor elements, for example a relationship between the sensitivities or current densities of the first and second sensor elements, which is determined from prior in vitro and/or in vivo data.
  • the known relationship which is defined by a function, is then used to calibrate the second sensor element.
  • sensor data from one sensor element is used to calibrate the other sensor element during an overlapping time period of use.
  • an output module provides output to the user via the user interface, for example.
  • the output is associated with one or more measured analyte values, which are determined by converting the received sensor data into calibrated sensor data.
  • User output can be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example.
  • Other representations of the estimated analyte values such as audio or tactile representations, for example, are also possible.
  • the processor module or output module is configured to output data, by using calibrated sensor data obtained from the particular sensor element associated with the range within which the measurement falls within.
  • sensor data from one sensor element including one or more calibrated sensor values, can be used to calibrate another sensor element, and so forth.
  • some analyte sensors can have an initial instability time period during which it is unstable for environmental, physiological, or other reasons.
  • its stabilization can be dependent upon the maturity of the tissue ingrowth around and within the sensor element (see, e.g., U.S. Patent Application Publication No. US-2005-0112169-A1).
  • determination of sensor stability may involve waiting a first time period.
  • wholly implantable sensors typically require a time period to allow for sufficient tissue ingrowth, and transdermal (e.g., transcutaneous) sensors are believed to typically have an initial period of noise due in part to wound healing within the host's tissue.
  • the waiting period may last from about one minute to about three weeks.
  • the waiting period can be determined by pretesting the sensor under similar conditions, or by analysis of the sensor data establishing that the sensor is stable.
  • the second sensor element is configured to measure the analyte concentration and provide data during the first time period. Once the first sensor element is deemed stable, data from the first sensor element may still require calibration, in order for it to provide accurate values.
  • data from the second sensor element in which sensor data from the second sensor element exhibits a correlative or predictive relationship with sensor data from the first sensor element, data from the second sensor element can be used to calibrate data from the first sensor element.
  • Calibration of sensor data from the first sensor element using sensor data provided by the second sensor element can facilitate the use of the first sensor element data sooner and may reduce or even obviate the need to calibrate the first sensor element with single point calibration techniques, e.g., fingerstick tests, optical measuring techniques, etc.
  • the sensor system comprises a plurality of sensor elements, each configured to measure values in various ranges.
  • each sensor element of the sensor system can be “tuned” to a particular range, this arrangement does not preclude each sensor element from measuring analyte values across a physiologically relevant range, and thereby providing valuable information.
  • error correction comprising error checking is used.
  • error checking can comprise checking for data integrity by comparing sensor data from two or more sensor elements.
  • FIG. 5 is a flowchart 500 that illustrates measuring and processing of sensor data, in one embodiment.
  • the processor module receives sensor data (e.g., a data stream) including one or more time-spaced sensor data points, from one or more of the plurality of sensor elements, which can be in wired or wireless communication with the sensor, such as described in more detail elsewhere herein.
  • the processor module is configured to evaluate sensor data from one or more of the plurality of sensor elements.
  • the processor module evaluates the sensor data by polling sensor data from the one or more of the plurality of sensor elements. It is contemplated that a wide range of polling intervals are possible, which can be chosen with consideration of processing power and accuracy. For example, polling can occur about every 1 second, 10 seconds, 1 minute, 5 minutes, or any other interval suitable for the application contemplated.
  • the processor module compares sensor data from a plurality of sensor elements. For example, the amplitudes of a first sensor element data (i.e., sensor data from a first sensor element) is compared to amplitudes of a second sensor element data (i.e., sensor data from a second sensor element). Accordingly, the sensor system can provide highly accurate measurement of analyte concentration by comparing the plurality of sensor element measurements.
  • the processor module averages and/or integrates the sensor data from a plurality of sensor elements.
  • the processor module may also accord the data generated by each of the plurality of sensor elements with a different weight.
  • a weighted arithmetic average can be used to estimate analyte concentration and be calculated by the equation:
  • x i is the analyte concentration measurement from a particular sensor element
  • x is the mean analyte concentration to be estimated
  • n is the number of sensor elements
  • w i is the weight accorded to the analyte concentration measurement from that particular sensor element.
  • weighted means e.g., a weighted geometric mean or a weighted harmonic mean
  • a weighted sum is used.
  • a weighted sum may be calculated by the equation:
  • the sensor system processes data by taking first sensor element data and second sensor element data and weighting both about equally to obtain values in the overlapping ranges of the first and second sensor elements.
  • Other examples include taking data from one sensor element and weighting it more heavily than data from another sensor element (e.g., taking 80% of a first sensor element data and 20% of a second sensor element data to obtain values in the first data range).
  • the sensor system comprises two sensor elements, with a first sensor element tuned to a glucose concentration of about 30 mg/dL to about 100 mg/dL and a second sensor element tuned to a glucose concentration of about 80 mg/dL to about 500 mg/dL.
  • the first and second sensor elements generate first and second signals, respectively.
  • the first signal and the second signal may be averaged or integrated to generate an estimate of a glucose concentration value.
  • the weights accorded to the first signal and the second signal may depend on an initial glucose concentration value estimation.
  • the sensor electronics may be programmed to instruct the processor to accord more weight to the first sensor element, and less weight (or no weight) accorded to the second sensor element.
  • the processor may be instructed to accord more weigh the second sensor element, and less weight (or no weight) to the first sensor element.
  • the distribution of weights among the different sensor elements may be a function of a parameter other than an analyte glucose concentration value.
  • the distribution of weights may be a function of any parameter (e.g., a parameter that affects measurement accuracy) or plurality of variables including, but not limited to, initial analyte concentration measurement, body temperature, oxygen concentration in host, presence of interferents, time since initiation of the sensor session, and combinations thereof.
  • the weight distribution among the different sensor elements may be based at least in part on an estimated value of the parameter and the estimated value's proximity to the different ranges associated with the parameters.
  • an oxygen concentration estimation of 0.5 mg/L may result in the processor module according most weight to the third sensor element, less (or no) weight to the second sensor element, and even less (or no) weight to the first sensor element.
  • At least two of the plurality of sensor elements may be configured (e.g., by membrane design) to have substantially the same baseline, but with different sensor sensitivities.
  • subtraction of one signal from the other signal with the same baseline can result in an additional signal that is substantially free from noise contribution (e.g., from interferents), because the noise component is subtracted out.
  • Having an extra signal can be advantageous as it provides another basis for comparison. Also, it can provide for improved polling of sensor data.
  • this extra signal includes substantially no noise contribution, it has a very high signal to noise ratio, and thus can provide high analyte concentration measurement accuracy.
  • the data provided by one sensor element signal is used during intervals of time when another sensor element is unable to obtain accurate measurements. For example, if a first sensor element is unable to obtain accurate data, during an interval of 5 minutes due to noise or other causes, data values from a second sensor element are used to fill in values for that particular 5-minute interval.
  • the values calculated are based completely on the second sensor element, but in other embodiments, the values are calculated by weighting data from both sensor elements. The weight accorded to the second sensor element versus the first sensor element can be dependent on the accuracy of the two sensor elements.
  • the weight percentage accorded to data provided by the first sensor element can be, e.g., about 0.9 and that of the second sensor element can be, e.g., about 0.1.
  • both sensor elements can be accorded about equal weight percentages.
  • This weight distribution mechanism of data from a plurality of different sensor elements can reduce noise, thereby providing smoother and more accurate data. Evaluations that can be provided by the processor module include, for example, error correction, supplementation of sensor data, weighting of various sensors' data, and the like. It is contemplated that a wide range of weighted averages are possible.
  • the processor module is configured to evaluate sensor data from a plurality of sensor elements by evaluating an accuracy of the one or more sensor data using known statistical and/or clinical evaluation methods. In some embodiments, the processor module evaluates accuracy of sensor data by comparing different levels of accuracy (e.g., reference data points within the overlapping portion of the first and second ranges of first and second sensor elements). In some embodiments, evaluating accuracy includes evaluating noise (e.g., analyte-related to non-analyte-related signal ratios of sensor data from two or more sensor elements). In some embodiments, the processor module evaluates the sensor data in order to validate one or more of the plurality of sensor elements and/or associated sensor data.
  • the processor module evaluates the sensor data in order to validate one or more of the plurality of sensor elements and/or associated sensor data.
  • an output module provides output to the user via the user interface, for example.
  • User output can be in the form of any of the variety of representations described elsewhere herein, such as the representations described in regard to step 406 .
  • FIG. 6A is a flowchart summarizing the steps of one embodiment for manufacturing a working electrode, such as the one illustrated in FIG. 1A , which comprises a plurality of sensor elements, each configured to measure analyte concentration in a range (e.g., analyte concentration range, time period range during a sensor session, etc.) different from that of the other sensor element(s).
  • a working electrode comprising a plurality of discrete electroactive surface sections is provided, with each section spaced apart from the other(s) along the longitudinal axis of the working electrode.
  • membranes are applied onto the plurality of electroactive surface sections by a dip coating process, whereby the thicknesses of the membranes are controlled by controlling the number of times a coating solution is applied to the electroactive surface sections. Control of membrane thicknesses in turn permits control of certain membrane properties (e.g., sensitivity, current density, permeability).
  • the working electrode is dipped into the coating solution at different depths. Because the plurality of electroactive surface sections are spaced apart along the longitudinal axis of the working electrode, by controlling the depth at which the working electrode is dipped into the coating solution, control can be obtained over whether a particular electroactive surface section is coated during a dipping sequence, or how thick the resulting coating is over a particular electroactive surface.
  • the entire working electrode is dipped five times into the coating solution, so that every electroactive surface section of the working electrode at that time is deposited with a membrane thickness associated with five dips.
  • one or more of the electroactive surface sections e.g., the one closest to the distal end of the working electrode
  • the coating solution an additional three times, thereby forming in that particular electroactive surface section a membrane with a thickness associated with a total of eight dips.
  • one or more sensor elements are formed with a thickness associated with five dips, while the other sensor element(s) are formed with a thickness associated with eight dips.
  • a first electroactive surface section associated with a first sensor element is dipped into the coating solution for a total of three times to achieve a first thickness
  • a second electroactive surface section associated with a second sensor element is dipped into the coating solution for a total of five times to achieve a second thickness
  • a third electroactive surface section associated with a third sensor element is dipped into the coating solution for a total of seven times to achieve a third thickness.
  • a single coating solution formulation can be used to form the different membranes.
  • different coating solution formulations are used to form different membranes.
  • a plurality of working electrodes are provided, with each working electrode comprising at least one electroactive surface section.
  • each working electrode is coated with a different coating solution, resulting in a plurality of working electrodes, with each comprising at least one sensor element with membrane properties different from that of the other sensor element(s) of other working electrode(s).
  • the plurality of working electrodes are fastened together to form a sensor system, such as the one illustrated in FIG. 1B , which comprises a plurality of working electrodes, with each comprising at least one sensor element.
  • a sensor system such as the one illustrated in FIG. 1B , which comprises a plurality of working electrodes, with each comprising at least one sensor element.
  • the method described above is not limited to the manufacturing of a sensor system comprising two working electrodes, with each comprising one sensor element, as illustrated in FIG. 1B .
  • the same concept can be applied to sensor systems comprising three, four, or more working electrodes, with each comprising one, two, three, four, five, or more sensor elements. Additional methods for manufacturing the sensors and membranes described herein are described in Provisional Application No. 61/222,815, filed Jul. 2, 2009 and U.S. patent application Ser. No. ______, filed Jul. 1, 2010, entitled “ANALYTE SENSORS AND METHOD OF MAKING SAME,” each of which is incorporated by reference herein in its entirety
  • a sensor system can be formed to comprise three working electrodes, with each working electrode comprising two sensor elements.
  • the three working electrodes are each coated with a different coating solution formulation, with each working electrode comprising sensor elements with different membrane thicknesses.
  • differences in membrane properties between different sensor elements are achieved by subjecting different sensor elements to different curing processes or conditions.
  • two electroactive surface sections are coated with one coating solution comprising a polymer system to form a first and a second sensor element. Thereafter, the first sensor element is subjected to high energy UV light for a certain period of time, while the second sensor element is subjected to the same UV light for a different period of time.
  • the crosslink densities of the first and second sensor elements are different, thereby resulting in membranes with different sensitivities and current densities.
  • differentiation of membrane properties is achieved by subjecting the sensor elements to other process condition variations, such as differences in radiation (e.g., different wavelengths of light) or differences in temperature, for example.
  • selective photolithography is used to achieve different sensitivities or current densities, for example, by selectively masking certain membranes associated with certain sensor elements during at least a portion of the photolithographic procedure.
  • a crosslinker is applied to the base polymer (e.g., polyurethane) to create different crosslink densities.
  • a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise.
  • a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.

Abstract

Devices and methods are provided for continuous measurement of an analyte concentration. The device can include a sensor having a plurality of sensor elements, each having at least one characteristic that is different from other sensor(s) of the device. In some embodiments, the plurality of sensor elements are each tuned to measure a different range of analyte concentration, thereby providing the device with the capability of achieving a substantially consistent level of measurement accuracy across a physiologically relevant range. In other embodiments, the device includes a plurality of sensor elements each tuned to measure during different time periods after insertion or implantation, thereby providing the sensor with the capability to continuously and accurately measure analyte concentrations across a wide range of time periods. For example, a sensor system 180 is provided having a first working electrode 150 comprising a first sensor element 102 and a second working electrode 160 comprising a second sensor element 104, and a reference electrode 108 for providing a reference value for measuring the working electrode potential of the sensor elements 102, 104.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Provisional Application No. 61/222,716 filed Jul. 2, 2009, U.S. Provisional Application No. 61/222,815 filed Jul. 2, 2009, and U.S. Provisional Application No. 61/222,751 filed Jul. 2, 2009, the disclosures of which are hereby expressly incorporated by reference in their entirety and are hereby expressly made a portion of this application.
  • FIELD OF THE INVENTION
  • The embodiments described herein relate generally to devices, systems, and methods for measuring an analyte in a host.
  • BACKGROUND OF THE INVENTION
  • Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events. A variety of intravascular, transcutaneous and implantable sensors have been developed for continuously detecting and quantifying blood glucose values. Many conventional implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate sensing of blood glucose. Additionally, many conventional transcutaneous and intravascular sensors have problems in accurately sensing and reporting back analyte values continuously over extended periods of time due to non-analyte-related signals caused by interfering species or unknown noise-causing events.
  • SUMMARY OF THE INVENTION
  • In a first aspect, a sensor system for measurement of an analyte concentration in a host is provided, the sensor system comprising: a first sensor element configured to measure an analyte concentration in a host over a first range of analyte concentrations; and a second sensor element configured to measure analyte concentration in the host over a second range of analyte concentrations, wherein the first range of analyte concentrations and the second range of analyte concentrations are different.
  • In an embodiment of the first aspect, the first range of analyte concentrations and the second range of analyte concentrations are both within a physiologically relevant range.
  • In an embodiment of the first aspect, the first range of analyte concentrations and the second range of analyte concentrations each comprise only a portion of the physiologically relevant range.
  • In an embodiment of the first aspect, the first range of analyte concentrations and the second range of analyte concentrations overlap partially, but not completely.
  • In an embodiment of the first aspect, the analyte is glucose, and wherein the first range of analyte concentrations is from about 30 mg/dL to about 120 mg/dL and the second range of analyte concentrations is from about 80 mg/dL to about 400 mg/dL.
  • In an embodiment of the first aspect, a lowest value of the second range of analyte concentrations is greater than a lowest value of the first range of analyte concentrations.
  • In an embodiment of the first aspect, the first sensor element and the second sensor element have different sensitivities.
  • In an embodiment of the first aspect, the sensitivity of the first sensor element is greater than the sensitivity of the second sensor element.
  • In an embodiment of the first aspect, the analyte is glucose, and wherein the first sensor element has a sensitivity of from about 1 pA/mg/dL to about 100 pA/mg/dL.
  • In an embodiment of the first aspect, the analyte is glucose, and wherein the second sensor element has a sensitivity of from about 20 pA/mg/dL to about 300 pA/mg/dL.
  • In an embodiment of the first aspect, the first sensor element and the second sensor element have different current densities.
  • In an embodiment of the first aspect, the analyte is glucose, and wherein the first sensor element has a current density of from about 3 pA/mg/dL/mm2 to about 325 pA/mg/dL/mm2.
  • In an embodiment of the first aspect, the analyte is glucose, and wherein the second sensor element has a current density of from about 65 pA/mg/dL/mm2 to about 1,000 pA/mg/dL/mm2.
  • In an embodiment of the first aspect, a lowest value of the first range of analyte concentrations is less than a lowest value of the second range of analyte concentrations.
  • In an embodiment of the first aspect, the first sensor element and the second sensor element have different analyte-related to non-analyte-related signal ratios.
  • In an embodiment of the first aspect, the analyte-related to non-analyte-related signal ratio of the first sensor element is greater than the analyte-related to non-analyte-related signal ratio of the second sensor element.
  • In an embodiment of the first aspect, the analyte is glucose, and wherein the sensor system is capable of achieving an accuracy of analyte concentration measurements wherein the measurements are within +/−20% of a true analyte concentration value 80% of the time during a time period greater than about 7 days.
  • In an embodiment of the first aspect, the first sensor element comprises a first membrane and the second sensor element comprises a second membrane, wherein the first membrane is different from the second membrane
  • In an embodiment of the first aspect, the first membrane and the second membrane have different membrane properties.
  • In an embodiment of the first aspect, the first membrane comprises a resistance domain different from a resistance domain of the second membrane.
  • In an embodiment of the first aspect, the first membrane comprises an interference domain different from an interference domain of the second membrane.
  • In an embodiment of the first aspect, the first membrane and the second membrane have a different number of domains.
  • In an embodiment of the first aspect, the first membrane and the second membrane each comprise glucose oxidase configured to generate hydrogen peroxide by reaction of glucose and oxygen with the glucose oxidase, wherein the first sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the first membrane, and wherein the second sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the second membrane.
  • In an embodiment of the first aspect, the first membrane is configured to consume more hydrogen peroxide than the second membrane.
  • In an embodiment of the first aspect, the first membrane is configured to direct more hydrogen peroxide to the first electrode than the second membrane system directs to the second electrode.
  • In an embodiment of the first aspect, at least one membrane selected from the group consisting of the first membrane and the second membrane is configured to recycle and/or reuse the hydrogen peroxide for a purpose other than for measurement.
  • In an embodiment of the first aspect, wherein the sensor system further comprises sensor electronics operably connected to the first sensor element and the second sensor elements wherein the sensor electronics comprise at least one potentiostat.
  • In an embodiment of the first aspect, the at least one potentiostat is configured to apply a first bias potential to the first sensor element and a second bias potential to the second sensor element, wherein the first bias potential is different from the second bias potential.
  • In an embodiment of the first aspect, the first bias potential is less than the second bias potential.
  • In an embodiment of the first aspect, a highest concentration of the first range of analyte concentrations is less than the lowest concentration of the second range of analyte concentrations.
  • In an embodiment of the first aspect, the sensor system is configured for implantation wholly in a tissue of a host.
  • In an embodiment of the first aspect, the sensor system is configured for transcutaneous placement through a skin of a host.
  • In an embodiment of the first aspect, the sensor system is configured for non-invasive measurement through a skin of a host.
  • In an embodiment of the first aspect, the sensor system is configured for fluid communication with a vascular system of a host.
  • In an embodiment of the first aspect, the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In a second aspect, a sensor system for measurement of an analyte concentration in a host is provided, the sensor system comprising: a first sensor element configured to measure analyte concentrations over a first range at a first current density; and a second sensor element configured to measure analyte concentrations over a second range at a second current density, wherein the first current density and the second current density are different.
  • In an embodiment of the second aspect, the first current density is greater than the second current density.
  • In an embodiment of the second aspect, the highest concentration of the first range is less than the lowest concentration of the second range.
  • In an embodiment of the second aspect, the analyte is glucose, and wherein the first sensor element has a sensitivity of from about 1 pA/mg/dL to about 100 pA/mg/dL.
  • In an embodiment of the second aspect, the analyte is glucose, and wherein the second sensor element has a sensitivity of from about 20 pA/mg/dL to about 300 pA/mg/dL.
  • In an embodiment of the second aspect, the analyte is glucose, and wherein the first second element has a current density of from about 3 pA/mg/dL/mm2 to about 325 pA/mg/dL/mm2
  • In an embodiment of the second aspect, the analyte is glucose, and wherein the second sensor element has a current density of from about 65 pA/mg/dL/mm2 to about 1,000 pA/mg/dL/mm2.
  • In an embodiment of the second aspect, the system is configured to measure at least one of a current selected from the group consisting of a current produced by the first sensor element and a current produced by the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In a third aspect, a sensor system for measurement of an analyte concentration in a host is provided, the sensor system comprising: a plurality of sensor elements, each wherein each sensor element is configured for measurement over a different range of analyte concentrations, wherein the plurality of sensor elements comprise: a first sensor element comprising a first membrane; and a second sensor element comprising a second membrane; wherein the first sensor membrane and the second sensor membrane have different membrane properties.
  • In an embodiment of the third aspect, the first membrane comprises a resistance domain different from a resistance domain of the second membrane.
  • In an embodiment of the third aspect, the first membrane comprises an interference domain different from an interference domain of the second membrane.
  • In an embodiment of the third aspect, a number of domains of the first membrane and a number of domains of the second membrane are different.
  • In an embodiment of the third aspect, the first membrane and the second membrane each comprise glucose oxidase configured to generate hydrogen peroxide by reaction of glucose and oxygen with the glucose oxidase, wherein the first sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the first membrane, and wherein the second sensor element comprises an electrode configured to measure at least some of the hydrogen peroxide generated within the second membrane.
  • In an embodiment of the third aspect, the first membrane is configured to consume more hydrogen peroxide than the second membrane.
  • In an embodiment of the third aspect, the first membrane is configured to direct more hydrogen peroxide to the first electrode than the second membrane directs to the second electrode.
  • In an embodiment of the third aspect, at least one membrane selected from the group consisting of the first membrane and the second membrane is configured to recycle and/or reuse the hydrogen peroxide for a purpose other than for measurement.
  • In an embodiment of the third aspect, the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In a fourth aspect, a sensor system for measurement of an analyte concentration in a host is provided, the sensor system comprising: a plurality of sensor elements, each configured to measure analyte concentrations over different time periods of in vivo implantation, wherein the plurality of sensor elements comprises a first sensor element configured to measure analyte concentrations over a first time period of in vivo implantation and a second sensor element configured to measure analyte concentrations over a second time period of in vivo implantation.
  • In an embodiment of the fourth aspect, the first time period is during an initial period of in vivo implantation, wherein the second time period is during a second time period of in vivo implantation, and wherein the second period begins after the initial period has begun.
  • In an embodiment of the fourth aspect, the first time period and the second time period overlap partially, but not completely.
  • In an embodiment of the fourth aspect, the first time period is from about day 1 post-implantation to about day 3 post-implantation and the second time period is from about day 2 post-implantation to about day 10 post-implantation.
  • In an embodiment of the fourth aspect, the first time period is from about day 1 post-implantation to about day 21 post-implantation and the second time period is from about day 10 post-implantation to about year 1 post-implantation.
  • In an embodiment of the fourth aspect, the first sensor element comprises a first biointerface membrane and the second sensor element comprises a second biointerface membrane, and wherein the first biointerface membrane has at least one property different from that of the second biointerface membrane.
  • In an embodiment of the fourth aspect, the first biointerface membrane comprises a three dimensional architecture.
  • In an embodiment of the fourth aspect, the second biointerface membrane comprises a three dimensional architecture that is different from the three dimensional architecture of the first biointerface membrane.
  • In an embodiment of the fourth aspect, the three dimensional architecture of the first biointerface membrane comprises pores within a first range of sizes and the three dimensional architecture of the second biointerface membranes comprises pores within a second range of sizes, wherein the largest size of the first range of sizes is smaller than the smallest size of the second range of sizes.
  • In an embodiment of the fourth aspect, the sensor system is configured for implantation wholly in a tissue of a host.
  • In an embodiment of the fourth aspect, the sensor system is configured for transcutaneous placement through a skin of a host.
  • In an embodiment of the fourth aspect, the sensor system is configured for fluid communication with a vascular system of a host.
  • In an embodiment of the fourth aspect, the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In a fifth aspect, a method for processing data from a sensor system configured for measurement of an analyte concentration in a host is provided, the method comprising: calibrating a first sensor element, wherein the first sensor element is configured to measure an analyte concentration within a first range of analyte concentrations; and calibrating a second sensor element, wherein the second sensor element is configured to measure an analyte concentration within a second range of analyte concentrations, wherein the second range is different from the first range.
  • In an embodiment of the fifth aspect, calibrating the first sensor element comprises receiving an external reference value.
  • In an embodiment of the fifth aspect, calibrating the first sensor element comprises receiving a calibration value provided by a manufacturer.
  • In an embodiment of the fifth aspect, calibrating the first sensor element comprises performing a first algorithm.
  • In an embodiment of the fifth aspect, calibrating the first sensor element further comprises performing a second algorithm, and wherein the second algorithm is different from the first algorithm.
  • In an embodiment of the fifth aspect, the first range and second range partially, but not completely, overlap within an overlapping range.
  • In an embodiment of the fifth aspect, calibrating the first sensor element comprises receiving an external reference value within the overlapping range.
  • In an embodiment of the fifth aspect, calibrating the second sensor element comprises receiving a value obtained from the first sensor element.
  • In an embodiment of the fifth aspect, the first sensor element and the second sensor element each have different current densities, and wherein calibrating the second sensor element utilizes a known relationship between the current density of the first sensor element and the current density of the second sensor elements.
  • In an embodiment of the fifth aspect, the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In a sixth aspect, a method for processing data from a sensor system configured for measurement of an analyte concentration in a host is provided, the method comprising: processing a first signal from a first sensor element, wherein the first sensor element is configured to measure an analyte concentration in a first range, and wherein the first signal is associated with the analyte concentration; and processing a second signal from a second sensor element, wherein the second sensor element is configured to measure an analyte concentration in a second range, wherein the second signal is associated with the analyte concentration, and wherein the first range is different from the second range.
  • In an embodiment of the sixth aspect, at least one of processing the first signal or processing the second signal comprises comparing the first signal to the second signal.
  • In an embodiment of the sixth aspect, at least one of processing the first signal or processing the second signal comprises averaging and/or integrating the first signal to the second signal.
  • In an embodiment of the sixth aspect, at least one of processing the first signal or processing the second signal comprises polling the first signal to the second signal.
  • In an embodiment of the sixth aspect, at least one of processing the first signal or processing the second signal comprises evaluating an accuracy of the first signal.
  • In an embodiment of the sixth aspect, the method further comprises: calibrating the first signal to generate a first calibrated signal; and calibrating the second signal to generate a second calibrated signal.
  • In an embodiment of the sixth aspect, at least one of processing the first signal or processing the second signal comprises evaluating an accuracy of the first calibrated signal and an accuracy of the second calibrated signal.
  • In an embodiment of the sixth aspect, the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In a seventh aspect, a method for manufacturing a sensor system configured for measurement of an analyte concentration in a host, the method comprising: manufacturing a first sensor element configured to measure an analyte concentration in a first range; and manufacturing a second sensor element configured to measure an analyte concentration in a second range, wherein the second range is different from the first range.
  • In an embodiment of the seventh aspect, manufacturing the first sensor element comprises forming a first electrode, and wherein manufacturing the second sensor element comprises forming a second electrode.
  • In an embodiment of the seventh aspect, manufacturing the first sensor element further comprises forming a first membrane on the first electrode, and wherein manufacturing the second sensor element further comprises forming a second membrane on the second electrode.
  • In an embodiment of the seventh aspect, the first membrane is configured to provide a first current density and the second membrane is configured to provide a second current density, and wherein the first current density is different from the second current density.
  • In an embodiment of the seventh aspect, forming the first membrane and forming the second membrane comprise optically curing the first membrane and the second membrane so as to provide a different sensitivity for the first membrane and the second membrane.
  • In an embodiment of the seventh aspect, optically curing the first membrane and the second membrane comprise using selective photolithography so as to provide a different current density for the first membrane and the second membrane.
  • In an embodiment of the seventh aspect, using selective photolithography comprises masking the first membrane during at least a portion of the photolithographic exposure of the second membrane.
  • In an embodiment of the seventh aspect, curing the first membrane and the second membrane comprises at least one method selected from the group consisting of drop coating, masking for spray coating, and dip coating to multiple depths.
  • In an embodiment of the seventh aspect, the system is configured to measure a current produced by at least one of the first sensor element or the second sensor element with substantial linearity at glucose concentrations of up to about 400 mg/dL in fluid with an oxygen concentration of less than about 0.6 mg/L.
  • In an eighth aspect, a sensor system is provided for continuous measurement of an analyte concentration in a host, the sensor system comprising a first sensor element configured to measure an analyte concentration and generate a first signal; a second sensor element configured to measure the analyte concentration and generate a second signal, the second sensor element having at least one characteristic different from the first sensor element; and sensor electronics configured to determine an analyte concentration value based on at least one of the first signal or the second signal.
  • In an embodiment of the eighth aspect, the sensor electronics are configured to estimate an analyte concentration value based on at least one of the first signal or the second signal and based on an estimation of a parameter.
  • In an embodiment of the eighth aspect, the sensor electronics are further configured to average or integrate the first signal and the second signal.
  • In an embodiment of the eighth aspect, the sensor electronics are further configured to assign a first weight to the first signal and assign a second weight to the second signal, wherein a magnitude of the first weight and a magnitude of the second weight are dependent on the estimation of the parameter.
  • In an embodiment of the eighth aspect, the parameter is associated with the analyte concentration.
  • In an embodiment of the eighth aspect, the parameter is associated with a time period of a sensor session.
  • In an embodiment of the eighth aspect, the parameter is associated with a presence of a level of an interferent.
  • In an embodiment of the eighth aspect, the parameter is associated with a concentration of oxygen.
  • In an embodiment of the eighth aspect, the first sensor element comprises a first membrane having a first hydrophilic component and a first hydrophobic component, wherein the second sensor element comprises a second membrane having a second hydrophilic component and a second hydrophobic component, and wherein the first sensor membrane and the second sensor membrane have a different hydrophilic to hydrophobic ratio.
  • In an embodiment of the eighth aspect, the first membrane comprises a first domain configured to reduce a flux of the analyte therethrough, wherein the second membrane comprises a second domain configured to reduce a flux of the analyte therethrough, and wherein the first domain and the second domain are different.
  • In an embodiment of the eighth aspect, the system further comprises a potentiostat configured to apply a first bias potential to the first sensor element and to apply a second bias potential to the second sensor element, wherein the first bias potential and the second bias potential are different.
  • In an embodiment of the eighth aspect, the first sensor element comprises a first membrane configured to reduce a flux of interferents therethrough, wherein the second sensor element comprises a second membrane configured to reduce a flux of interferents therethrough, and wherein interferent blocking characteristics of the first membrane and the second membrane are different.
  • In an embodiment of the eighth aspect, the first sensor element is further configured to monitor at least one levels of an interferent.
  • In a ninth aspect, a method is provided for processing data from a sensor system configured for continuous measurement of an analyte concentration in a host, the method comprising receiving a first signal, associated with an analyte concentration in a host, from a first sensor element; receiving a second signal, associated with the analyte concentration in the host, from a second sensor element, wherein the second sensor element hays at least one characteristic different from the first sensor element; and determining, using sensor electronics, an analyte concentration value based on at least one of the first signal or the second signal.
  • In an embodiment of the ninth aspect, determining the analyte concentration value is further based on an estimation of a parameter.
  • In an embodiment of the ninth aspect, determining the analyte concentration value comprises averaging or integrating the first signal and the second signal.
  • In an embodiment of the ninth aspect, averaging or integrating the first signal and the second signal comprises assigning a first weight to the first signal and assigning a second weight to the second signal, wherein a magnitude of the first weight and a magnitude of the second weight are dependent on the estimation of the parameter.
  • In an embodiment of the ninth aspect, the parameter is associated with the analyte concentration.
  • In an embodiment of the ninth aspect, the parameter is associated with a time period of a sensor session.
  • In an embodiment of the ninth aspect, the parameter is associated with a presence of a level of an interferent.
  • In an embodiment of the ninth aspect, the parameter is associated with a concentration of oxygen.
  • In an embodiment of the ninth aspect, the method further comprises applying a first bias potential to the first sensor element and a second bias potential to the second sensor element, wherein the first bias potential and the second bias potential are different.
  • In a tenth embodiment, a sensor system is provided for continuous measurement of an analyte concentration in a host, the sensor system comprising a first sensor element configured to measure analyte concentrations over a first time period of in vivo implantation; and a second sensor element configured to measure analyte concentrations over a second time period of in vivo implantation, wherein the first time period and the second time period are different.
  • In an embodiment of the tenth aspect, the first time period is associated with an initial period of in vivo implantation, wherein the second time period is associated with a second time period of in vivo implantation, and wherein the second period begins after the initial period of in vivo implantation has begun.
  • In an embodiment of the tenth aspect, the first time period and the second time period overlap partially, but not completely.
  • In an embodiment of the tenth aspect, the first time period and the second time period do not overlap.
  • In an embodiment of the tenth aspect, the first time period is from about day 1 post-implantation to about day 3 post-implantation, and wherein the second time period is from about day 2 post-implantation to about day 10 post-implantation.
  • In an embodiment of the tenth aspect, the first time period is from about day 1 post-implantation to about day 21 post-implantation, and wherein the second time period is from about day 10 post-implantation to about year 1 post-implantation.
  • In an embodiment of the tenth aspect, the sensor system is configured for implantation wholly in a tissue of a host.
  • In an embodiment of the tenth aspect, the sensor system is configured for transcutaneous placement through a skin of a host.
  • In an embodiment of the tenth aspect, the sensor system is configured for fluid communication with a vascular system of a host.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is perspective view of one embodiment of a continuous analyte sensor.
  • FIG. 1B is a perspective view of another embodiment of a continuous analyte sensor.
  • FIG. 2A is a cross-sectional view through the analyte sensor of FIG. 1A on line 2A-2A, illustrating one embodiment of the membrane system.
  • FIG. 2B is a cross-sectional view through the analyte sensor of FIG. 1A on line 2B-2B, illustrating one embodiment of the membrane system.
  • FIG. 2C is a cross-sectional view through the analyte sensor of FIG. 1A on line 2C-2C, illustrating one embodiment of the membrane system.
  • FIG. 3 is a block diagram illustrating continuous glucose sensor electronics, in one embodiment.
  • FIG. 4 is a flowchart illustrating the measuring and processing of sensor data, in one embodiment.
  • FIG. 5 is a flowchart illustrating the measuring and processing of sensor data, in another embodiment.
  • FIG. 6A is a flowchart illustrating one embodiment for manufacturing of a sensor system.
  • FIG. 6B is a flowchart illustrating another embodiment for manufacturing of a sensor system.
  • DETAILED DESCRIPTION
  • In order to facilitate an understanding of the embodiments described herein, a number of terms are defined below.
  • The term “analyte,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological sample (e.g., bodily fluids, including, blood, serum, plasma, interstitial fluid, cerebral spinal fluid, lymph fluid, ocular fluid, saliva, oral fluid, urine, excretions or exudates). Analytes can include naturally occurring substances, artificial substances, metabolites, or reaction products. In some embodiments, the analyte for measurement by the sensing elements, devices, and methods is albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, metabolic markers, and drugs. However, other analytes are contemplated as well, including but not limited to acetaminophen, dopamine, ephedrine, terbutaline, ascorbate, uric acid, oxygen, d-amino acid oxidase, plasma amine oxidase, xanthine oxidase, NADPH oxidase, alcohol oxidase, alcohol dehydrogenase, pyruvate dehydrogenase, diols, Ros, NO, bilirubin, cholesterol, triglycerides, gentisic acid, ibuprophen, L-Dopa, methyl dopa, salicylates, tetracycline, tolazamide, tolbutamide, acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), histamine, Advanced Glycation End Products (AGEs) and 5-hydroxyindoleacetic acid (FHIAA).
  • The terms “continuous” and “continuously,” as used herein in reference to analyte sensing, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to the continuous, continual, or intermittent (e.g., regular) monitoring of analyte concentration, such as, for example, performing a measurement about every 1 to 10 minutes.
  • The term “operably connected,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to one or more components linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit. In this case, the electrode is “operably connected” to the electronic circuitry.
  • The term “host” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to animals (e.g., humans) and plants.
  • The terms “electrochemically reactive surface” and “electroactive surface,” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to the surface of an electrode where an electrochemical reaction takes place. As one example, in a working electrode, H2O2 (hydrogen peroxide) produced by an enzyme-catalyzed reaction of an analyte being detected reacts and thereby creates a measurable electric current. For example, in the detection of glucose, glucose oxidase produces H2O2 as a byproduct. The H2O2 reacts with the surface of the working electrode to produce two protons (2H+), two electrons (2e), and one molecule of oxygen (O2), which produces the electric current being detected. In the case of the counter electrode, a reducible species, for example, O2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
  • The term “sensor element,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the region or mechanism of a monitoring device responsible for the detection of a particular analyte.
  • The terms “raw data stream” and “data stream,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an analog or digital signal directly related to the measured glucose concentration from the glucose sensor. In one example, the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a glucose concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
  • The term “counts,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode. In another example, counter electrode voltage measured in counts is directly related to a voltage.
  • The phrase “distal to,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a sensor include an electrode covered by a membrane system having a diffusion resistance domain and an enzyme domain. If the electrode is deemed to be the point of reference and the diffusion resistance domain is positioned farther from the electrode than the enzyme domain, then the diffusion resistance domain is more distal to the electrode than the enzyme domain.
  • The phrase “proximal to,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a sensor include an electrode covered by a membrane system having a diffusion resistance domain and an enzyme domain. If the electrode is deemed to be the point of reference and the enzyme domain is positioned nearer to the electrode than the diffusion resistance domain, then the enzyme domain is more proximal to the sensor than the diffusion resistance domain.
  • The term “domain,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to regions of a membrane that can be layers, uniform or non-uniform gradients (i.e., anisotropic) or provided as portions of the membrane.
  • The term “baseline,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the component of an analyte sensor signal that is not related to the analyte concentration. In one example of a glucose sensor, the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide). In some embodiments wherein a calibration is defined by solving for the equation y=mx+b, the value of b represents the baseline of the signal.
  • The term “sensitivity,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an amount of electrical current produced by a predetermined amount (unit) of the measured analyte. For example, in one embodiment, a sensor has a sensitivity (or slope) of about 1 to about 300 picoAmps of current for every 1 mg/dL of glucose analyte.
  • The term “current density,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an amount of electrical current per area produced by a predetermined amount (unit) of the measured analyte. For example, in one embodiment, a sensor has a sensitivity (or slope) of about 3 to about 1,000 picoAmps of current per mm2 of electroactive surface, for every 1 mg/dL of glucose analyte.
  • Conventional continuous analyte sensors have typically lacked the capability to achieve a substantially consistent level of measurement accuracy across a physiologically relevant range. For instance, while some conventionally designed sensors have been capable of achieving high measurement accuracy in high-analyte-concentration environments, this measurement accuracy has typically been achieved by sacrificing measurement accuracy in low-analyte-concentration environments. Accordingly, designers of conventional continuous analyte sensors have typically had to choose between a sensor design that provided high measurement accuracy in a low analyte level environment, or alternatively a sensor design that provided high measurement accuracy in a high analyte level environment, but not a sensor design capable of providing high measurement accuracy in both low and high analyte level environments. Simply put, it has been a technical challenge to design a continuous analyte sensor capable of obtaining accurate measurements across a physiological relevant range.
  • Described herein is an improved sensor system with a plurality of sensor elements, in which each sensor element is designed to measure analyte concentration and to have a different characteristic, attribute, or configuration than the other sensor element(s) of the system. In some embodiments, sensor data from each of the plurality of different sensor elements is selectively used when a certain predetermined condition is present. The predetermined condition can relate to any of a variety of parameters, such as, oxygen concentration, time since initiation of the sensor session, presence of a certain level of interference activity, for example. The predetermined condition can also relate to analyte concentration. In certain embodiments, the continuous analyte sensor system comprises a plurality of sensor elements that are each configured to provide a preselected level of accuracy in two or more physiologically relevant ranges, so that the system can accurately measure an analyte concentration across a physiologically relevant range. In some embodiments, the plurality of sensor elements may provide the system with the capability of performing highly accurate measurements of glucose concentration in both hyperglycemic and hypoglycemic ranges.
  • Various methods for confirming accuracy of a sensor include, but are not limited to, the Clarke Error Grid, Parkes Error Grid, Continuous Glucose Error grid, Mean Absolute Relative Difference (MARD) analysis, and YSI (Yellow Springs Instrument) analysis. Some or all of these methods can be used to verify the accuracy of the sensor's measurements. In certain embodiments, the sensor's level of accuracy is verified by confirming that a high percentage (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98%) of its paired data points within zone A of the Clarke Error Grid. Alternatively, in other embodiments, the sensor's level of accuracy is verified by using a MARD analysis, such that the sensor's accuracy is confirmed with an MARD of about 30% or less, or about 25% or less, or about 20% or less, or about 15% or less, or about 10% or less, or about 5% or less. In yet other embodiments, the sensor's level of accuracy is verified by using YSI analysis, such that a large percentage of readings (e.g., about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or more) are within about 20 mg/dL of a YSI reading.
  • Various housing arrangements for the sensor elements are contemplated. For example, in some embodiments, the plurality of sensor elements are housed within the same body, but in alternative embodiments the sensor elements are housed in different bodies. With embodiments in which a plurality of sensor elements are housed in the same body, in some of these embodiments, the sensor elements are physiologically connected or separated by a spacing.
  • FIG. 1A provides a perspective view of one embodiment of a sensor system 180 and illustrates an in vivo portion of a working electrode 100 comprising two analyte sensor elements 102 and 104 and a reference electrode 108. The reference electrode 108 is used to provide a reference value for measuring the working electrode potential of the sensor elements 102, 104. In this particular embodiment, an insulator 106 is disposed between the two sensor elements 102 and 104, and between the sensor element 104 and the reference electrode 108, to provide necessary electrical insulation therebetween. In some embodiments, the insulator spacing separating the two sensor elements 102 and 104 may be minimized, so that the sensor elements 102 and 104 may both function under almost identical physiological conditions. In certain further embodiments, the insulator spacing can be from about 0.001 to about 100 microns, or from about 0.1 to about 50 microns, or from about 10 to about 25 microns. FIG. 1B provides a perspective view of another embodiment comprising a sensor system 180 having a first working electrode 150 comprising a first sensor element 102 and a second working electrode 160 comprising a second sensor element 104. Similar to the embodiment shown in FIG. 1A, the sensor system 180 also includes a reference electrode 108 for providing a reference value for measuring the working electrode potential of the sensor elements 102, 104. Both the first working electrode 150 and the second working electrode 160 comprise an insulator 106 that separates the sensor elements 102 and 104 from the reference electrode 108. Sensor element 102 is associated with a membrane 142, and sensor element 104 is associated with another membrane 152. In some embodiments, the thickness, composition, and/or structure of one or more layers (e.g., electrode, interference, or enzyme domains) of membrane system 142 differs from that of membrane system 152, but in other embodiments membranes 142, 152 may be substantially the same. Additional sensor systems and configuration are described in U.S. Provisional Application No. 61/222,751 filed Jul. 2, 2009 and U.S. patent application Ser. No. ______, filed Jul. 1, 2010, and entitled “ANALYTE SENSORS AND METHODS FOR MANUFACTURING SAME,” each of which is incorporated by reference herein in its entirety.
  • A wide variety of sensor configurations are contemplated with respect to sensor placement. For example, in some embodiments, the sensor is configured for transdermal (e.g., transcutaneous) placement, but in other embodiments the sensor is configured for intravascular placement, subcutaneous placement, intramuscular placement, or intraosseous placement. The sensor may use any method to provide an output signal indicative of the concentration of the analyte of interest; these methods may include, for example, invasive, minimally invasive, or non-invasive sensing techniques.
  • The output signal associated with the analyte concentration of the host is typically a raw signal used to provide a useful value of the analyte of interest to a user (e.g., a patient or physician) using the device. Accordingly, appropriate smoothing, calibration, or evaluation methods can be applied to the signal or system as a whole to provide relevant and acceptable estimated analyte data to the user.
  • It is contemplated that the sensor may use any of a wide variety of known suitable detection methods. These methods may include, but are not limited to, enzymatic, chemical, physical, electrochemical, immunochemical, optical, radiometric, calorimetric, protein binding, microscale methods of detection, and the like. Additional description of analyte sensor configurations and detection methods can be found, e.g., in U.S. Patent Publication No. US-2007-0213611-A1, U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2005-0143635-A1, U.S. Patent Publication No. US-2007-0020641-A1, U.S. Patent Publication No. US-2007-0020641-A1, U.S. Patent Publication No. US-2005-0196820, U.S. Pat. No. 5,517,313, U.S. Pat. No. 5,512,246, U.S. Pat. No. 6,400,974, U.S. Pat. No. 6,711,423, U.S. Pat. No. 7,308,292, U.S. Pat. No. 7,303,875, U.S. Pat. No. 7,289,836, U.S. Pat. No. 7,289,204, U.S. Pat. No. 5,156,972, U.S. Pat. No. 6,528,318, U.S. Pat. No. 5,738,992, U.S. Pat. No. 5,631,170, U.S. Pat. No. 5,114,859, U.S. Pat. No. 7,273,633, U.S. Pat. No. 7,247,443, U.S. Pat. No. 6,007,775, U.S. Pat. No. 7,074,610, U.S. Pat. No. 6,846,654, U.S. Pat. No. 7,288,368, U.S. Pat. No. 7,291,496, U.S. Pat. No. 5,466,348, U.S. Pat. No. 7,062,385, U.S. Pat. No. 7,244,582, U.S. Pat. No. 7,211,439, U.S. Pat. No. 7,214,190, U.S. Pat. No. 7,171,312, U.S. Pat. No. 7,135,342, U.S. Pat. No. 7,041,209, U.S. Pat. No. 7,061,593, U.S. Pat. No. 6,854,317, U.S. Pat. No. 7,315,752, and U.S. Pat. No. 7,312,040. Although the illustrated sensor configurations and associated text describe a few methods for forming a sensor, any of a variety of known sensor configurations can be employed with the analyte sensor system, such as, for example, U.S. Pat. No. 5,711,861 to Ward et al., U.S. Pat. No. 6,642,015 to Vachon et al., U.S. Pat. No. 6,654,625 to Say et al., U.S. Pat. No. 6,565,509 to Say et al., U.S. Pat. No. 6,514,718 to Heller, U.S. Pat. No. 6,465,066 to Essenpreis et al., U.S. Pat. No. 6,214,185 to Offenbacher et al., U.S. Pat. No. 5,310,469 to Cunningham et al., and U.S. Pat. No. 5,683,562 to Shaffer et al., U.S. Pat. No. 6,579,690 to Bonnecaze et al., U.S. Pat. No. 6,484,046 to Say et al., U.S. Pat. No. 6,103,033 to Say et al., U.S. Pat. No. 6,512,939 to Colvin et al., U.S. Pat. No. 6,424,847 to Mastrototaro et al., and U.S. Pat. No. 6,424,847 to Mastrototaro et al. The sensors described in the above-referenced patents are not inclusive of all applicable analyte sensors; rather, the disclosed embodiments can be applicable to any of a variety of analyte sensor configurations. The description of the embodiments herein, for example the membrane system described below, can be implemented not only with in vivo sensors, but also with in vitro sensors, such as blood glucose meters (SMBG), and any other known analyte sensors.
  • As described above, in some embodiments, the sensor system comprises a plurality of sensor elements, each or some of which are configured to measure different ranges of analyte concentration. For example, the sensor system may include a first sensor element configured to accurately measure analyte concentration in a first range of analyte concentrations and a second sensor element configured to accurately measure analyte concentration in a second range of analyte concentrations. In some embodiments, the sensor system is configured to measure glucose concentration over a range of from about 30, 40, 50, 60, 70, or 80 mg/dL to about 200, 250, 300, 350, 400, 450, 500, 550 or 600 mg/dL. As described above, in some embodiments, the sensor system includes a plurality of sensor elements configured to measure different analyte concentration ranges, each of which comprises a portion of the physiologically relevant range. In some of these embodiments, the different ranges do not overlap, but in other embodiments, the ranges overlap, either partially or entirely. By way of example, in one embodiment, the sensor system comprises a first sensor element configured to measure a glucose concentration of from about 30 mg/dL to about 120 mg/dL and a second sensor element configured to measure a glucose concentration of from about 80 mg/dL to about 400 mg/dL. In this particular embodiment, there is a partial overlapping of measurement ranges of from about 80 mg/dL to about 120 mg/dL. In alternative embodiments, other measurement ranges are contemplated for each of the plurality of sensor elements. For example, in some embodiments, the first sensor element is configured to measure a glucose concentration of from about 30 mg/dL to about 120 mg/dL, or from about 40 mg/dL to about 100 mg/dL, and the second sensor element is configured to measure a glucose concentration of from about 60 mg/dL to about 500 mg/dL, or from about 90 mg/dL to about 450 mg/dL.
  • Although the examples provided above describe a sensor system comprising two sensor elements, it is contemplated that the sensor system can comprise any number of sensor elements. In some embodiments, the plurality of sensor elements may each be tuned to measure at a particular analyte concentration range, tuned to measure at a particular time period during a sensor session, and/or to tuned to measure at any particular range of any of a variety of parameters (e.g., parameters relating to concentration of oxygen, concentration of a interferent, etc.). For instance, in some embodiments, the sensor system comprises three sensor elements configured to measure a first range, a second range, and a third range, e.g., with a first sensor element associated with a range of about 30-90 mg/dL, a second sensor element associated with a range of about 80-160 mg/dL, and a third sensor element associated with a range of about 140-400 mg/dL. In other embodiments, the sensor system is provided with 4, 5, 6, 7, 8, 9, 10, 20, 40, or more sensor elements.
  • As used herein, language associating sensor measurement or output of analyte concentration to a particular range of analyte concentrations, particular range of time, or any other range corresponding to a parameter or condition, should not be construed as precluding the sensor element from measuring outside the particular range described or from having its signal used to form an estimation of an analyte concentration value (e.g., estimation by using a weighted average or weighted sum of a plurality of signals). Rather, such language should be construed to mean that the sensor element is configured to be tuned (with respect to measurement accuracy) to a particular range, such that all or a weighted portion of the sensor output of analyte concentrations in that particular range comes from the sensor element particularly tuned thereto. By way of example, in a sensor system with a first sensor element and a second sensor element, each sensor element may have a different configuration and be tuned to measure analyte concentration within a preselected analyte concentration range (e.g., high glucose concentration range vs. low glucose concentration range). Even though each of the two sensor elements may be capable of measuring at any analyte concentration, the exemplary sensor system is configured to provide output to a user from the first sensor element, second sensor element, or both, based, at least in part, on the analyte concentration range that the first or second sensor element is particularly tuned for. In addition, as used herein, the phrase “accurately measure,” or the like, should be construed as referring to a level of accuracy that provides clinically useful analyte measurements.
  • In some of these embodiments, the sensitivity or current density (i.e., sensitivity divided by surface area of the electroactive surface) of one or more of the sensor elements is substantially higher than the sensitivities or current densities of other sensor elements, but in other embodiments, the sensitivities or current densities of the sensor elements are substantially equal. In some embodiments, the sensor system includes a first sensor element having a first sensitivity and a second sensor element having a second sensitivity, wherein the first sensitivity is higher than the second sensitivity. In some embodiments, the first sensitivity is from about 1 pA/mg/dL to about 100 pA/mg/dL, or from about 1 pA/mg/dL to about 25 pA/mg/dL, and the second sensitivity is from about 20 pA/mg/dL to about 300 pA/mg/dL, or from about 50 pA/mg/dL to about 100 pA/mg/dL. In some embodiments, the sensor system includes a first sensor element having a first current density and a second sensor element having a second current density, wherein the first current density is higher than the second current density. In some of these embodiments, the current density of the first element is from about 3 pA/mg/dL/mm2 to about 325 pA/mg/dL/mm2, or from about 3 pA/mg/dL/mm2 to about 85 pA/mg/dL/mm2, and the current density of the second element is from about 65 pA/mg/dL/mm2 to about 1,000 pA/mg/dL/mm2, or from about 165 pA/mg/dL/mm2 to about 1,700 pA/mg/dL/mm2.
  • In some embodiments, the sensor element with the higher sensitivity or higher current density is used to measure or provide output at low glucose concentration ranges, while the sensor element with the lower sensitivity or lower current density is used to measure or provide output at high glucose concentration ranges. Advantageously, in some embodiments, improved glucose concentration measurement accuracy at both low and high glucose levels is achieved by configuring the first sensor element to have a higher sensitivity or higher current density and the second to have a lower sensitivity or lower current density.
  • In some embodiments, the sensor elements each have a different bias potential applied against it by a potentiostat. An increased bias potential applied against a sensor element may not only facilitate the oxidization and measurement of H2O2, but may also facilitate the oxidization of water or other electroactive species. In one example, the bias setting is increased by about 0.05 V to about 0.4 V above what is necessary for sufficient H2O2 measurements. By increasing the bias potential, an electrolysis reaction of water (and possibly other electroactive species) may be carried out, whereby oxygen is produced at the electroactive surface of sensor element. The oxygen produced then diffuses in various directions, including up to the glucose oxidase directly above the electroactive surface. This production of oxygen increases sensor function, particularly in low oxygen environments.
  • Referring back to embodiments described above, in one further embodiment, the sensor system comprises a first sensor element configured with a first bias setting (for example, +0.6V) for measuring a signal only from the product of the enzyme reaction, and a second sensor element configured with a second bias setting (for example, +1.0V) that oxidizes and measures water or other electroactive species. In this embodiment, the first sensor element is configured to measure at low analyte ranges, where the oxygen-to-glucose molar ratio is high, and the second element is configured to measure at high analyte ranges, where the oxygen-to-glucose molar ratio is low and where additional oxygen can be helpful for preventing a molar excess of glucose relative to oxygen.
  • In some embodiments, the sensor elements each have different analyte-related to non-analyte-related signal ratios. For example, in one embodiment, wherein the sensor system includes first and second sensor elements, and wherein the first sensor element has a higher sensitivity or higher current density than the second sensor element, the first sensor element also has higher analyte-related to non-analyte-related signal ratio than the second sensor element. Advantageously, in some embodiments, the combination of a higher sensitivity or higher current density and a higher analyte-related to non-analyte-related signal ratio further improves measurement accuracy at low analyte levels. An increase or decrease of the analyte-related to non-analyte-related signal ratio may be obtained by modifying membrane properties (e.g., composition, thickness, etc.).
  • As described elsewhere herein in regard to membrane systems, it is contemplated that in some embodiments, the sensor system has a plurality of sensor elements, in which one or more of the sensor elements are configured to have a different membrane system (i.e., with different membrane properties) than the other sensor element(s). In some embodiments, the plurality of sensor elements each comprises a membrane with a hydrophilic component and a hydrophobic component, with the membrane of each sensor element having a different hydrophilic component to hydrophobic component ratio than the ratio(s) of the membrane(s) of other sensor element(s). By altering the hydrophilic component to hydrophobic component ratio (as determined by weight), membrane properties can be changed. These membrane property changes can include changes to, for example, permeability of analyte, sensitivity to analyte, permeability of interferents, sensitivity to interferents, permeability to oxygen, expected sensor life, accuracy at certain periods during a sensor session, etc.
  • In addition, changing the hydrophilic component to hydrophobic component ratio can also change the sensor run-in-time (i.e., the time between the insertion of the sensor subcutaneously and stabilization of the sensor). It has been found that an increase in this ratio (i.e., larger amounts of the hydrophilic component than the hydrophobic component) can substantially reduce run-in time. While not wishing to be bound by theory, it is believed that this phenomenon may be attributed at least in part to faster hydration of membranes having a greater proportion of hydrophilic components, when the sensor is inserted into the patient and contacts a biological sample. In certain embodiments, the sensor system may comprise one sensor element with a reduced run-in-time (e.g., about 0.1 hour, 0.2 hour, 0.3 hour, 0.4 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 4, hours, or 6 hours) that is tuned to an early portion of the sensor session and other sensor element(s) that are tuned to other portions of the sensor session. In further embodiments, the sensor element configured with the reduced run-in-time may be used to calibrate the other sensor elements.
  • There typically exists a molar excess of glucose relative to the amount of oxygen in blood. To achieve accurate sensor measurements of glucose concentration, the amount of oxygen present for the glucose-oxidase-catalyzed reaction has to be greater than that of glucose. Otherwise, an oxygen limiting reaction, instead of a glucose limiting reaction, may occur, especially at high glucose concentration levels. More specifically, when a glucose-monitoring reaction is oxygen limited, the glucose sensor's linearity may be lost at concentrations of glucose within a physiologically relevant range. In order to achieve high sensitivity or high current density, sensor elements can be formed with a membrane that permits a greater flux of glucose molecules into the enzyme layer (which may comprise glucose oxidase) of the membrane, than sensor elements designed for low sensitivity or low current density. To overcome potential issues relating to a molar excess of glucose relative to oxygen in a high sensitivity or high current density sensor element, in some embodiments, the sensor system is designed to comprise a plurality of sensor elements, each of which is configured to have different membrane characteristics, with respect to oxygen permeability and/or glucose permeability. In some embodiments, each of the plurality of sensor elements may have a different sensitivity or current density. For example, in one embodiment, the sensor system comprises a first sensor element configured with a high sensitivity or high current density and a second sensor element configured with a low sensitivity or low current density. It has been found that high glucose sensitivity sensor elements typically perform worse in lower oxygen environments than the low glucose sensitivity sensor element. Thus, in certain analyte concentration levels where oxygen is a limiting reactant or in low oxygen environments, the sensor system can be configured to accept data from the low sensitivity or low current density sensor element, instead of the high sensitivity or high current density sensor element. Alternatively, data from the high sensitivity or high current density sensor element may still be accepted, but accorded less weight than data from the low sensitivity or low current density sensor element.
  • As described elsewhere herein, in some embodiments, comparison and analysis is performed on signals. The comparison and analysis can include integrating or averaging signals from a plurality of sensor elements. In some embodiments, the sensor electronics may be configured to accord less (or no) weight to a high sensitivity sensor element, as compared to a low sensitivity sensor element, in environments associated with low oxygen and high glucose concentration. Conversely, the sensor electronics may be configured to accord more weight to the high sensitivity sensor element in environments associated with high oxygen and low glucose concentration. As an alternative to weighting, the sensor electronics may be configured to poll sensor data from the low glucose sensitivity sensor only when an environment associated with a low oxygen environment is detected.
  • In some embodiments, signals received from the two sensor elements can be compared and analyzed to provide information not only about glucose concentration, but information about other parameters that can affect sensor performance. For example, during a sensor session, if the oxygen level near the sensor elements diminishes below a certain level, the high sensitivity sensor element may no longer be accurate. Under these conditions, the high sensitivity sensor may become noisy and thus become less accurate, while the low sensitivity sensor element can continue to measure accurately. Accordingly, in some embodiments in which comparison and analysis of signals is made by integrating or averaging signals from a plurality of sensor elements, the sensor electronics may be configured to accord less (or no) weight to a high sensitivity sensor element, as compared to a low sensitivity sensor element, in environments associated with low oxygen and high glucose concentration. Conversely, the sensor electronics may be configured to accord more weight to the high sensitivity sensor element in environments associated with high oxygen and low glucose concentration. As an alternative to weighting, the sensor electronics may be configured to poll sensor data from the low glucose sensitivity sensor only when an environment associated with a low oxygen environment is detected.
  • In some embodiments, the noise that may be present in data from a high sensitivity sensor element (e.g., one in the presence of a low oxygen environment) may provide an indication that a low glucose sensitivity sensor is approaching an environment in which it may also become inaccurate as well. Accordingly, the sensor electronics may be configured to monitor, on the high sensitivity sensor element, a noise pattern that corresponds to a low oxygen environment. Following detection of the noise pattern, the sensor electronics can be instructed to poll data from the low sensitivity only, or alternatively adjust the weight accorded to the high sensitivity sensor with respect to the low sensitivity sensor.
  • While not wishing to be bound by theory, it is believed that oxygen availability typically decreases with time during the age of a sensor, as the amount of oxygen that can be transported across the membrane of a sensor element diminishes. While not wishing to be bound by theory, it is believed that this phenomenon may be attributed at least in part to the body's response to a foreign object (e.g., a continuous glucose sensor), whereby barrier cells are formed surrounding the sensor elements. In turn, the barrier cells reduce or completely block the transport of oxygen across the membrane of the sensor elements. In some embodiments, the sensor system is formed with a high sensitivity or high current density sensor element that provides greater accuracy during a large duration of the sensor system's life, and a low sensitivity or low current density sensor element that provides better low oxygen performance, and thus can be used near the end of the sensor system's life.
  • In some embodiments, the sensor system comprises a plurality of sensor elements used to continuously provide sensor data after insertion of the sensor, even during time periods which may be problematic for conventional sensors. In some of these embodiments, the sensor system comprises a first sensor element and a second sensor element, each with different membrane properties. The first sensor element is tuned to measure analyte concentration during a first period, such as an initial time period after sensor implantation (e.g., during about the first 0.1 hour, 0.2 hour, 0.5 hour. 0.75 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days post-insertion). In certain embodiments, the first sensor element is designed with a particular membrane (e.g., a membrane that hydrates quickly after insertion into interstitial fluid) that is tuned for accuracy during the initial period after sensor insertion. The second sensor element is tuned to measure analyte concentration during a second time period (e.g., after about 0.2 hour, 0.5 hour, 0.75 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4, days, 5 days, 7 days, 2 weeks, or 1 year post-insertion), where the second period begins after the initial period begins. In some embodiments, the time periods of the different sensor elements overlap. As described herein elsewhere in more detail, by varying the membrane properties of a sensor element, sensor elements can be tuned to measure accurately over a specific time period. In some embodiments, the time periods overlap partially, but in other embodiments, there is no overlap of time periods. In one example of a sensor system with partial overlap of time periods, the first time period is from about hour 0.2 to about day 3 post-insertion, and the second time period is from about hour 6 to about day 10 post-insertion. Thus, in this particular example, there is partial overlap between hour 6 and day 3 post-insertion. Other examples include, but are not limited to, a sensor system having the first time period of from about day 1 to about day 21, and a second time period of from about day 10 to about year one. In yet another embodiment, the time period of one sensor may completely overlap the time period of another sensor. In one example of a sensor system with complete overlap of time periods, the first time period is from about hour 0.5 to about day 2, the second time period is from about hour 6 to about day 10, and the third time period is from about day 3 to about day 10. In this particular example, the second time period completely overlaps the third time period. In some embodiments, the second sensor element tuned to measure at a later time period may be formed with a robust biointerface to create strong vascularized tissue ingrowth, thereby providing more durability, but also a longer break in time. By having a plurality of sensor elements tuned to different time periods, the sensor system is capable of continuously and accurately measuring analyte concentrations across a wide range of time periods.
  • In some embodiments, the sensor includes a membrane system comprising a single layer deposited onto the electroactive surfaces of the sensor, wherein the single layer includes one or more functional domains (e.g., distinct portions). In other embodiments, however, the membrane system includes two or more deposited layers, each of which is configured to perform different functions. For example, FIG. 2A is a cross-sectional view through one embodiment of the sensor element 102 of FIG. 1A on line 2A-2A, illustrating one exemplary embodiment of a membrane system 132 covering an elongated conductive body 200. The term “elongated conductive body” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an elongated body formed at least in part of a conductive material and includes any number of coatings formed thereon. By way of example, an “elongated conductive body” may be in the form of a bare elongated core (e.g., a metal wire, a wire formed of a conductive polymer, a planar substrate formed of a non-conductive material) or an elongated core covered (e.g., coated, plated, cladded, etc.) with one, two, three, four, five, or more layers or domains of material that may be conductive or non-conductive.
  • As illustrated in FIG. 2A, the membrane system 132 comprises a plurality of domains, including an electrode domain 202, an interference domain 204, an enzyme domain 206, and a diffusion resistance domain 208. FIG. 2B is a cross-sectional view through one embodiment of the sensor element 104 of FIG. 1A on line 2B-2B, illustrating one exemplary embodiment of a membrane system 122 covering an elongated conductive body 200 covered by an insulating domain 212 and a conductive domain 214. As illustrated in FIG. 2B, similar to the membrane system 132 associated with sensor element 102, in one embodiment, the membrane system 122 associated with sensor element 104 also comprises an electrode domain 202, an interference domain 204, an enzyme domain 206, and a diffusion resistance domain 208. FIG. 2C illustrates a cross-sectional view through line 2C-2C of FIG. 1A. In some embodiments, the thickness, composition, and/or structure of one or more layers (e.g., electrode, interference, or enzyme domains) of membrane system 132 differs from that of membrane system 122.
  • Although not shown, it is contemplated that this particular embodiment can also include a high oxygen solubility domain, a biointerface domain, or a bioprotective domain, such as is described in more detail in U.S. Patent Application Publication No. US-2005-0245799-A1, U.S. Patent Application Publication No. US-2009-0247856-A1, and U.S. Patent Application Publication No. US-2009-0247855-A1, and such as are described in more detail below.
  • During manufacturing, the membrane system can be deposited on the exposed electroactive surfaces using known thin film techniques including, but not limited to, conventional vapor deposition, spraying, electro-depositing, dipping, and the like. For example, in some embodiments, the domains are deposited by dipping the sensor into a solution and drawing out the sensor at a speed that provides the desired domain thickness. As another example, the domains are deposited by spraying a solution onto the sensor for a period of time which provides the desired domain thickness. In other embodiments, a combination of different deposition techniques is used for the different domains being deposited. For example, in one embodiment, dipping processes are used to deposit the electrode and enzyme domains onto the electrode, whereas a spraying process is used to deposit the diffusion resistance domain.
  • In alternative embodiments, other vapor deposition processes (e.g., physical or chemical vapor deposition processes) are also used, in addition to or in place of the above-mentioned techniques, to provide one or more of the insulating or membrane layers. These processes include, but are not limited to, ultrasonic vapor deposition, electrostatic deposition, evaporative deposition, deposition by sputtering, pulsed laser deposition, high velocity oxygen fuel deposition, thermal evaporator deposition, electron beam evaporator deposition, deposition by reactive sputtering molecular beam epitaxy, atmospheric pressure chemical vapor deposition (CVD), atomic layer CVD, hot wire CVD, low-pressure CVD, microwave plasma-assisted CVD, plasma-enhanced CVD, rapid thermal CVD, remote plasma-enhanced CVD, and ultra-high vacuum CVD, for example. However, the membrane system can be disposed over (or deposited on) the electroactive surfaces using any known method.
  • In some embodiments, one or more domains of the membrane system is formed from one or more materials such as silicone, polytetrafluoroethylene, polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, polyamides, polyimides, polystyrenes, cellulosic polymers, polysulfones and block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers. U.S. Patent Application Publication No. US-2005-0245799-A1 describes biointerface and membrane system configurations and materials that can be employed in connection with the membrane systems of certain embodiments.
  • In some embodiments, the membrane system comprises an electrode domain. Providing the electrode domain 202 ensures that an electrochemical reaction occurs between the electroactive surfaces of the working electrode and the reference electrode, and thus the electrode domain may be situated more proximal to the electroactive surfaces than the interference or enzyme domain. In some of these embodiments, the electrode domain includes a coating that maintains a layer of water at the electrochemically reactive surfaces of the sensor. In other words, the presence of the electrode domain provides an environment between the surfaces of the working electrode and the reference electrode which facilitates an electrochemical reaction between the electrodes. For example, a humectant in a binder material can be employed as an electrode domain; this allows for the full transport of ions in the aqueous environment. The electrode domain can also assist in stabilizing the operation of the sensor by accelerating electrode start-up and drifting problems caused by inadequate electrolyte. The material that forms the electrode domain can also provide an environment that protects against pH-mediated damage that can result from the formation of a large pH gradient due to the electrochemical activity of the electrodes.
  • In one embodiment, the electrode domain includes a hydrophilic polymer film (e.g., a flexible, water-swellable, hydrogel) having a “dry film” thickness of from about 0.05 microns or less to about 20 microns or more, or from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, or from about 3, 2.5, 2, or 1 microns, or less, to about 3.5, 4, 4.5, or 5 microns or more. “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation by standard coating techniques.
  • In some embodiments, the electrode domain is formed of a curable mixture of a urethane polymer and a hydrophilic polymer. In certain embodiments, coatings are formed of a polyurethane polymer having carboxylate or hydroxyl functional groups and non-ionic hydrophilic polyether segments, wherein the polyurethane polymer undergoes aggregation with a water-soluble carbodiimide (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)) in the presence of polyvinylpyrrolidone and cured at a moderate temperature of, e.g., about 50° C.
  • In some embodiments, the electrode domain is formed from one or more hydrophilic polymers (e.g., a polylactone, a polyimide, a polylactam, a functionalized polyamide, a functionalized polylactone, a functionalized polyimide, a functionalized polylactam or a combination thereof) that renders the electrode domain substantially more hydrophilic than an overlying domain, (e.g., interference domain, enzyme domain). In some embodiments, the electrode domain is formed substantially entirely or primarily from a hydrophilic polymer. In some embodiments, the electrode domain is formed substantially entirely from poly-N-vinylpyrrolidone (PVP). In some embodiments, the electrode domain is formed entirely from a hydrophilic polymer. Useful hydrophilic polymers include but are not limited to poly-N-vinylpyrrolidone, poly-N-vinyl-2-piperidone, poly-N-vinyl-2-caprolactam, poly-N-vinyl-3-methyl-2-caprolactam, poly-N-vinyl-3-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-caprolactam, poly-N-vinyl-3-ethyl-2-pyrrolidone, poly-N-vinyl-4,5-dimethyl-2-pyrrolidone, polyvinylimidazole, poly-N,N-dimethylacrylamide, polyvinyl alcohol, polyacrylic acid, polyethylene oxide, poly-2-ethyl-oxazoline, copolymers thereof and mixtures thereof. A blend of two or more hydrophilic polymers may be desirable in some embodiments. In some embodiments, the hydrophilic polymer(s) is not crosslinked, but in other embodiments, crosslinking is performed. In such embodiments, crosslinking can be promoted by, e.g., adding a crosslinking agent, such as but not limited to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, or by irradiation at a wavelength sufficient to promote crosslinking between the hydrophilic polymer molecules. While not wishing to be bound by theory, it is believed that crosslinking creates a more tortuous diffusion path through the domain. Although an independent electrode domain is described herein, in some embodiments sufficient hydrophilicity is provided in the interference domain or enzyme domain (the domain adjacent to the electroactive surfaces) so as to provide for the full transport of ions in the aqueous environment (e.g., without a distinct electrode domain). In these embodiments, an electrode domain may not be necessary.
  • In some embodiments, the sensor system comprises a plurality of sensor elements, each with different electrode domain properties. For example, in one embodiment, one of the plurality of sensor elements may be designed to allow for quick hydration of the electrode domain following insertion of the sensor into the body. It has been found that fast hydration of the electrode domain may lead to a reduction in run-in time of the sensor.
  • It is contemplated that in some embodiments, the membrane system is provided with an optional interference domain, also referred to as an interference layer. The interference domain substantially reduces the flux of one or more interferents into the electrochemically reactive surfaces. The interference domain may be configured to be much less permeable to one or more of the interferents than to the measured species, e.g., the product of an enzymatic reaction that is measured at the electroactive surface(s), such as H2O2, for example. In turn, the reduction of interferent permeability corresponds to a reduction or a blocking of artificial signals. Some known interferents for a glucose sensor include acetaminophen, lidocaine, ascorbic acid, bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen, L-dopa, methyl dopa, salicylate, tetracycline, tolazamide, tolbutamide, triglycerides, and uric acid, for example. Advantageously, the interference domain contemplated in certain embodiments is configured to improve interferent blocking in certain key ranges (e.g., a hypoglycemic range), where a flux of interferents substantially exaggerates the response signal, thereby leading to false or misleading results. This can be achieved by modifying the thickness or composition of the interference domain to obtain an interference domain with the desired properties. Use of an interference domain in the membrane may result in longer membrane diffusion times (e.g., 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes or more) for the measured species, because of the interference layer's additional thickness to the membrane. Use of the interference domain may also result in increased startup times (e.g., 30 minutes, 1 hour, 3 hours, 6 hours, 9 hours, or 12 hours), due to the additional time required for the sensor to hydrate and break in. Accordingly, by building a sensor with two or more different sensor elements, each selected for different measurement ranges, properties, or time periods for start up, the sensor system can be tuned or adjusted with respect to measurement accuracy across a physiological relevant range of glucose concentrations, start up time, diffusional time lags, and the like. In some embodiments, the sensor system comprises a first sensor element and a second sensor element, each with different interference domain properties. For example, in some embodiments, the first sensor element is configured to measure glucose concentrations in hypoglycemic ranges by being formed with an interference layer with an increased thickness to substantially reduce or block the flux of interferents. In contrast, the second sensor element is configured to measure glucose concentrations in hyperglycemic ranges by being formed without an interference layer, or alternatively by being formed with an interference layer with decreased thickness.
  • In one embodiment, the interference domain is formed from one or more cellulosic derivatives. Cellulosic derivatives include, but are not limited to, cellulose esters and cellulose ethers. In general, cellulosic derivatives include polymers such as cellulose acetate, cellulose acetate butyrate, 2-hydroxyethyl cellulose, cellulose acetate phthalate, cellulose acetate propionate, cellulose acetate trimellitate, and the like, as well as their copolymers and terpolymers with other cellulosic or non-cellulosic monomers. Cellulose is a polysaccharide polymer of β-D-glucose. While cellulosic derivatives are used in some embodiments, other polymeric polysaccharides having similar properties to cellulosic derivatives can also be employed. Descriptions of cellulosic interference domains can be found in U.S. Patent Application Publication No. US-2006-0229512-A1, U.S. Patent Application Publication No. US-2007-0173709-A1, U.S. Patent Application Publication No. US-2006-0253012-A1 and U.S. Patent Application Publication No. US-2007-0213611-A1.
  • In some embodiments, other polymer types that can be utilized as a base material for the interference domain include, but are not limited to, polyurethanes, polymers having pendant ionic groups, and polymers having controlled pore size. In one such alternative embodiment, the interference domain includes a thin, hydrophobic membrane that is non-swellable and restricts diffusion of high molecular weight species. The interference domain in certain embodiments is permeable to relatively low molecular weight substances, such as hydrogen peroxide, but also restricts the passage of higher molecular weight substances, including glucose and ascorbic acid. Other systems and methods for reducing or eliminating interference species that can be applied to the membrane system are described in U.S. Pat. No. 7,074,307, U.S. Patent Application Publication No. US-2005-0176136-A1, U.S. Pat. No. 7,081,195, and U.S. Patent Application Publication No. US-2005-0143635-A1. In some alternative embodiments, a distinct interference domain is not included in the membrane system or is functionally combined with another layer. In some embodiments, the interference domain is deposited either directly onto the electroactive surfaces of the sensor or onto the distal surface of the electrode domain. It is contemplated that in some embodiments the thickness of the interference domain is from about 0.01 microns or less to about 20 microns or more. In some of these embodiments, the thickness of the interference domain is from about 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns. In some of these embodiments, the thickness of the interference domain is from about 0.2, 0.4, 0.5, or 0.6, microns to about 0.8, 0.9, 1, 1.5, 2, 3, or 4 microns.
  • In some embodiments, the sensor system comprises a plurality of sensor elements, each with different interference domain properties. It has been found that certain interference domains lack completely precise specificity with respect to interferents. In other words, with certain interference domains, the membrane not only reduces the flux of interferents, but also reduces the flux of glucose or measured species such as hydrogen peroxide generated from an enzyme-catalyzed reaction. In these embodiments, having an interference domain that substantially reduces the flux of an interferent may result in a sensor element with decreased sensitivity and a lower signal level than an equivalent sensor element without the interference domain. In view of the tradeoff that exists in certain interference domains between sensor sensitivity and interference blocking capability, it is contemplated that in certain embodiments, the sensor system may comprise a plurality of sensor elements, with each having different levels of interference blocking capabilities and/or having specificity for different interferents. Alternatively or additionally, the plurality of sensor elements may each have different specificity for different interferents. In one exemplary embodiment, the sensor system may comprise a first sensor element that has an interference domain specifically designed to substantially reduce (or block) the flux of a certain interferent (e.g., acetaminophen), a second sensor element that has a different interference domain specifically designed to substantially reduce (or block) the flux of another interferent (e.g., uric acid), a third sensor element that has yet another different interference domain specifically designed to substantially reduce (or block) the flux of yet another interferent (e.g., ascorbic acid), and a fourth sensor element that has no interference domain.
  • Detection of an elevated level of one or more interferents may be obtained by comparing signals associated with the different sensor elements. In certain embodiments, the processor module may be programmed to identify the presence of interferents by comparing sensor data with certain data patterns known to correspond to the presence of interferents. Upon detection of elevated levels of one or more interferents, processing of the plurality of data streams associated with their respective plurality of sensor elements may be adjusted. For example, in embodiments in which weighted averages or weighted sums are used to estimate analyte concentration value, sensor data associated with the sensor element configured with a higher interferent blocking ability may be accorded more weight, and sensor data associated with the sensor element(s) without or with minimal interferent blocking ability may be accorded less (or no) weight. Alternatively or additionally, a different filtering algorithm may be used on the sensor data, the sensor system may stop displaying data to the user if the interference level exceeds a certain threshold, and/or an alert or alarm may be triggered to prompt the user to take certain actions (e.g., to perform additional calibrations).
  • In some embodiments, the membrane system further includes an enzyme domain 206 disposed more distally from the electroactive surfaces than the interference domain; however other configurations are also contemplated. In some embodiments, the enzyme domain provides an enzyme to catalyze the reaction of the analyte and its co-reactant, as described in more detail below. In the some embodiments of a glucose sensor, the enzyme domain includes glucose oxidase (GOX); however other enzymes, for example, alcohol dehydrogenase, galactose oxidase or uricase oxidase, can also be used. In some embodiments, the enzyme domain is configured and arranged for detection of at least one of substance such as albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, a drug, various minerals, various metabolites, and the like. In a further embodiment, the sensor is configured and arranged to detect two or more of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, a drug, various minerals, various metabolites, and the like.
  • For an enzyme-based electrochemical glucose sensor to perform well, the sensor's response may be limited by neither enzyme activity nor co-reactant concentration. Because enzymes, including glucose oxidase, are subject to deactivation as a function of time even in ambient conditions, this behavior can be compensated for in forming the enzyme domain. In some embodiments, the enzyme domain is constructed of aqueous dispersions of colloidal polyurethane polymers including the enzyme. However, in alternative embodiments the enzyme domain is constructed from an oxygen enhancing material, such as silicone, or fluorocarbon, for example, in order to provide a supply of excess oxygen during transient ischemia. In some embodiments, the enzyme is immobilized within the domain. See, e.g., U.S. Patent Application Publication No. US-2005-0054909-A1.
  • In some embodiments, the enzyme domain is deposited onto the interference domain for a domain thickness of from about 0.05 micron or less to about 20 microns or more, or from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, or from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. However in some embodiments, the enzyme domain is deposited directly onto the electroactive surfaces. In other embodiments, the enzyme domain is formed by dip coating or spray coating one or more layers at a predetermined concentration of the coating solution, insertion rate, dwell time, withdrawal rate, or desired thickness.
  • In some embodiments, the sensor system comprises a plurality of sensor elements, each with different enzyme domain properties. As described elsewhere herein, in certain embodiments, the sensor system comprises a plurality of sensor elements each designed to have a different sensitivity or current sensitivity than the other sensor element(s). In one embodiment, the differences in sensor sensitivity or current density may be achieved by modifying each sensor element to have a different amount of enzyme. In other embodiments, one of the plurality of sensor elements may have an enzyme domain which comprises polymers that contain mediators and enzymes that chemically attach to the polymers. The mediator used may oxidize at lower potentials than hydrogen peroxide, and thus fewer oxidizable interferents are oxidized at these low potentials. Accordingly, one of the sensor elements may have a very low baseline (i.e., a baseline that approaches a zero baseline and that does not receive substantial signal contribution from non-glucose-related noise), such that the signal generated therefrom can be used to compare with the signal from another sensor element operating at a higher bias potential. By comparing the signals, the presence of interferents can be detected. Furthermore, in certain embodiments, the baseline present in the signal from the sensor element operating at a higher bias potential may be calculated (from the signal generated from the sensor element operating with a baseline of about zero) by comparing the signals from the two sensor elements (e.g., by subtracting one signal from another signal after accounting for scaling). In turn, signal contribution from non-glucose-related noise can be subtracted from the signal of the sensor element operating at a higher bias potential, thereby improving its signal's the signal to noise ratio, which results in greatly improved sensor accuracy. In certain embodiments, one of the plurality of sensor elements may have an enzyme domain which uses a mediator that may reduce or eliminate the need for oxygen, as the mediator take the place of oxygen in the enzyme reaction. Such a sensor element may be tuned for (and configured to detect) low oxygen environments, while other sensor elements are used in normal or high in vivo oxygen environments.
  • In some embodiments, the membrane system is provided with a diffusion resistance domain, also referred to as a diffusion resistance layer, a resistance domain, or a resistance layer. In some embodiments, the membrane system is situated more distal to the electrode relative to the enzyme, electrode, and interference domains. The diffusion resistance domain serves to control the flux of oxygen and other analytes (for example, glucose) to the underlying enzyme domain. As described in more detail elsewhere herein, there typically exists a molar excess of glucose relative to the amount of oxygen in blood, i.e., for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present (see, e.g., Updike et al., Diabetes Care 5:207-21(1982)). However, an immobilized enzyme-based sensor employing oxygen as cofactor is supplied with oxygen in non-rate-limiting excess in order to respond linearly to changes in glucose concentration, while not responding to changes in oxygen tension. More specifically, when a glucose-monitoring reaction is oxygen-limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels may be obtained only up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 500 mg/dL.
  • The diffusion resistance domain of certain embodiments includes a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme domain, thereby rendering oxygen in non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the diffusion resistance domain. In some embodiments, the diffusion resistance domain exhibits an oxygen-to-glucose permeability ratio of approximately 200:1, but in other embodiments the oxygen-to-glucose permeability ratio is approximately 100:1, 125:1, 130:1, 135:1, 150:1, 175:1, 225:1, 250:1, 275:1, 300:1, or 500:1. As a result of the high oxygen-to-glucose permeability ratio, one-dimensional reactant diffusion may provide sufficient excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes et al., Anal. Chem., 66:1520-1529 (1994)). In some embodiments, a lower ratio of oxygen-to-glucose is sufficient to provide excess oxygen by using a high oxygen soluble domain (for example, a silicone material) to enhance the supply/transport of oxygen to the enzyme membrane or electroactive surfaces. By enhancing the oxygen supply through the use of a silicone composition, for example, glucose concentration is less of a limiting factor. In other words, if more oxygen is supplied to the enzyme or electroactive surfaces, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess. Although the description provided herein is directed to a resistance domain for a glucose sensor, the resistance domain can be modified for other analytes and co-reactants as well.
  • In one embodiment, the resistance domain includes a polyurethane membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to an analyte sensor, the membrane being fabricated from commercially available materials. Suitable hydrophobic polymer components include polyurethane and polyetherurethaneurea. Polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material. A polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material. Diisocyanates that may be used include, but are not limited to, aliphatic diisocyanates containing from about 4 to about 8 methylene units. Diisocyanates containing cycloaliphatic moieties can also be useful in the preparation of the polymer and copolymer components of the membranes, in accordance with some embodiments. The material that forms the basis of the hydrophobic matrix of the resistance domain can be any of those known in the art as appropriate for use as membranes in sensor devices and as having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes. Examples of materials that can be used to make non-polyurethane type membranes include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials, and mixtures or combinations thereof.
  • A suitable hydrophilic polymer component as employed in certain embodiments is polyethylene oxide. For example, one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethylene oxide. The polyethylene oxide portions of the copolymer are thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic polymer component. The 20% polyethylene oxide-based soft segment portion of the copolymer used to form the final blend affects the water pick-up and subsequent glucose permeability of the membrane.
  • In other embodiments, a lower ratio of oxygen-to-glucose is sufficient to provide excess oxygen by using a high oxygen solubility domain (for example, a silicone or fluorocarbon-based material or domain) to enhance the supply/transport of oxygen to the enzyme domain. If more oxygen is supplied to the enzyme, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess. In alternative embodiments, the resistance domain is formed from a silicone composition, such as is described in U.S. Patent Application Publication No. US-2005-0090607-A1.
  • In yet other embodiments, an oxygen conduit (for example, a high oxygen solubility domain formed from silicone or fluorochemicals) is provided that extends from the ex vivo portion of the sensor to the in vivo portion of the sensor to increase oxygen availability to the enzyme. The oxygen conduit can be formed as a part of the coating (insulating) material or can be a separate conduit associated with the assembly of wires that forms the sensor.
  • In some embodiments, the resistance domain deposited onto the enzyme domain yields a domain thickness of from about 0.05 microns or less to about 20 microns or more, or from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, or from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. The resistance domain can be deposited onto the enzyme domain using any of a variety of known deposition techniques, such as, but not limited to, vapor deposition, spray coating, or dip coating. In some embodiments, spray coating is desired. The spraying process atomizes and mists the solution, and therefore most or all of the solvent is evaporated prior to the coating material settling on the underlying domain, thereby minimizing contact of the solvent with the enzyme.
  • In some embodiments, the sensor system comprises a plurality of sensor elements, each with different diffusion resistance domain properties, such that each sensor element is configured to control the flux of the analyte or a co-analyte differently than the other sensor elements. For example, in some of these embodiments, each or some of the diffusion resistance domains of certain sensor element(s) can have sensitivities or current densities different from the other sensor elements, which allows for accuracy to be tuned or designed at low and high values, for example. Differences in diffusion resistance domain properties can be achieved by modifying the diffusion resistance domain, e.g., by modifying the thickness or composition of the diffusion resistance domain.
  • In some sensors, membranes are configured to provide, to generate, or to consume hydrogen peroxide molecules, depending upon the relevant physiological range that the sensor is configured to measure. This arrangement, in turn provides for more accurate measurements. Membranes configured to consume hydrogen peroxide molecules include superoxide dismutase, catalase, horseradish, and/or like compounds.
  • In one embodiment including first and second sensor elements with first and second membranes, respectively, the first and second membranes each comprise an enzyme (e.g., glucose oxidase) configured to generate hydrogen peroxide by reaction of glucose and oxygen with the enzyme, wherein the first and second sensor elements each comprise an electrode configured to measure at least some of the hydrogen peroxide generated within the first and second membranes. In certain of these embodiments, the first membrane is configured to consume more hydrogen peroxide than the second membrane system, for example, by providing in one of the membranes a hydrogen peroxide-consuming enzyme configured to reduce exogenous hydrogen peroxide originating from a source outside the sensor. Although one method or system for consuming hydrogen peroxide is described herein, any of a variety of systems and methods for consuming hydrogen peroxide in a membrane can alternatively or additionally be used. Advantageously, by configuring one membrane to consume more hydrogen peroxide than another membrane, the glucose-related to non-glucose-related signal ratio of one of the sensors element or its sensor sensitivity or current density can be adjusted (e.g., relative to the other sensor element). In certain embodiments, one of the membranes is configured to direct more hydrogen peroxide to its associated electrode than the other membrane, which can be accomplished by a membrane configured to block at least some of the hydrogen peroxide from escaping from the sensor element, for example. Although one method of directing hydrogen peroxide is described herein, any of a variety of systems and methods for directing hydrogen peroxide in a membrane can alternatively or additionally be used. Advantageously, by designing one membrane to direct more hydrogen peroxide to its associated electrode than the other membrane, the glucose-related to non-glucose-related signal ratio of one of the sensor element or its sensor sensitivity or current density can be adjusted (e.g., relative to the other sensor element).
  • In some embodiments, sensor elements comprising the membrane system have been found to provide sustained function (at least 90% signal strength), even at low oxygen levels (for example, at about 0.6 mg/L O2). While not wishing to be bound by theory, it is believed that the diffusion resistance domain provides sufficient diffusion resistivity, such that oxygen limitations of the sensor occur at a substantially lower oxygen concentration than with conventional sensors.
  • In some embodiments, one or more of the sensor elements of a sensor system exhibits a 100±10% functionality, or about 100% functionality over physiological glucose concentrations (from about 40 mg/dL to about 400 mg/dL) at oxygen concentrations as low as about 0.6 mg/L or less, or about 0.3 mg/L or less, or about 0.25 mg/L or less, or about 0.15 mg/L or less, or about 0.1 mg/L or less, or about 0.05 mg/L or less. The glucose sensors of some embodiments consume 1 μg or less of enzyme over their operational lifetimes (e.g., 7 days or less).
  • Many conventional analyte sensors encounter initial noise caused in part by metabolic processes that react due to a foreign body response when a sensor is introduced into the body. It has been found that with conventional analyte sensors inserted into a host, measurement performance is generally better a few days post-insertion, as compared to measurement performance during the time period right after insertion. This effect is evident by the increased level of non-analyte-related signals or the suppression of analyte-related signals which occurs during approximately the first 2 to 36 or more hours after sensor insertion. These measurement anomalies are typically resolved spontaneously, after which the sensors become less noisy, show improved sensitivity, and are generally more accurate than during the period right after insertion. Moreover, with these conventional analyte sensors, during the period right after insertion, non-analyte-related signals often predominate over analyte signals when hosts are sleeping or sedentary for a period of time. Other examples of noise are described in more detail in U.S. Pat. No. 7,310,544. It is contemplated that the sensors described herein of certain embodiments can include a biointerface membrane that encases the entire sensor or encases a portion of the sensor, to minimize migration or growth of host inflammatory cells, immune cells, or soluble factors to sensitive regions of the device. In some embodiments, the biointerface membrane promotes vascularization of the device and facilitates transport of solutes across the device-tissue interface to enhance the device's performance. In some embodiments, a sensor with a biointerface domain has an initial sleep period (e.g., the first few hours, days, or weeks after implant), during which the sensor does not provide accurate measurements, as vascularization of the sensor progresses. Other embodiments of the biointerface are described in more detail in U.S. Patent Application Publication No. US-2007-0027370-A1.
  • In some embodiments of the sensor system comprising a first sensor element with a first biointerface domain and a second sensor element with a second biointerface domain, the first and second biointerface membranes comprise three dimensional architectures that are different from each other. For example, the three dimensional architecture of the first biointerface membrane can comprise pores defined by a first range of sizes, and the three dimensional architecture of the second biointerface membranes can comprise pores defined by a second range of sizes. In some exemplary embodiments, the first range of sizes (e.g., less than about 20 microns) is smaller than the second range of sizes (e.g., greater than about 20 microns). As another example, the three dimensional architecture of the first or second sensor element is porous while that of the other sensor element is nonporous. Other embodiments of the three dimensional architecture are described in more detail in U.S. Patent Application Publication No. US-2005-0251083-A1.
  • FIG. 3 is a block diagram illustrating one embodiment of the sensor electronics 300. In this embodiment, the ASIC 305 is coupled to a communication port 338 and a battery 334. Although the illustrated embodiment includes an Application Specific Integrated Circuit (ASIC) 305 that includes much of the electronic circuitry, in other embodiments, the ASIC 305 is replaced with one or more of any suitable logic device, such as, for example, field programmable gate arrays (FPGA), microprocessors, analog circuitry, or other digital or analog circuitry.
  • In the embodiment shown in FIG. 3, a potentiostat 310 is coupled to a glucose sensor in order to receive sensor data from the glucose sensor. Any of a variety of mechanisms can be used to couple the potentiostat 310 to the glucose sensor. For example, in one embodiment, the one or more ends of the working electrode(s) is exposed to provide electrical connection between the potentiostat and the first and second sensor elements. In one embodiment, the potentiostat 310 provides a voltage to the glucose sensor in order to bias the sensor to enable measurement of a current value indicative of the analyte concentration in the host (also referred to as the analog portion). The potentiostat can have one channel or multiple channels, depending on the number of working electrodes, for example. In some embodiments, the potentiostat 310 includes a resistor (not shown) that translates the current into voltage. In some embodiments, a current to frequency converter is provided that is configured to continuously integrate the measured current, for example, using a charge counting device. In some embodiments, an A/D converter digitizes the analog signal into “counts” for processing. Accordingly, the resulting raw data stream in counts is directly related to the current measured by the potentiostat 310.
  • A processor module 314 is the central control unit that controls the processing of the sensor electronics. In some embodiments, the processor module 314 is formed as part of a custom chip, such as an ASIC, however a computer system other than an ASIC can be used to process data as described herein, for example a microprocessor can be used for some or all of the sensor electronics module processing. The processor module 314 typically provides a program memory 316, which provides semi-permanent storage of data, for example, storing data such as sensor identifier (ID) and programming to process data streams (for example, filtering, calibration, fail-safe checking, and the like). The processor additionally can be used for the system's cache memory, for example for temporarily storing recent sensor data. In some embodiments, the processor module comprises memory storage components such as ROM, RAM, dynamic-RAM, static-RAM, non-static RAM, EEPROM, rewritable ROMs, flash memory, and the like. In one exemplary embodiment, RAM 318 can be used for the system's cache memory, for example for temporarily storing recent sensor data.
  • In some embodiments, the processor module 314 comprises a digital filter, for example, an IIR or FIR filter, configured to smooth the raw data stream from the A/D converter. Generally, digital filters are programmed to filter data sampled at a predetermined time interval (also referred to as a sample rate). In some embodiments, such as when the potentiostat 310 is configured to measure the analyte at discrete time intervals, these time intervals determine the sample rate of the digital filter. In some alternative embodiments, wherein the potentiostat 310 is configured to continuously measure the analyte, for example, using a current-to-frequency converter, the processor module 314 can be programmed to request a digital value from the integrator at a predetermined time interval, also referred to as the acquisition time. In these alternative embodiments, the values obtained by the processor module 314 are advantageously averaged over the acquisition time due the continuity of the current measurement. Accordingly, the acquisition time determines the sample rate of the digital filter.
  • In one embodiment, the processor module 314 is further configured to generate data packages for transmission to one or more display devices. Furthermore, the processor module 314 generates data packets for transmission to these outside sources, e.g., via telemetry. As discussed above, the data packages can be customizable for each display device, for example, and may include any available data, such as displayable sensor information having customized sensor data or transformed sensor data, sensor/sensor electronics module ID code, raw data, filtered data, calibrated data, rate of change information, trend information, error detection or correction, or the like. A data storage memory 320 is operably connected to the processor module 314 and is configured to store a variety of sensor information. In some embodiments, the data storage memory stores 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30 or more days of continuous analyte sensor data. In some embodiments, the data storage memory 220 stores sensor information such as raw sensor data (one or more raw analyte concentration values), transformed sensor data, or any other displayable sensor information.
  • In some embodiments, the sensor electronics are configured to receive and store contact information in the data storage memory (or program memory), including a phone number or email address for the sensor's host or health care providers for the host (e.g., family member(s), nurse(s), doctor(s), or other health care provider(s)), which enables communication with a contact person (e.g., via phone, pager or text messaging in response to an alarm (e.g., a hypoglycemic alarm that has not been responded to by the host)). In some embodiments, user parameters can be programmed into (or modified in) the data storage memory (or program memory) of the sensor electronics module, via a display device such as a personal computer, personal digital assistant, or the like. User parameters can include contact information, alert/alarms settings (e.g., thresholds, sounds, volume, or the like), calibration information, font size, display preferences, defaults (e.g., screens), or the like. Alternatively, the sensor electronics module can be configured for direct programming of certain user parameters.
  • In one embodiment, clinical data of a medical practitioner is uploaded to the sensor electronics and stored on the data storage memory 320, for example. Thus, information regarding the host's condition, treatments, medications, etc., can be stored on the sensor electronics and can be viewable by the host or other authorized user. In one embodiment, certain of the clinical data are included in a data package that is transmitted to a display device in response to triggering of an alert. The clinical data can be uploaded to the sensor electronics via any available communication protocol, such as direct transmission via a wireless Bluetooth, infrared, or RF connection, or via a wired USB connection, for example. Additionally, the clinical data can be uploaded to the sensor electronics via indirect transmission, such as via one or more networks (e.g., local area, personal area, or wide area networks, or the Internet) or via a repeater device that receives the clinical data from a device of the medical practitioner and retransmits the clinical data to the sensor electronics module.
  • Any of a variety of configurations of separate data storage and program memories can be used, including one or multiple memories that provide the necessary storage space to support the sensor electronic data processing and storage requirements. Accordingly, the described location of storage of any particular information or programming is not meant to be limiting, but rather exemplary.
  • In some embodiments, the sensor electronics is configured to perform smoothing or filtering algorithms on the sensor data (e.g., raw data stream or other sensor information), wherein the smoothed or filtered data is stored in the data storage memory as transformed data. U.S. Patent Application Publication No. US-2005-0043598-A1, U.S. Patent Application Publication No. US-2007-0032706-A1, U.S. Patent Application Publication No. US-2007-0016381-A1 and U.S. Patent Application Publication No. US-2008-0033254-A1 describe some algorithms useful in performing data smoothing or filtering herein (including signal artifacts replacement).
  • In some embodiments, the sensor electronics are configured to calibrate the sensor data, and the data storage memory 320 stores the calibrated sensor data points as transformed sensor data. In some further embodiments, the sensor electronics are configured to wirelessly receive calibration information from a display device, from which the sensor electronics module is configured to calibrate the sensor data. U.S. Pat. No. 7,310,544 and U.S. Pat. No. 6,931,327 describe some algorithms useful in sensor calibration herein.
  • In some embodiments, the sensor electronics are configured to perform additional algorithmic processing on the sensor data (e.g., raw data stream or other sensor information) and the data storage memory 320 is configured to store the transformed sensor data or sensor diagnostic information associated with the algorithms. U.S. Pat. No. 7,310,544 and U.S. Pat. No. 6,931,327 describe some algorithms that can be processed by the sensor electronics module.
  • A user interface 322 can include any of a variety of interfaces, such as one or more buttons 324, a liquid crystal display (LCD) 326, a vibrator 328, an audio transducer (e.g., speaker) 330, backlight, or the like. A backlight can be provided, for example, to aid the user in reading the LCD in low light conditions. The components that comprise the user interface 322 provide controls to interact with the user (e.g., the host). One or more buttons 324 can allow, for example, toggle, menu selection, option selection, status selection, yes/no response to on-screen questions, a “turn off” function (e.g., for an alarm), a “snooze” function (e.g., for an alarm), a reset, or the like. The LCD 326 can be provided, for example, to provide the user with visual data output. The audio transducer 330 (e.g., speaker) provides audible signals in response to triggering of certain alerts, such as present or predicted hyper- and hypoglycemic conditions. In some embodiments, audible signals are differentiated by tone, volume, duty cycle, pattern, duration, or the like. In some embodiments, the audible signal is configured to be silenced (e.g., snoozed or turned off) by pressing one or more buttons 324 on the sensor electronics module or by signaling the sensor electronics module using a button or selection on a display device (e.g., key fob, cell phone, or the like).
  • In some embodiments, the audio transducer 330 is mounted to the circuit board or the sensor electronics module housing. In some embodiments, the sound produced by the audio transducer 330 exits the device from a sound port in the sensor electronics, such as a hole on the sensor electronics. The hole may be waterproofed or otherwise protected from moisture by a waterproof material that easily allows sound waves there through. In one embodiment, the hole is protected from moisture by an acoustically transparent venting material (wherein the material allows at least about 60%, 70%, 80%, 90%, 95%, or more of the transmitted sound waves therethrough), such as a screw-in vent, a press-fit vent, a snap-in vent, an o-ring vent, and adhesive vent, or the like. One manufacturer that provides acoustically transparent venting material is W.L. Gore & Associates (Elkton, Md.) under the trade name Protective Vents (Acoustic Vents).
  • The vibrator 328 can include a motor that provides, for example, tactile signals or alerts for reasons such as described with reference to the audio transducer, above. In one embodiment, the vibrator motor 328 provides a signal in response to triggering of one or more alerts, which can be triggered by the processor module 314 that processes algorithms useful in determining whether alert conditions associated with one or more alerts have been met, for example, present or predicted hyper- and hypoglycemic conditions. In some embodiments, one or more different alerts are differentiated by intensity, quantity, pattern, duration, or the like. In some embodiments, the alarm is configured to be silenced (e.g., snoozed or turned off) by pressing one or more buttons 324 on the sensor electronics or by signaling the sensor electronics using a button or selection on a display device (e.g., key fob, cell phone, or the like).
  • In some embodiments, the vibrator motor 328 is mounted to the circuit board or the sensor electronics housing. The diameter of the motor may be less than or equal to about 6 mm, 5 mm, 4 mm, 3.5 mm, 3 mm, 2.5 mm, or 2 mm. The overall length of the vibrator motor may be less than or equal to about 18 mm, 16 mm, 14 mm, 12 mm, or 10 mm. By providing a low power vibrator motor, the motor can be placed in the sensor electronics without significantly affecting the low profile nature of the on-skin sensor electronics.
  • In some embodiments, the vibrator motor 328 is used to provide a vibratory alarm that creates vibration or movement of the sensor within the host. While not wishing to be bound by theory, it is believed that a concentration increase of non-analyte-signal-causing electroactive species, such as electroactive metabolites from cellular metabolism and wound healing, can interfere with sensor function and cause noise observed during host start-up or sedentary periods. For example, local lymph pooling, which can occur when a part of the body is compressed or when the body is inactive, can cause, in part, this local build up of interferents (e.g., electroactive metabolites). Similarly, a local accumulation of wound healing metabolic products (e.g., at the site of sensor insertion) likely causes noise on the sensor during the first few hours to days after sensor insertion. Accordingly, it is believed vibration or movement of the sensor at the insertion site, after sensor insertion, can reduce or eliminate pooling of local interfering species caused by the wound healing process described above. In some embodiments, the sensor is vibrated or moved at predetermined intervals or in response to noise artifacts detected on the sensor signal. U.S. Patent Application Publication No. US-2005-0043598-A1, U.S. Patent Application Publication No. US-2007-0032706-A1, U.S. Patent Application Publication No. US-2007-0016381-A1 and U.S. Patent Application Publication No. US-2008-0033254-A1 describe systems and methods for detection of noise artifacts, noise episodes or classification of noise, which can be useful with the embodiments described herein.
  • In another alternative embodiment, the sensor electronics are configured to transmit sound waves into the host's body (e.g., abdomen or other body part) that are felt by the host, thereby alerting the host without calling attention to the host, or allowing a hearing-impaired visually-impaired, or tactilely-impaired host to be alerted. In some embodiments, the sound waves are transmitted into the host's body using the electrodes of the sensor itself. In some embodiments, one or more transcutaneous electrodes (other than the electrodes related to analyte measurement) are provided for transmitting sound waves. In some embodiments, electrodes are provided in the adhesive patch that holds the sensor/sensor electronics module onto the host's body, which can be used to transmit the sound waves. In some embodiments, different sound waves are used to transmit different alarm conditions to the host. The sound waves can be differentiated by any sound characteristic, such as but not limited to amplitude, frequency and pattern.
  • In another alternative embodiment, mild electric shock can be used to transmit one or more alarms to the host. The level of shock can be designed such that the shock is not overly uncomfortable to the host; however, the intensity of the level of shock can be configured to increase when a host does not respond to (e.g., snooze or turn off) an alert within an amount of time. In some embodiments, the shock is delivered to the host's body using the electrodes of the sensor itself. In some embodiments, the sensor system includes one or more additional electrodes configured for delivering the shock to the host (alone or in combination with the electrodes related to analyte measurement). In still another example, the one or more electrodes are disposed on the host's skin, such as in the adhesive patch, for delivering the shock. Alternatively, one or more additional patches, each including an electrode, are provided, for delivering the shock. The additional patches can be in wired or wireless communication with the sensor electronics module.
  • A telemetry module 332 is operably connected to the processor module 314 and provides the hardware, firmware, and/or software that enable wireless communication between the sensor electronics and one or more display devices. A variety of wireless communication technologies that can be implemented in the telemetry module 332 include radio frequency (RF), infrared (IR), Bluetooth, spread spectrum communication, frequency hopping communication, ZigBee, IEEE 802.11/802.16, wireless (e.g., cellular) telecommunication, paging network communication, magnetic induction, satellite data communication, GPRS, ANT, or the like. In one embodiment, the telemetry module comprises a Bluetooth chip. In some embodiments, Bluetooth technology is implemented in a combination of the telemetry module 332 and the processor module 314.
  • A battery 334 is operatively connected to the processor module 314 (and possibly other components of the sensor electronics) and provides the necessary power for the sensor electronics. In one embodiment, the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used (e.g., AAA, Nickel-cadmium, Zinc-carbon, Alkaline, Lithium, Nickel-metal hydride, Lithium-ion, Zinc-air, Zinc-mercury oxide, Silver-zinc, or hermetically-sealed). In some embodiments the battery is rechargeable. In some embodiments, a plurality of batteries is used to power the system. In still other embodiments, the receiver is transcutaneously powered via an inductive coupling, for example.
  • A battery charger or regulator 336 can be configured to receive energy from an internal or external charger. In one embodiment, a battery regulator (or balancer) 336 regulates the recharging process by bleeding off excess charge current to allow all cells or batteries in the sensor electronics module to be fully charged without overcharging other cells or batteries. In some embodiments, the battery 334 (or batteries) is configured to be charged via an inductive or wireless charging pad. Any of a variety of known methods of charging batteries can be employed, which can be implemented with the system described herein, including wired (cable/plug) and wireless methods.
  • One or more communication ports 338, also referred to as external connector(s), can be provided to allow communication with other devices, for example a PC communication (com) port can be provided to enable communication with systems that are separate from, or integral with, the sensor electronics module. The communication port, for example, can comprise a serial (e.g., universal serial bus or “USB”) communication port, allows for communicating with another computer system (e.g., PC, personal digital assistant or “PDA,” server, or the like). In one exemplary embodiment, the sensor electronics is able to transmit historical data to a PC or other computing device for retrospective analysis by a patient or physician.
  • In continuous analyte sensor systems, the processor module of the sensor electronics and/or another computer system is configured to execute prospective algorithms used to generate transformed sensor data or displayable sensor information, including, for example, algorithms that: evaluate a clinical acceptability of reference or sensor data, evaluate calibration data for best calibration based on inclusion criteria, evaluate a quality of the calibration, compare estimated analyte values with time corresponding measured analyte values, analyze a variation of estimated analyte values, evaluate a stability of the sensor or sensor data, detect signal artifacts (noise), replace signal artifacts, determine a rate of change or trend of the sensor data, perform dynamic and intelligent analyte value estimation, perform diagnostics on the sensor or sensor data, set modes of operation, evaluate the data for aberrancies, or the like, which are described in more detail in U.S. Pat. No. 7,310,544, U.S. Pat. No. 6,931,327, U.S. Patent Application Publication No. US-2005-0043598-A1, U.S. Patent Application Publication No. US-2007-0032706-A1, U.S. Patent Application Publication No. US-2007-0016381-A1, U.S. Patent Application Publication No. US-2008-0033254-A1, U.S. Patent Application Publication No. US-2005-0203360-A1, U.S. Patent Application Publication No. US-2005-0154271-A1, U.S. Patent Application Publication No. US-2005-0192557-A1, U.S. Patent Application Publication No. US-2006-0222566-A1, U.S. Patent Application Publication No. US-2007-0203966-A1 and U.S. Patent Application Publication No. US-2007-0208245-A1. Furthermore, the sensor electronics can be configured to store the transformed sensor data (e.g., values, trend information) and to communicate the displayable sensor information to a plurality of different display devices. In some embodiments, the display devices are “dummy” devices, namely, they are configured to display the displayable sensor information as received from the sensor electronics, without any additional sensor data processing.
  • In an exemplary embodiment of an electrochemical analyte sensor, the sensor electronics is operatively connected to at least one sensor element configured to measure an analyte concentration in a first predetermined range and a second sensor element configured to measure an analyte concentration in a second predetermined range. In the example, the first range is for the most part different from the second range. In the exemplary embodiment, there can be an overlap of values in both ranges. For example, the first range can be used to measures glucose concentration values from about 0 mg/dL to about 100 mg/dL and the second range can be used to measure glucose concentration values from about 80 mg/dL to about 400 mg/dL.
  • A variety of conventional continuous glucose sensors have been developed for detecting and quantifying glucose concentration in a host. These sensors typically require one or more blood glucose measurements, or the like, from which calibration of the continuous glucose sensor is performed to calculate the relationship between the current output of the sensor and blood glucose measurements, so that meaningful glucose concentration values can be accurately calculated and communicated to a patient or doctor. Unfortunately, continuous glucose sensors can be sensitive to changes in the baseline current or sensitivity over time, for example, due to changes in a host's metabolism, maturation of the tissue at the biointerface of the sensor, presence of interfering species which cause a measurable increase or decrease in the signal, or the like. Therefore, in addition to initial calibration, continuous glucose sensors may be responsive to baseline or sensitivity changes over time. To achieve this, recalibration of the sensor may be required periodically. Consequently, users of conventional continuous glucose sensors may be required to obtain numerous blood glucose measurements daily or weekly, in order to maintain accurate calibration of the sensor over time. Some of the embodiments provide improved calibration techniques that utilize calibration and matched data points of one sensor element to further calibrate the second sensor element. In certain embodiments, a known reference value can be used to calibrate a plurality of sensor elements accurately.
  • FIG. 4 is a flowchart 400 illustrating calibration and output of sensor data, in one embodiment. Some of the embodiments provide a method for processing data from a sensor system configured for measurement of an analyte concentration in a host, where the sensor system includes a plurality of sensor elements, each or some of which measure different ranges of analyte concentration within the host and/or different time periods of implantation with a predetermined level of accuracy.
  • In step 402, the processor module receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from one or more of the plurality of sensor elements, each or some of which can be in wired or wireless communication with the sensor. In some embodiments, wherein the sensor system has two or more sensors elements configured and arranged to provide values in different analyte concentration ranges, the sensor data from the two or more sensor elements is received substantially simultaneously, such as within the same or serially received data transmissions. In some embodiments, wherein the sensor system has two or more sensor elements configured and arranged to provide values for different periods of implantation, sensor data from each of the sensor elements is received serially, for example.
  • In step 404, the processor module calibrates the first and/or second sensor elements. In some embodiments, calibrating the first sensor element includes processing an external reference value and/or one or more values provided by a manufacturer. For example, the user can administer a self-monitored blood analyte test to obtain an analyte value (e.g., a point) using any suitable analyte sensor, and then enter the numeric analyte value into the computer system.
  • In some embodiments, when the received sensor data is within an overlapping range of the predetermined measurement range of two sensor elements, the two sensor elements can be calibrated with the same calibration information. In some of these embodiments, a first sensor element is calibrated first, and then one or more calibrated sensor values from the first sensor element are then used to calibrate a second and/or another sensor element.
  • In some embodiments, a known relationship is defined between the first and second sensor elements, for example a relationship between the sensitivities or current densities of the first and second sensor elements, which is determined from prior in vitro and/or in vivo data. In such an embodiment, after calibration of the first sensor element, the known relationship, which is defined by a function, is then used to calibrate the second sensor element. In some embodiments, wherein first and second sensor elements are used for different time periods of a sensor session and/or sensor implantation, sensor data from one sensor element is used to calibrate the other sensor element during an overlapping time period of use.
  • In step 406, an output module provides output to the user via the user interface, for example. The output is associated with one or more measured analyte values, which are determined by converting the received sensor data into calibrated sensor data. User output can be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example. Other representations of the estimated analyte values, such as audio or tactile representations, for example, are also possible.
  • In some embodiments, wherein a plurality of sensor elements are configured and arranged to accurately measure within certain predetermined analyte concentration ranges, the processor module or output module is configured to output data, by using calibrated sensor data obtained from the particular sensor element associated with the range within which the measurement falls within. In some embodiments, wherein a plurality of sensor elements are configured and arranged for different time periods of sensor function, sensor data from one sensor element, including one or more calibrated sensor values, can be used to calibrate another sensor element, and so forth.
  • As discussed in more detail elsewhere herein, some analyte sensors can have an initial instability time period during which it is unstable for environmental, physiological, or other reasons. For example, for a sensor element implanted subcutaneously, its stabilization can be dependent upon the maturity of the tissue ingrowth around and within the sensor element (see, e.g., U.S. Patent Application Publication No. US-2005-0112169-A1). Accordingly, determination of sensor stability may involve waiting a first time period. As examples, wholly implantable sensors typically require a time period to allow for sufficient tissue ingrowth, and transdermal (e.g., transcutaneous) sensors are believed to typically have an initial period of noise due in part to wound healing within the host's tissue. Depending on the specific configuration of the sensor, the waiting period may last from about one minute to about three weeks. The waiting period can be determined by pretesting the sensor under similar conditions, or by analysis of the sensor data establishing that the sensor is stable. In some embodiments of a sensor system comprising a first sensor element and a second sensor element, the second sensor element is configured to measure the analyte concentration and provide data during the first time period. Once the first sensor element is deemed stable, data from the first sensor element may still require calibration, in order for it to provide accurate values. In some embodiments, in which sensor data from the second sensor element exhibits a correlative or predictive relationship with sensor data from the first sensor element, data from the second sensor element can be used to calibrate data from the first sensor element. Calibration of sensor data from the first sensor element using sensor data provided by the second sensor element can facilitate the use of the first sensor element data sooner and may reduce or even obviate the need to calibrate the first sensor element with single point calibration techniques, e.g., fingerstick tests, optical measuring techniques, etc.
  • As described above, in some embodiments, the sensor system comprises a plurality of sensor elements, each configured to measure values in various ranges. As also described above, although each sensor element of the sensor system can be “tuned” to a particular range, this arrangement does not preclude each sensor element from measuring analyte values across a physiologically relevant range, and thereby providing valuable information. Accordingly, it is contemplated that in certain embodiments, error correction comprising error checking is used. For example, error checking can comprise checking for data integrity by comparing sensor data from two or more sensor elements.
  • FIG. 5 is a flowchart 500 that illustrates measuring and processing of sensor data, in one embodiment. In step 502, the processor module receives sensor data (e.g., a data stream) including one or more time-spaced sensor data points, from one or more of the plurality of sensor elements, which can be in wired or wireless communication with the sensor, such as described in more detail elsewhere herein. In step 504, the processor module is configured to evaluate sensor data from one or more of the plurality of sensor elements. In some embodiments, the processor module evaluates the sensor data by polling sensor data from the one or more of the plurality of sensor elements. It is contemplated that a wide range of polling intervals are possible, which can be chosen with consideration of processing power and accuracy. For example, polling can occur about every 1 second, 10 seconds, 1 minute, 5 minutes, or any other interval suitable for the application contemplated.
  • In some embodiments, the processor module compares sensor data from a plurality of sensor elements. For example, the amplitudes of a first sensor element data (i.e., sensor data from a first sensor element) is compared to amplitudes of a second sensor element data (i.e., sensor data from a second sensor element). Accordingly, the sensor system can provide highly accurate measurement of analyte concentration by comparing the plurality of sensor element measurements.
  • In some embodiments, the processor module averages and/or integrates the sensor data from a plurality of sensor elements. The processor module may also accord the data generated by each of the plurality of sensor elements with a different weight. A weighted arithmetic average can be used to estimate analyte concentration and be calculated by the equation:
  • x _ = i = 1 n w i x i w i
  • in which xi is the analyte concentration measurement from a particular sensor element, x is the mean analyte concentration to be estimated, n is the number of sensor elements, and wi is the weight accorded to the analyte concentration measurement from that particular sensor element. It is contemplated that other weighted means (e.g., a weighted geometric mean or a weighted harmonic mean) may also be used, in accordance with other embodiments. In other embodiments, a weighted sum is used. A weighted sum may be calculated by the equation:
  • x _ = i = 1 n w i x i
  • In an exemplary embodiment, the sensor system processes data by taking first sensor element data and second sensor element data and weighting both about equally to obtain values in the overlapping ranges of the first and second sensor elements. Other examples include taking data from one sensor element and weighting it more heavily than data from another sensor element (e.g., taking 80% of a first sensor element data and 20% of a second sensor element data to obtain values in the first data range).
  • In an exemplary embodiment, the sensor system comprises two sensor elements, with a first sensor element tuned to a glucose concentration of about 30 mg/dL to about 100 mg/dL and a second sensor element tuned to a glucose concentration of about 80 mg/dL to about 500 mg/dL. The first and second sensor elements generate first and second signals, respectively. During use, the first signal and the second signal may be averaged or integrated to generate an estimate of a glucose concentration value. In certain embodiments, the weights accorded to the first signal and the second signal may depend on an initial glucose concentration value estimation. For example, if the initial glucose concentration value was estimated to be about 35 mg/dL, the sensor electronics may be programmed to instruct the processor to accord more weight to the first sensor element, and less weight (or no weight) accorded to the second sensor element. Instead, if the initial glucose concentration value was estimated to be about 300 mg/dL, the processor may be instructed to accord more weigh the second sensor element, and less weight (or no weight) to the first sensor element.
  • It should be understood that the distribution of weights among the different sensor elements may be a function of a parameter other than an analyte glucose concentration value. For example, the distribution of weights may be a function of any parameter (e.g., a parameter that affects measurement accuracy) or plurality of variables including, but not limited to, initial analyte concentration measurement, body temperature, oxygen concentration in host, presence of interferents, time since initiation of the sensor session, and combinations thereof. Additionally, the weight distribution among the different sensor elements may be based at least in part on an estimated value of the parameter and the estimated value's proximity to the different ranges associated with the parameters. For example, in a sensor system comprising three sensors elements, with a first sensor element tuned to an oxygen concentration range of from about 0.1 mg/L to 0.3 mg/L, a second sensor element tuned to an oxygen concentration range of from about 0.3 mg/L to 0.4 mg/L, and third sensor element tuned to an oxygen concentration range of from about 0.4 mg/L to 0.6 mg/L, an oxygen concentration estimation of 0.5 mg/L may result in the processor module according most weight to the third sensor element, less (or no) weight to the second sensor element, and even less (or no) weight to the first sensor element.
  • In some embodiments, at least two of the plurality of sensor elements may be configured (e.g., by membrane design) to have substantially the same baseline, but with different sensor sensitivities. In these embodiments, subtraction of one signal from the other signal with the same baseline can result in an additional signal that is substantially free from noise contribution (e.g., from interferents), because the noise component is subtracted out. Having an extra signal can be advantageous as it provides another basis for comparison. Also, it can provide for improved polling of sensor data. In addition, because this extra signal includes substantially no noise contribution, it has a very high signal to noise ratio, and thus can provide high analyte concentration measurement accuracy.
  • In various embodiments, the data provided by one sensor element signal is used during intervals of time when another sensor element is unable to obtain accurate measurements. For example, if a first sensor element is unable to obtain accurate data, during an interval of 5 minutes due to noise or other causes, data values from a second sensor element are used to fill in values for that particular 5-minute interval. In some embodiments, the values calculated are based completely on the second sensor element, but in other embodiments, the values are calculated by weighting data from both sensor elements. The weight accorded to the second sensor element versus the first sensor element can be dependent on the accuracy of the two sensor elements. For example, if during a time period the first sensor element is determined to be much more accurate than the second sensor element, the weight percentage accorded to data provided by the first sensor element can be, e.g., about 0.9 and that of the second sensor element can be, e.g., about 0.1. However, if during a time period the first and second sensor elements are both providing data that are determined to be similarly accurate, both sensor elements can be accorded about equal weight percentages. This weight distribution mechanism of data from a plurality of different sensor elements can reduce noise, thereby providing smoother and more accurate data. Evaluations that can be provided by the processor module include, for example, error correction, supplementation of sensor data, weighting of various sensors' data, and the like. It is contemplated that a wide range of weighted averages are possible.
  • In some embodiments, the processor module is configured to evaluate sensor data from a plurality of sensor elements by evaluating an accuracy of the one or more sensor data using known statistical and/or clinical evaluation methods. In some embodiments, the processor module evaluates accuracy of sensor data by comparing different levels of accuracy (e.g., reference data points within the overlapping portion of the first and second ranges of first and second sensor elements). In some embodiments, evaluating accuracy includes evaluating noise (e.g., analyte-related to non-analyte-related signal ratios of sensor data from two or more sensor elements). In some embodiments, the processor module evaluates the sensor data in order to validate one or more of the plurality of sensor elements and/or associated sensor data.
  • In step 506, an output module provides output to the user via the user interface, for example. User output can be in the form of any of the variety of representations described elsewhere herein, such as the representations described in regard to step 406.
  • It is contemplated that the electrodes and sensor elements described herein can be manufactured by employing a variety of techniques, such as drop coating, spray coating, and dip coating, for example. FIG. 6A is a flowchart summarizing the steps of one embodiment for manufacturing a working electrode, such as the one illustrated in FIG. 1A, which comprises a plurality of sensor elements, each configured to measure analyte concentration in a range (e.g., analyte concentration range, time period range during a sensor session, etc.) different from that of the other sensor element(s). In step 610, a working electrode comprising a plurality of discrete electroactive surface sections is provided, with each section spaced apart from the other(s) along the longitudinal axis of the working electrode. In step 620, membranes are applied onto the plurality of electroactive surface sections by a dip coating process, whereby the thicknesses of the membranes are controlled by controlling the number of times a coating solution is applied to the electroactive surface sections. Control of membrane thicknesses in turn permits control of certain membrane properties (e.g., sensitivity, current density, permeability). When in a vertical orientation, the working electrode is dipped into the coating solution at different depths. Because the plurality of electroactive surface sections are spaced apart along the longitudinal axis of the working electrode, by controlling the depth at which the working electrode is dipped into the coating solution, control can be obtained over whether a particular electroactive surface section is coated during a dipping sequence, or how thick the resulting coating is over a particular electroactive surface. For example, in one embodiment, during one dipping sequence, the entire working electrode is dipped five times into the coating solution, so that every electroactive surface section of the working electrode at that time is deposited with a membrane thickness associated with five dips. Subsequently, one or more of the electroactive surface sections (e.g., the one closest to the distal end of the working electrode) is dipped into the coating solution an additional three times, thereby forming in that particular electroactive surface section a membrane with a thickness associated with a total of eight dips. In this particular example, one or more sensor elements are formed with a thickness associated with five dips, while the other sensor element(s) are formed with a thickness associated with eight dips.
  • The method described above is not limited to the manufacturing of a working electrode comprising two sensor elements, as illustrated in FIG. 1A. The same concept can be applied to working electrodes comprising three, four, five, or more sensor elements. For example, in one embodiment, a first electroactive surface section associated with a first sensor element is dipped into the coating solution for a total of three times to achieve a first thickness, a second electroactive surface section associated with a second sensor element is dipped into the coating solution for a total of five times to achieve a second thickness, and a third electroactive surface section associated with a third sensor element is dipped into the coating solution for a total of seven times to achieve a third thickness.
  • In the embodiments described above, because membrane properties are controlled at least in part by membrane thickness, a single coating solution formulation can be used to form the different membranes. In other embodiments, however, different coating solution formulations are used to form different membranes. For example, as illustrated in FIG. 6B, in one embodiment, in step 650, a plurality of working electrodes are provided, with each working electrode comprising at least one electroactive surface section. Next, in step 660, each working electrode is coated with a different coating solution, resulting in a plurality of working electrodes, with each comprising at least one sensor element with membrane properties different from that of the other sensor element(s) of other working electrode(s). Afterwards, in step 670, the plurality of working electrodes are fastened together to form a sensor system, such as the one illustrated in FIG. 1B, which comprises a plurality of working electrodes, with each comprising at least one sensor element. The method described above is not limited to the manufacturing of a sensor system comprising two working electrodes, with each comprising one sensor element, as illustrated in FIG. 1B. The same concept can be applied to sensor systems comprising three, four, or more working electrodes, with each comprising one, two, three, four, five, or more sensor elements. Additional methods for manufacturing the sensors and membranes described herein are described in Provisional Application No. 61/222,815, filed Jul. 2, 2009 and U.S. patent application Ser. No. ______, filed Jul. 1, 2010, entitled “ANALYTE SENSORS AND METHOD OF MAKING SAME,” each of which is incorporated by reference herein in its entirety.
  • It is contemplated that in some embodiments, the aforementioned coating methods can be combined. For example, in one embodiment, a sensor system can be formed to comprise three working electrodes, with each working electrode comprising two sensor elements. In a further embodiment, the three working electrodes are each coated with a different coating solution formulation, with each working electrode comprising sensor elements with different membrane thicknesses.
  • In some embodiments, differences in membrane properties between different sensor elements are achieved by subjecting different sensor elements to different curing processes or conditions. For example, in one embodiment, two electroactive surface sections are coated with one coating solution comprising a polymer system to form a first and a second sensor element. Thereafter, the first sensor element is subjected to high energy UV light for a certain period of time, while the second sensor element is subjected to the same UV light for a different period of time. Thus, in this embodiment, the crosslink densities of the first and second sensor elements are different, thereby resulting in membranes with different sensitivities and current densities. Alternatively, differentiation of membrane properties is achieved by subjecting the sensor elements to other process condition variations, such as differences in radiation (e.g., different wavelengths of light) or differences in temperature, for example. In another example, selective photolithography is used to achieve different sensitivities or current densities, for example, by selectively masking certain membranes associated with certain sensor elements during at least a portion of the photolithographic procedure. In yet another example, a crosslinker is applied to the base polymer (e.g., polyurethane) to create different crosslink densities.
  • While various embodiments of the invention have been described above, it should be understood that they have been presented by way of example only, and not by way of limitation. Likewise, the various diagrams may depict an example architectural or other configuration for the disclosure, which is done to aid in understanding the features and functionality that can be included in the disclosure. The disclosure is not restricted to the illustrated example architectures or configurations, but can be implemented using a variety of alternative architectures and configurations. Additionally, although the disclosure is described above in terms of various exemplary embodiments and implementations, it should be understood that the various features and functionality described in one or more of the individual embodiments are not limited in their applicability to the particular embodiment with which they are described. They instead can be applied, alone or in some combination, to one or more of the other embodiments of the disclosure, whether or not such embodiments are described, and whether or not such features are presented as being a part of a described embodiment. Thus the breadth and scope of the present disclosure should not be limited by any of the above-described exemplary embodiments.
  • It will be appreciated that, for clarity purposes, the above description has described embodiments with reference to different functional units. However, it will be apparent that any suitable distribution of functionality between different functional units may be used without detracting from the invention. For example, functionality illustrated to be performed by separate computing devices may be performed by the same computing device. Likewise, functionality illustrated to be performed by a single computing device may be distributed amongst several computing devices. Hence, references to specific functional units are only to be seen as references to suitable means for providing the described functionality, rather than indicative of a strict logical or physical structure or organization.
  • All references cited herein are incorporated herein by reference in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
  • Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to a person of ordinary skill in the art, and are not to be limited to a special or customized meaning unless expressly so defined herein.
  • Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as ‘known’, ‘normal’, ‘standard’, and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like ‘preferably,’ ‘preferred,’ ‘desired,’ or ‘desirable,’ and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the invention, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the invention. Likewise, a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise. Similarly, a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.
  • With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.
  • It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
  • All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term ‘about.’ Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
  • Furthermore, although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it is apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather to also cover all modification and alternatives coming with the true scope and spirit of the invention.

Claims (31)

1. A sensor system for continuous measurement of an analyte concentration in a host, the sensor system comprising:
a first sensor element configured to measure an analyte concentration and generate a first signal;
a second sensor element configured to measure the analyte concentration and generate a second signal, the second sensor element having at least one characteristic different from the first sensor element; and
sensor electronics configured to determine an analyte concentration value based on at least one of the first signal or the second signal.
2. The system of claim 1, wherein the sensor electronics are configured to estimate an analyte concentration value based on at least one of the first signal or the second signal and based on an estimation of a parameter.
3. The system of claim 2, wherein the sensor electronics are further configured to average or integrate the first signal and the second signal.
4. The system of claim 3, wherein the sensor electronics are further configured to assign a first weight to the first signal and assign a second weight to the second signal, wherein a magnitude of the first weight and a magnitude of the second weight are dependent on the estimation of the parameter.
5. The system of claim 4, wherein the parameter is associated with the analyte concentration.
6. The system of claim 2, wherein the parameter is associated with a time period of a sensor session.
7. The system of claim 2, wherein the parameter is associated with a presence of a level of an interferent.
8. The system of claim 2, wherein the parameter is associated with a concentration of oxygen.
9. The system of claim 1, wherein the first sensor element comprises a first membrane having a first hydrophilic component and a first hydrophobic component, wherein the second sensor element comprises a second membrane having a second hydrophilic component and a second hydrophobic component, and wherein the first sensor membrane and the second sensor membrane have a different hydrophilic to hydrophobic ratio.
10. The sensor system of claim 9, wherein the first membrane comprises a first domain configured to reduce a flux of the analyte therethrough, wherein the second membrane comprises a second domain configured to reduce a flux of the analyte therethrough, and wherein the first domain and the second domain are different.
11. The system of claim 1, further comprising a potentiostat configured to apply a first bias potential to the first sensor element and to apply a second bias potential to the second sensor element, wherein the first bias potential and the second bias potential are different.
12. The system of claim 1, wherein the first sensor element comprises a first membrane configured to reduce a flux of interferents therethrough, wherein the second sensor element comprises a second membrane configured to reduce a flux of interferents therethrough, and wherein interferent blocking characteristics of the first membrane and the second membrane are different.
13. The system of claim 1, wherein the first sensor element is further configured to monitor at least one levels of an interferent.
14. A method for processing data from a sensor system configured for continuous measurement of an analyte concentration in a host, the method comprising:
receiving a first signal, associated with an analyte concentration in a host, from a first sensor element;
receiving a second signal, associated with the analyte concentration in the host, from a second sensor element, wherein the second sensor element has at least one characteristic different from the first sensor element; and
determining, using sensor electronics, an analyte concentration value based on at least one of the first signal or the second signal.
15. The method of claim 14, wherein determining the analyte concentration value is further based on an estimation of a parameter.
16. The method of claim 15 wherein determining the analyte concentration value comprises averaging or integrating the first signal and the second signal.
17. The method of claim 16, wherein averaging or integrating the first signal and the second signal comprises assigning a first weight to the first signal and assigning a second weight to the second signal, wherein a magnitude of the first weight and a magnitude of the second weight are dependent on the estimation of the parameter.
18. The method of claim 17, wherein the parameter is associated with the analyte concentration.
19. The method of claim 15, wherein the parameter is associated with a time period of a sensor session.
20. The method of claim 15, wherein the parameter is associated with a presence of a level of an interferent.
21. The method of claim 15, wherein the parameter is associated with a concentration of oxygen.
22. The method of claim 14, further comprising applying a first bias potential to the first sensor element and a second bias potential to the second sensor element, wherein the first bias potential and the second bias potential are different.
23. A sensor system for continuous measurement of an analyte concentration in a host, the sensor system comprising:
a first sensor element configured to measure analyte concentrations over a first time period of in vivo implantation; and
a second sensor element configured to measure analyte concentrations over a second time period of in vivo implantation, wherein the first time period and the second time period are different.
24. The sensor system of claim 23, wherein the first time period is associated with an initial period of in vivo implantation, wherein the second time period is associated with a second time period of in vivo implantation, and wherein the second period begins after the initial period of in vivo implantation has begun.
25. The sensor system of claim 24, wherein the first time period and the second time period overlap partially, but not completely.
26. The sensor system of claim 24, wherein the first time period and the second time period do not overlap.
27. The sensor system of claim 24, wherein the first time period is from about day 1 post-implantation to about day 3 post-implantation, and wherein the second time period is from about day 2 post-implantation to about day 10 post-implantation.
28. The sensor system of claim 24, wherein the first time period is from about day 1 post-implantation to about day 21 post-implantation, and wherein the second time period is from about day 10 post-implantation to about year 1 post-implantation.
29. The sensor system of claim 23, wherein the sensor system is configured for implantation wholly in a tissue of a host.
30. The sensor system of claim 23, wherein the sensor system is configured for transcutaneous placement through a skin of a host.
31. The sensor system of claim 23, wherein the sensor system is configured for fluid communication with a vascular system of a host.
US12/829,264 2009-07-02 2010-07-01 Analyte sensor Abandoned US20110024307A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/829,264 US20110024307A1 (en) 2009-07-02 2010-07-01 Analyte sensor
US14/057,720 US9907497B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US14/058,091 US9320466B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US15/877,682 US10420494B2 (en) 2009-07-02 2018-01-23 Analyte sensor
US16/537,419 US11559229B2 (en) 2009-07-02 2019-08-09 Analyte sensor
US18/145,220 US20230129853A1 (en) 2009-07-02 2022-12-22 Analyte sensor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22275109P 2009-07-02 2009-07-02
US22271609P 2009-07-02 2009-07-02
US22281509P 2009-07-02 2009-07-02
US12/829,264 US20110024307A1 (en) 2009-07-02 2010-07-01 Analyte sensor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/058,091 Continuation US9320466B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US14/057,720 Continuation US9907497B2 (en) 2009-07-02 2013-10-18 Analyte sensor

Publications (1)

Publication Number Publication Date
US20110024307A1 true US20110024307A1 (en) 2011-02-03

Family

ID=43411768

Family Applications (21)

Application Number Title Priority Date Filing Date
US12/829,306 Active 2034-03-23 US9237864B2 (en) 2009-07-02 2010-07-01 Analyte sensors and methods of manufacturing same
US12/829,337 Abandoned US20110024043A1 (en) 2009-07-02 2010-07-01 Continuous analyte sensors and methods of making same
US12/829,339 Abandoned US20110027453A1 (en) 2009-07-02 2010-07-01 Continuous analyte sensors and methods of making same
US12/829,296 Active 2030-12-27 US8828201B2 (en) 2009-07-02 2010-07-01 Analyte sensors and methods of manufacturing same
US12/829,318 Active 2034-04-15 US9131885B2 (en) 2009-07-02 2010-07-01 Analyte sensors and methods of manufacturing same
US12/829,264 Abandoned US20110024307A1 (en) 2009-07-02 2010-07-01 Analyte sensor
US12/829,340 Abandoned US20110027458A1 (en) 2009-07-02 2010-07-01 Continuous analyte sensors and methods of making same
US14/057,720 Active US9907497B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US14/058,091 Active US9320466B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US14/155,814 Abandoned US20140123893A1 (en) 2009-07-02 2014-01-15 Continuous analyte sensors and methods of making same
US14/451,332 Abandoned US20140343386A1 (en) 2009-07-02 2014-08-04 Continuous analyte sensors and methods of making same
US14/960,011 Active US9763608B2 (en) 2009-07-02 2015-12-04 Analyte sensors and methods of manufacturing same
US15/683,657 Abandoned US20180000388A1 (en) 2009-07-02 2017-08-22 Analyte sensors and methods of manufacturing same
US15/877,682 Active US10420494B2 (en) 2009-07-02 2018-01-23 Analyte sensor
US16/250,992 Abandoned US20190167163A1 (en) 2009-07-02 2019-01-17 Analyte sensors and methods of manufacturing same
US16/452,364 Abandoned US20190307371A1 (en) 2009-07-02 2019-06-25 Continuous analyte sensors and methods of making same
US16/537,419 Active 2032-05-30 US11559229B2 (en) 2009-07-02 2019-08-09 Analyte sensor
US17/444,148 Abandoned US20210353185A1 (en) 2009-07-02 2021-07-30 Analyte sensors and methods of manufacturing same
US17/867,608 Pending US20220346674A1 (en) 2009-07-02 2022-07-18 Continuous analyte sensors and methods of making same
US18/145,220 Pending US20230129853A1 (en) 2009-07-02 2022-12-22 Analyte sensor
US18/182,941 Pending US20230301563A1 (en) 2009-07-02 2023-03-13 Analyte sensors and methods of manufacturing same

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US12/829,306 Active 2034-03-23 US9237864B2 (en) 2009-07-02 2010-07-01 Analyte sensors and methods of manufacturing same
US12/829,337 Abandoned US20110024043A1 (en) 2009-07-02 2010-07-01 Continuous analyte sensors and methods of making same
US12/829,339 Abandoned US20110027453A1 (en) 2009-07-02 2010-07-01 Continuous analyte sensors and methods of making same
US12/829,296 Active 2030-12-27 US8828201B2 (en) 2009-07-02 2010-07-01 Analyte sensors and methods of manufacturing same
US12/829,318 Active 2034-04-15 US9131885B2 (en) 2009-07-02 2010-07-01 Analyte sensors and methods of manufacturing same

Family Applications After (15)

Application Number Title Priority Date Filing Date
US12/829,340 Abandoned US20110027458A1 (en) 2009-07-02 2010-07-01 Continuous analyte sensors and methods of making same
US14/057,720 Active US9907497B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US14/058,091 Active US9320466B2 (en) 2009-07-02 2013-10-18 Analyte sensor
US14/155,814 Abandoned US20140123893A1 (en) 2009-07-02 2014-01-15 Continuous analyte sensors and methods of making same
US14/451,332 Abandoned US20140343386A1 (en) 2009-07-02 2014-08-04 Continuous analyte sensors and methods of making same
US14/960,011 Active US9763608B2 (en) 2009-07-02 2015-12-04 Analyte sensors and methods of manufacturing same
US15/683,657 Abandoned US20180000388A1 (en) 2009-07-02 2017-08-22 Analyte sensors and methods of manufacturing same
US15/877,682 Active US10420494B2 (en) 2009-07-02 2018-01-23 Analyte sensor
US16/250,992 Abandoned US20190167163A1 (en) 2009-07-02 2019-01-17 Analyte sensors and methods of manufacturing same
US16/452,364 Abandoned US20190307371A1 (en) 2009-07-02 2019-06-25 Continuous analyte sensors and methods of making same
US16/537,419 Active 2032-05-30 US11559229B2 (en) 2009-07-02 2019-08-09 Analyte sensor
US17/444,148 Abandoned US20210353185A1 (en) 2009-07-02 2021-07-30 Analyte sensors and methods of manufacturing same
US17/867,608 Pending US20220346674A1 (en) 2009-07-02 2022-07-18 Continuous analyte sensors and methods of making same
US18/145,220 Pending US20230129853A1 (en) 2009-07-02 2022-12-22 Analyte sensor
US18/182,941 Pending US20230301563A1 (en) 2009-07-02 2023-03-13 Analyte sensors and methods of manufacturing same

Country Status (3)

Country Link
US (21) US9237864B2 (en)
EP (4) EP3970610A3 (en)
WO (3) WO2011003036A2 (en)

Cited By (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171921A1 (en) * 1998-04-30 2004-09-02 James Say Analyte monitoring device and methods of use
US20060189863A1 (en) * 1998-04-30 2006-08-24 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US20070203410A1 (en) * 1998-04-30 2007-08-30 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20080086039A1 (en) * 2001-01-02 2008-04-10 Abbott Diabetes Care, Inc. Analyte Monitoring Device And Methods Of Use
US20080200897A1 (en) * 2007-02-19 2008-08-21 Abbott Diabetes Care, Inc. Modular combination of medication infusion and analyte monitoring
US20080300476A1 (en) * 2007-05-31 2008-12-04 Abbott Diabetes Care, Inc. Insertion devices and methods
US20090054746A1 (en) * 2005-09-30 2009-02-26 Abbott Diabetes Care, Inc. Device for channeling fluid and methods of use
US20090063402A1 (en) * 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US20100057042A1 (en) * 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Closed Loop Control With Improved Alarm Functions
US20100056992A1 (en) * 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Variable Rate Closed Loop Control And Methods
US20100081906A1 (en) * 2008-09-30 2010-04-01 Abbott Diabetes Care, Inc. Analyte Sensor Sensitivity Attenuation Mitigation
US20100204557A1 (en) * 2007-02-18 2010-08-12 Abbott Diabetes Care Inc. Multi-Function Analyte Test Device and Methods Therefor
US20100234710A1 (en) * 2008-03-28 2010-09-16 Abbott Diabetes Care Inc. Analyte Sensor Calibration Management
US20110021889A1 (en) * 2009-07-23 2011-01-27 Abbott Diabetes Care Inc. Continuous Analyte Measurement Systems and Systems and Methods for Implanting Them
US20110054275A1 (en) * 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Mounting Unit Having a Sensor and Associated Circuitry
US20120097554A1 (en) * 2010-10-18 2012-04-26 Medtronic Minimed, Inc. Analyte sensors comprising electrodes having selected electrochemical and mechanical properties
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20130053665A1 (en) * 2011-08-26 2013-02-28 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US20130211219A1 (en) * 2010-08-24 2013-08-15 Micro CHIPS ,Inc. Implantable Biosensor Device and Methods of Use Thereof
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8532935B2 (en) 2009-01-29 2013-09-10 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8545403B2 (en) 2005-12-28 2013-10-01 Abbott Diabetes Care Inc. Medical device insertion
WO2013152090A2 (en) 2012-04-04 2013-10-10 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8602991B2 (en) 2005-08-30 2013-12-10 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
WO2013184566A2 (en) 2012-06-05 2013-12-12 Dexcom, Inc. Systems and methods for processing analyte data and generating reports
US8612163B2 (en) 2007-05-14 2013-12-17 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20140005505A1 (en) * 2012-06-29 2014-01-02 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
WO2014004450A1 (en) * 2012-06-29 2014-01-03 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
WO2014011488A2 (en) 2012-07-09 2014-01-16 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US8676513B2 (en) 2009-01-29 2014-03-18 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8682615B2 (en) 2007-05-14 2014-03-25 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20140088389A1 (en) * 2012-09-24 2014-03-27 Dexcom, Inc. Multiple electrode system for a continuous analyte sensor, and related methods
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
WO2014052080A1 (en) 2012-09-28 2014-04-03 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8718739B2 (en) 2008-03-28 2014-05-06 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8764657B2 (en) 2010-03-24 2014-07-01 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
WO2014158327A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Advanced calibration for analyte sensors
WO2014158405A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US8852101B2 (en) 2005-12-28 2014-10-07 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US8862198B2 (en) 2006-09-10 2014-10-14 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9031630B2 (en) 2006-02-28 2015-05-12 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9113828B2 (en) 2006-10-25 2015-08-25 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2015156966A1 (en) 2014-04-10 2015-10-15 Dexcom, Inc. Sensors for continuous analyte monitoring, and related methods
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US9310230B2 (en) 2009-04-29 2016-04-12 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US9320466B2 (en) 2009-07-02 2016-04-26 Dexcom, Inc. Analyte sensor
US9320468B2 (en) 2008-01-31 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9326727B2 (en) 2006-01-30 2016-05-03 Abbott Diabetes Care Inc. On-body medical device securement
US9332934B2 (en) 2007-10-23 2016-05-10 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US9357959B2 (en) 2006-10-02 2016-06-07 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9402570B2 (en) 2011-12-11 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9439586B2 (en) 2007-10-23 2016-09-13 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US9541556B2 (en) 2008-05-30 2017-01-10 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9558325B2 (en) 2007-05-14 2017-01-31 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
WO2017044654A1 (en) 2015-09-10 2017-03-16 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9662056B2 (en) 2008-09-30 2017-05-30 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9721063B2 (en) 2011-11-23 2017-08-01 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US20170265795A1 (en) * 2008-03-28 2017-09-21 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US9882660B2 (en) 2006-10-26 2018-01-30 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US9903755B2 (en) * 2015-10-05 2018-02-27 Microsoft Technology Licensing, Llc Indoors / outdoors detection
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9913600B2 (en) 2007-06-29 2018-03-13 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9931075B2 (en) 2008-05-30 2018-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US9980670B2 (en) 2002-11-05 2018-05-29 Abbott Diabetes Care Inc. Sensor inserter assembly
US20180153456A1 (en) * 2005-02-14 2018-06-07 Optiscan Biomedical Corporation Analyte detection systems and methods using multiple measurements
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10028680B2 (en) 2006-04-28 2018-07-24 Abbott Diabetes Care Inc. Introducer assembly and methods of use
US10031002B2 (en) 2007-05-14 2018-07-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10078380B2 (en) 2010-03-10 2018-09-18 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US10117606B2 (en) 2009-10-30 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US10152947B2 (en) 2016-04-06 2018-12-11 Microsoft Technology Licensing, Llc Display brightness updating
US10173007B2 (en) 2007-10-23 2019-01-08 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US10194850B2 (en) 2005-08-31 2019-02-05 Abbott Diabetes Care Inc. Accuracy of continuous glucose sensors
US10194863B2 (en) 2005-09-30 2019-02-05 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
WO2019046853A1 (en) * 2017-09-02 2019-03-07 Biocrede Inc. Medical device with integrated biosensor
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US10328201B2 (en) 2008-07-14 2019-06-25 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US10410538B2 (en) 2015-05-07 2019-09-10 Dexcom, Inc. System and method for educating users, including responding to patterns
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US20190350499A1 (en) * 2011-04-15 2019-11-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10561349B2 (en) 2016-03-31 2020-02-18 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US20200072827A1 (en) * 2016-12-09 2020-03-05 Abbott Point Of Care Inc. Dual range cardiac troponin immunoassay devices and methods using immunosensor and magnetic immunosensor
EP3654348A1 (en) 2012-11-07 2020-05-20 Dexcom, Inc. Systems and methods for managing glycemic variability
US10674944B2 (en) 2015-05-14 2020-06-09 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
US10685749B2 (en) 2007-12-19 2020-06-16 Abbott Diabetes Care Inc. Insulin delivery apparatuses capable of bluetooth data transmission
WO2020140017A1 (en) * 2018-12-28 2020-07-02 Dexcom, Inc. Analyte sensor break-in mitigation
USD902408S1 (en) 2003-11-05 2020-11-17 Abbott Diabetes Care Inc. Analyte sensor control unit
US10856736B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US10860687B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US10874338B2 (en) 2010-06-29 2020-12-29 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10932672B2 (en) 2015-12-28 2021-03-02 Dexcom, Inc. Systems and methods for remote and host monitoring communications
US10952621B2 (en) 2017-12-05 2021-03-23 Cardiac Pacemakers, Inc. Multimodal analyte sensor optoelectronic interface
US10985804B2 (en) 2013-03-14 2021-04-20 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
US11071478B2 (en) 2017-01-23 2021-07-27 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
EP3669175A4 (en) * 2017-08-14 2021-08-11 Senseonics, Incorporated Methods and systems for calculating analyte levels
US11089983B2 (en) 2017-12-01 2021-08-17 Cardiac Pacemakers, Inc. Multimodal analyte sensors for medical devices
US20210251526A1 (en) * 2012-03-16 2021-08-19 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11112377B2 (en) 2015-12-30 2021-09-07 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
US11129557B2 (en) 2017-05-31 2021-09-28 Cardiac Pacemakers, Inc. Implantable medical device with chemical sensor
US11193924B2 (en) * 2013-01-03 2021-12-07 Dexcom, Inc. End of life detection for analyte sensors
EP3925522A1 (en) 2017-06-23 2021-12-22 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US11229382B2 (en) 2013-12-31 2022-01-25 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
WO2022136712A1 (en) * 2020-12-21 2022-06-30 Bioquochem S.L. Method for selectively measuring a concentration of a compound in a complex sample
USD961778S1 (en) 2006-02-28 2022-08-23 Abbott Diabetes Care Inc. Analyte sensor device
EP4046571A1 (en) 2015-10-21 2022-08-24 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
USD962446S1 (en) 2009-08-31 2022-08-30 Abbott Diabetes Care, Inc. Analyte sensor device
US11439304B2 (en) 2017-08-10 2022-09-13 Cardiac Pacemakers, Inc. Systems and methods including electrolyte sensor fusion
US11504004B2 (en) 2015-09-10 2022-11-22 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11571151B2 (en) 2017-08-23 2023-02-07 Cardiac Pacemakers, Inc. Implantable chemical sensor with staged activation
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
USD982762S1 (en) 2020-12-21 2023-04-04 Abbott Diabetes Care Inc. Analyte sensor inserter
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
USD1002852S1 (en) 2019-06-06 2023-10-24 Abbott Diabetes Care Inc. Analyte sensor device

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US7310544B2 (en) 2004-07-13 2007-12-18 Dexcom, Inc. Methods and systems for inserting a transcutaneous analyte sensor
US8702932B2 (en) 2007-08-30 2014-04-22 Pepex Biomedical, Inc. Electrochemical sensor and method for manufacturing
WO2009051901A2 (en) 2007-08-30 2009-04-23 Pepex Biomedical, Llc Electrochemical sensor and method for manufacturing
US8951377B2 (en) 2008-11-14 2015-02-10 Pepex Biomedical, Inc. Manufacturing electrochemical sensor module
US9445755B2 (en) 2008-11-14 2016-09-20 Pepex Biomedical, Llc Electrochemical sensor module
US8506740B2 (en) 2008-11-14 2013-08-13 Pepex Biomedical, Llc Manufacturing electrochemical sensor module
US9351677B2 (en) 2009-07-02 2016-05-31 Dexcom, Inc. Analyte sensor with increased reference capacity
CN105396215A (en) 2010-08-13 2016-03-16 导管治疗有限公司 A Catheter Sheath And A Method Of Manufacturing
US9090114B1 (en) * 2010-09-08 2015-07-28 Brian A Stumm Machine including LED-based UV radiation sources to process coatings
US8652860B2 (en) 2011-01-09 2014-02-18 Bridgelux, Inc. Packaging photon building blocks having only top side connections in a molded interconnect structure
US8536605B2 (en) 2011-11-28 2013-09-17 Bridgelux, Inc. Micro-bead blasting process for removing a silicone flash layer
US9504162B2 (en) 2011-05-20 2016-11-22 Pepex Biomedical, Inc. Manufacturing electrochemical sensor modules
JP6321540B2 (en) 2011-07-26 2018-05-09 グリセンス インコーポレイテッド Implantable analyte sensor with hermetically sealed housing and method of manufacturing the sensor
US20130060099A1 (en) * 2011-08-30 2013-03-07 Abbott Diabetes Care Inc. Methods for Subcutaneously Positioning an Analyte Sensing Device
US10111588B2 (en) 2012-03-29 2018-10-30 Senseonics, Incorporated Analyte sensor transceiver configured to provide tactile, visual, and/or aural feedback
US10327714B2 (en) 2012-03-29 2019-06-25 Senseonics, Incorporated Analyte concentration alert function for analyte sensor system
EP2664354B1 (en) 2012-05-16 2015-09-16 Sorin CRM SAS Medical lead with a ring electrode for implantation in a cardiac or cerebral blood vessel and a method for its manufacture
US10561353B2 (en) * 2016-06-01 2020-02-18 Glysens Incorporated Biocompatible implantable sensor apparatus and methods
US10660550B2 (en) 2015-12-29 2020-05-26 Glysens Incorporated Implantable sensor apparatus and methods
US11246213B2 (en) 2012-09-11 2022-02-08 L.I.F.E. Corporation S.A. Physiological monitoring garments
US10462898B2 (en) 2012-09-11 2019-10-29 L.I.F.E. Corporation S.A. Physiological monitoring garments
JP2016501137A (en) * 2012-11-09 2016-01-18 エボニック インダストリーズ アクチエンゲゼルシャフトEvonik Industries AG Use and manufacture of coated filaments for 3D printing processes based on extrusion
EP2925229A4 (en) 2012-12-03 2017-01-25 Pepex Biomedical, Inc. Sensor module and method of using a sensor module
US9945824B2 (en) * 2013-03-15 2018-04-17 Ohio State Innovation Foundation Core-shell nanofiber-based sensors
KR101297791B1 (en) * 2013-03-22 2013-08-19 이기세 Tip structure for a skin care apparatus
EP3022668A1 (en) 2013-07-19 2016-05-25 Dexcom, Inc. Time averaged basal rate optimizer
PL3030150T3 (en) * 2013-08-09 2023-09-18 Senseonics, Incorporated Analyte sensor transceiver configured to provide tactile, and optionally visual and / or aural, feedback
WO2015065922A1 (en) 2013-10-28 2015-05-07 Dexcom, Inc. Devices used in connection with continuous analyte monitoring that provide the user with one or more notifications, and related methods
EP3063686A2 (en) 2013-10-31 2016-09-07 Dexcom, Inc. Adaptive interface for continuous monitoring devices
WO2015073588A1 (en) 2013-11-14 2015-05-21 Dexcom, Inc. Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods
DK3069279T3 (en) 2013-11-14 2020-11-30 Dexcom Inc DEVICES AND METHODS FOR CONTINUOUS ANALYTICAL MONITORING
WO2015103620A1 (en) 2014-01-06 2015-07-09 Andrea Aliverti Systems and methods to automatically determine garment fit
JP2017506090A (en) 2014-01-27 2017-03-02 アンジオメトリックス コーポレーション Method and apparatus for assembling an electrically stable connector
WO2015122964A1 (en) 2014-02-11 2015-08-20 Dexcom, Inc. Packaging system for analyte sensors
US20150289788A1 (en) * 2014-04-10 2015-10-15 Dexcom, Inc. Sensors for continuous analyte monitoring, and related methods
AU2015244291B2 (en) 2014-04-10 2017-06-22 Dexcom, Inc. Glycemic urgency assessment and alerts interface
US10232167B2 (en) * 2014-05-07 2019-03-19 Medtronic, Inc. Electrode construction for implantable medical electrical leads
CN107003264B (en) 2014-06-04 2020-02-21 普佩克斯生物医药有限公司 Electrochemical sensor and method of manufacturing an electrochemical sensor using advanced printing techniques
JP6269373B2 (en) * 2014-07-29 2018-01-31 日立金属株式会社 Manufacturing method and manufacturing apparatus for enameled wire
CA2953577A1 (en) 2014-09-22 2016-03-31 Dexcom, Inc. System and method for mode switching
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
WO2016051268A1 (en) * 2014-10-01 2016-04-07 L.I.F.E. Corporation S.A. Devices and methods for use with physiological monitoring garments
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
WO2016138176A1 (en) 2015-02-24 2016-09-01 Elira Therapeutics Llc Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
EP3297708B1 (en) 2015-05-22 2022-02-23 DexCom, Inc. Needle for transcutaneous analyte sensor delivery
US10575767B2 (en) * 2015-05-29 2020-03-03 Medtronic Minimed, Inc. Method for monitoring an analyte, analyte sensor and analyte monitoring apparatus
US9730639B2 (en) 2015-06-01 2017-08-15 Autonomix Medical, Inc. Elongated conductors and methods of making and using the same
US10426555B2 (en) * 2015-06-03 2019-10-01 Covidien Lp Medical instrument with sensor for use in a system and method for electromagnetic navigation
WO2016196516A1 (en) 2015-06-03 2016-12-08 William Kenneth Ward Measurement of glucose in an insulin delivery catheter by minimizing the adverse effects of insulin preservatives
CA2994362C (en) 2015-07-20 2023-12-12 L.I.F.E. Corporation S.A. Flexible fabric ribbon connectors for garments with sensors and electronics
CN108697322A (en) * 2015-10-23 2018-10-23 外分泌腺系统公司 The device that can carry out sample concentration of extension sensing for sweat analyte
US10688596B2 (en) * 2015-12-18 2020-06-23 Illinois Tool Works Inc. Wire manufactured by additive manufacturing methods
WO2017116915A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. Transcutaneous analyte sensor systems and methods
US10213144B2 (en) 2016-01-25 2019-02-26 International Business Machines Corporation Nanopatterned biosensor electrode for enhanced sensor signal and sensitivity
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
CA3211813A1 (en) 2016-05-02 2017-11-09 Dexcom, Inc. System and method for providing alerts optimized for a user
WO2017192836A1 (en) * 2016-05-06 2017-11-09 The Johns Hopkins University A potentiometric wearable sweat sensor
US11298059B2 (en) * 2016-05-13 2022-04-12 PercuSense, Inc. Analyte sensor
US10638962B2 (en) 2016-06-29 2020-05-05 Glysens Incorporated Bio-adaptable implantable sensor apparatus and methods
CA3029445A1 (en) 2016-07-01 2018-01-04 L.I.F.E. Corporation S.A. Biometric identification by garments having a plurality of sensors
KR20190019204A (en) * 2016-07-15 2019-02-26 브레우어 사이언스 인코포레이션 Dielectric materials for laser cutting
US10376193B2 (en) * 2016-07-25 2019-08-13 International Business Machines Corporation Embedded sacrificial layer to enhance biosensor stability and lifetime for nanopatterned electrodes
US20190231236A1 (en) * 2016-09-21 2019-08-01 University Of Cincinnati Accurate enzymatic sensing of sweat analytes
CN106475268A (en) * 2016-12-22 2017-03-08 苏州振瑞昌材料科技有限公司 A kind of strengthening core masking liquid equipment
US10161898B2 (en) 2017-01-30 2018-12-25 International Business Machines Corporation Nanopatterned biosensor electrode for enhanced sensor signal and sensitivity
US10548530B2 (en) 2017-03-01 2020-02-04 International Business Machines Corporation Biosensor calibration structure containing different sensing surface area
JP7271502B2 (en) * 2017-03-22 2023-05-11 フェポッド・オイ・リミテッド Electrochemical assay for detection of opioids
US11452466B2 (en) 2017-06-19 2022-09-27 Dexcom, Inc. Applicators for applying transcutaneous analyte sensors and associated methods of manufacture
US10638979B2 (en) 2017-07-10 2020-05-05 Glysens Incorporated Analyte sensor data evaluation and error reduction apparatus and methods
CA3072853A1 (en) 2017-08-21 2019-02-28 Dexcom, Inc. Continuous glucose monitors and related sensors utilizing mixed model and bayesian calibration algorithms
FI3700422T3 (en) 2017-10-24 2023-04-27 Roche Diabetes Care Gmbh Electrochemical sensor and method for producing thereof
US11078025B2 (en) * 2017-11-21 2021-08-03 Chemcut Holdings LLC Lightweight roller
US10734505B2 (en) * 2017-11-30 2020-08-04 International Business Machines Corporation Lateral bipolar junction transistor with dual base region
US11278668B2 (en) 2017-12-22 2022-03-22 Glysens Incorporated Analyte sensor and medicant delivery data evaluation and error reduction apparatus and methods
US11255839B2 (en) 2018-01-04 2022-02-22 Glysens Incorporated Apparatus and methods for analyte sensor mismatch correction
JP7443235B2 (en) 2018-02-09 2024-03-05 デックスコム・インコーポレーテッド Decision support systems and methods
US11576595B2 (en) 2018-04-06 2023-02-14 Zense-Life Inc. Enhanced sensor for a continuous biological monitor
WO2019195661A1 (en) * 2018-04-06 2019-10-10 Zense-Life Inc. Continuous glucose monitoring device
CA3099177A1 (en) 2018-05-03 2019-11-07 Dexcom, Inc. Automatic analyte sensor calibration and error detection
WO2019217199A1 (en) * 2018-05-09 2019-11-14 President And Fellows Of Harvard College Luminescent devices
EP3603721B1 (en) 2018-07-31 2022-05-11 Heraeus Deutschland GmbH & Co. KG Catheter with segmented electrodes and methods of making same
CN109893140B (en) * 2019-02-28 2021-08-03 孙云峰 Needle-shaped enzyme sensor
EP3766414A1 (en) * 2019-07-16 2021-01-20 Heraeus Deutschland GmbH & Co KG Process for preparing a processed filament, processed filament and its use
SG10202006835UA (en) * 2019-08-01 2021-03-30 Heraeus Deutschland Gmbh & Co Kg A device for processing a filament, the device comprising a processing beam source and a guiding means
EP3798628A1 (en) 2019-09-27 2021-03-31 Heraeus Deutschland GmbH & Co KG Method for manufacturing an electrochemical sensor
CN112570198B (en) * 2019-09-30 2022-06-17 天津恩泰智能装备有限公司 Overhead bare conductor insulating material coating device
WO2021097183A1 (en) * 2019-11-15 2021-05-20 President And Fellows Of Harvard College Device and method for analyte detection
WO2021154419A1 (en) * 2020-01-28 2021-08-05 Gyrus Acmi, Inc. D/B/A Olympus Surgical Technologies America Medical devices with biliary diagnostic devices
EP3905462A1 (en) * 2020-04-30 2021-11-03 Heraeus Deutschland GmbH & Co KG Wire handling system and method for laser ablation
DE102020119187A1 (en) 2020-07-21 2022-01-27 Heinrich Kuper Gmbh Device and method for producing an adhesive thread and for connecting workpieces with the adhesive thread
DK4048152T3 (en) 2020-07-29 2024-03-11 Biolinq Incorporated SYSTEM FOR CONTINUOUS ANALYTE MONITORING WITH MICRON NEEDLE ARRANGEMENT
US11612779B2 (en) * 2020-11-04 2023-03-28 Timothy Karl Schumacher Water jug/ water can exercise device/ equipment system
US11776714B2 (en) * 2020-11-13 2023-10-03 E-Wireligner Co., Ltd. Device for coating a wire with polymer fibers and method thereof
CN112450918B (en) * 2020-11-27 2022-12-06 浙江凯立特医疗器械有限公司 Implanting device of implantable biosensor
US20220296867A1 (en) 2021-03-19 2022-09-22 Dexcom, Inc. Drug releasing membrane for analyte sensor
CA3198391A1 (en) 2021-03-31 2022-10-06 Dexcom, Inc. Filtering of continuous glucose monitor (cgm) signals with a kalman filter
CA3201805A1 (en) 2021-04-02 2022-10-06 Dexcom, Inc. Personalized modeling of blood glucose concentration impacted by individualized sensor characteristics and individualized physiological characteristics
EP4323995A1 (en) 2021-04-15 2024-02-21 Dexcom, Inc. Global configuration service
CN116113454A (en) 2021-05-08 2023-05-12 比奥林股份有限公司 Continuous analyte monitoring device fault detection based on microneedle arrays
EP4137047A1 (en) * 2021-08-18 2023-02-22 Roche Diabetes Care GmbH Insertion device for transcutaneous insertion
CA3230350A1 (en) 2021-09-15 2023-03-23 Shanger Wang Bioactive releasing membrane for analyte sensor
WO2023081659A1 (en) 2021-11-02 2023-05-11 Dexcom, Inc. Prediction funnel for generation of hypo- and hyper glycemic alerts based on continuous glucose monitoring data
US20230181065A1 (en) 2021-12-13 2023-06-15 Dexcom, Inc. End-of-life detection for analyte sensors experiencing progressive sensor decline
US20230301553A1 (en) 2022-03-18 2023-09-28 Dexcom, Inc. Continuous analyte monitoring sensor systems and methods of using the same
WO2023177896A1 (en) 2022-03-18 2023-09-21 Dexcom, Inc. Continuous multi-analyte sensor systems
WO2023235443A1 (en) 2022-06-01 2023-12-07 Dexcom, Inc. Sensing systems and methods for diagnosing kidney disease
WO2023239929A1 (en) 2022-06-10 2023-12-14 Dexcom, Inc. Apparatuses, systems, and methods of controlling sensor deployment
CN114767105B (en) * 2022-06-22 2022-10-14 苏州百孝医疗科技有限公司 Implantable electrochemical biosensor, testing method and implantable medical device
EP4316372A1 (en) * 2022-08-05 2024-02-07 PharmaSens AG Electrochemical analyte sensor having improved reproducibility and associated fabrication process
WO2024050124A1 (en) 2022-09-02 2024-03-07 Dexcom, Inc. Devices and methods for measuring a concentration of a target analyte in a biological fluid in vivo

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206755A (en) * 1977-04-21 1980-06-10 Association Pour La Recherche Et Le Developpement Des Methodes Et Processus Industriels A.R.M.I.N.E.S. Method and apparatus for the control and regulation of glycemia
US4225410A (en) * 1978-12-04 1980-09-30 Technicon Instruments Corporation Integrated array of electrochemical sensors
US4568444A (en) * 1984-04-30 1986-02-04 Kuraray Co., Ltd. Chemical substance measuring apparatus
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4736748A (en) * 1986-04-05 1988-04-12 Kuraray Co., Ltd. Blood component monitoring system
US4739380A (en) * 1984-01-19 1988-04-19 Integrated Ionics, Inc. Integrated ambient sensing devices and methods of manufacture
US4837049A (en) * 1986-06-17 1989-06-06 Alfred E. Mann Foundation For Scientific Research Method of making an electrode array
US4925444A (en) * 1987-08-07 1990-05-15 Baxter Travenol Laboratories, Inc. Closed multi-fluid delivery system and method
US4935345A (en) * 1987-04-07 1990-06-19 Arizona Board Of Regents Implantable microelectronic biochemical sensor incorporating thin film thermopile
US5002055A (en) * 1988-04-13 1991-03-26 Mic Medical Instruments Corporation Apparatus for the biofeedback control of body functions
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5513636A (en) * 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5711861A (en) * 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US5904666A (en) * 1997-08-18 1999-05-18 L.Vad Technology, Inc. Method and apparatus for measuring flow rate and controlling delivered volume of fluid through a valve aperture
US5904708A (en) * 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US5959191A (en) * 1995-03-27 1999-09-28 California Institute Of Technology Sensor arrays for detecting analytes in fluids
US5957854A (en) * 1993-09-04 1999-09-28 Besson; Marcus Wireless medical diagnosis and monitoring equipment
US6016448A (en) * 1998-10-27 2000-01-18 Medtronic, Inc. Multilevel ERI for implantable medical devices
US6032667A (en) * 1997-10-30 2000-03-07 Instrumentarium Corporation Variable orifice pulse valve
US6066448A (en) * 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US6088608A (en) * 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6091975A (en) * 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US6117290A (en) * 1997-09-26 2000-09-12 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US6122536A (en) * 1995-07-06 2000-09-19 Animas Corporation Implantable sensor and system for measurement and control of blood constituent levels
US6175767B1 (en) * 1998-04-01 2001-01-16 James H. Doyle, Sr. Multichannel implantable inner ear stimulator
US6223080B1 (en) * 1998-04-29 2001-04-24 Medtronic, Inc. Power consumption reduction in medical devices employing multiple digital signal processors and different supply voltages
US6223083B1 (en) * 1999-04-16 2001-04-24 Medtronic, Inc. Receiver employing digital filtering for use with an implantable medical device
US6230059B1 (en) * 1999-03-17 2001-05-08 Medtronic, Inc. Implantable monitor
US6400974B1 (en) * 2000-06-29 2002-06-04 Sensors For Medicine And Science, Inc. Implanted sensor processing system and method for processing implanted sensor output
US6432050B1 (en) * 1997-12-30 2002-08-13 Remon Medical Technologies Ltd. Implantable acoustic bio-sensing system and method
US6447448B1 (en) * 1998-12-31 2002-09-10 Ball Semiconductor, Inc. Miniature implanted orthopedic sensors
US20020128546A1 (en) * 2000-05-15 2002-09-12 Silver James H. Implantable sensor
US20030050546A1 (en) * 2001-06-22 2003-03-13 Desai Shashi P. Methods for improving the performance of an analyte monitoring system
US6546268B1 (en) * 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
US20030076082A1 (en) * 2001-10-23 2003-04-24 Morgan Wayne A. Implantable sensor electrodes and electronic circuitry
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US20030130616A1 (en) * 1999-06-03 2003-07-10 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6609071B2 (en) * 2000-12-06 2003-08-19 Project Cd System for monitoring and controlling pressure and concentration values in a fluid conduit
US20040039298A1 (en) * 1996-09-04 2004-02-26 Abreu Marcio Marc Noninvasive measurement of chemical substances
US6749587B2 (en) * 2001-02-22 2004-06-15 Insulet Corporation Modular infusion device and method
US20040152187A1 (en) * 2002-11-13 2004-08-05 Haight Levoy Golden System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors
US20040176672A1 (en) * 2000-05-15 2004-09-09 Silver James H. Implantable, retrievable, thrombus minimizing sensors
US20040180391A1 (en) * 2002-10-11 2004-09-16 Miklos Gratzl Sliver type autonomous biosensors
US20050027182A1 (en) * 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US20050107677A1 (en) * 2003-09-24 2005-05-19 W. Kenneth Ward Implantable biosensor
US20050112358A1 (en) * 2003-11-24 2005-05-26 Potyrailo Radislav A. Methods for deposition of sensor regions onto optical storage media substrates and resulting devices
US20060079740A1 (en) * 2000-05-15 2006-04-13 Silver James H Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction
US20060142651A1 (en) * 2004-07-13 2006-06-29 Mark Brister Analyte sensor
US7081195B2 (en) * 2003-12-08 2006-07-25 Dexcom, Inc. Systems and methods for improving electrochemical analyte sensors
US20060258929A1 (en) * 2005-03-10 2006-11-16 Goode Paul V Jr System and methods for processing analyte sensor data for sensor calibration
US20070016381A1 (en) * 2003-08-22 2007-01-18 Apurv Kamath Systems and methods for processing analyte sensor data
US7169289B2 (en) * 2002-06-28 2007-01-30 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Electrochemical detection method and device
US7226978B2 (en) * 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US20070131549A1 (en) * 2005-12-14 2007-06-14 Nova Biomedical Corporation Glucose biosensor and method
US20070151868A1 (en) * 2005-11-12 2007-07-05 Arnulf Staib Implantable electrode system, method and apparatus for measuring an analyte concentration in a human or animal body
US20070197889A1 (en) * 2006-02-22 2007-08-23 Mark Brister Analyte sensor
US20070203407A1 (en) * 2006-02-28 2007-08-30 Abbott Diabetes Care, Inc. Analyte sensors and methods of use
US20080027301A1 (en) * 2006-07-28 2008-01-31 Ward W Kenneth Analyte sensing and response system
US20080086044A1 (en) * 2006-10-04 2008-04-10 Dexcom, Inc. Analyte sensor
US7366556B2 (en) * 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20080154101A1 (en) * 2006-09-27 2008-06-26 Faquir Jain Implantable Biosensor and Methods of Use Thereof
US7399277B2 (en) * 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7402153B2 (en) * 1997-06-09 2008-07-22 Medtronic Minimed, Inc. Closed-loop method for controlling insulin infusion
US20080200788A1 (en) * 2006-10-04 2008-08-21 Dexcorn, Inc. Analyte sensor
US20080200791A1 (en) * 2006-10-04 2008-08-21 Dexcom, Inc. Analyte sensor
US20080200789A1 (en) * 2006-10-04 2008-08-21 Dexcom, Inc. Analyte sensor
US20090018424A1 (en) * 2006-10-04 2009-01-15 Dexcom, Inc. Analyte sensor
US20090099435A1 (en) * 1998-04-30 2009-04-16 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20090124964A1 (en) * 2003-12-05 2009-05-14 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US20090131768A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090131769A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090131776A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090131777A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090137887A1 (en) * 2006-10-04 2009-05-28 Dexcom, Inc. Analyte sensor
US20090137886A1 (en) * 2006-10-04 2009-05-28 Dexcom, Inc. Analyte sensor
US20090143659A1 (en) * 2003-08-01 2009-06-04 Dexcom, Inc. Analyte sensor
US20090156924A1 (en) * 2007-12-17 2009-06-18 Dexcom, Inc. Systems and methods for processing sensor data
US20100030045A1 (en) * 2008-07-31 2010-02-04 Medtronic Minimed, Inc. Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them

Family Cites Families (353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008A (en) 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US119703A (en) 1871-10-10 Improvement in ironing-tables
US1966575A (en) * 1931-04-23 1934-07-17 E M F Electric Company Proprie Automatic weld rod manufacturing apparatus
US2497894A (en) * 1944-10-14 1950-02-21 Nat Standard Co Method of electroplating fine wire of low elastic limit
US2489456A (en) * 1945-08-21 1949-11-29 Robert A Liebel Method of applying uniform coating by immersion
US2728831A (en) * 1951-11-09 1955-12-27 Phys Chemical Res Corp Electric hygrometer
US2889239A (en) * 1958-03-12 1959-06-02 Bell Telephone Labor Inc Method for making a transposed conductor structure
US3658571A (en) * 1970-04-29 1972-04-25 Owens Corning Fiberglass Corp Glass fiber reinforced elastomers
US3933593A (en) * 1971-02-22 1976-01-20 Beckman Instruments, Inc. Rate sensing batch analysis method
US3957613A (en) * 1974-11-01 1976-05-18 General Electric Company Miniature probe having multifunctional electrodes for sensing ions and gases
US3930462A (en) * 1975-05-08 1976-01-06 United Technologies Corporation Slurry dip tank
US4126510A (en) * 1977-10-06 1978-11-21 Rca Corporation Etching a succession of articles from a strip of sheet metal
US4190040A (en) * 1978-07-03 1980-02-26 American Hospital Supply Corporation Resealable puncture housing for surgical implantation
DE2932761A1 (en) 1979-08-13 1981-02-26 Akzo Gmbh POLYCARBONATE-POLYAETHER-COPOLYMER MEMBRANE
IE51643B1 (en) 1980-10-15 1987-01-21 Smith & Nephew Ass Coated articles and materials suitable for coating
US4826706A (en) * 1981-04-29 1989-05-02 Phelps Dodge Industries, Inc. Method and apparatus for manufacturing magnet wire
US4442841A (en) * 1981-04-30 1984-04-17 Mitsubishi Rayon Company Limited Electrode for living bodies
US4422583A (en) * 1981-12-14 1983-12-27 Usm Corporation Wire feeder
EP0098592A3 (en) 1982-07-06 1985-08-21 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
US4614514A (en) 1983-02-16 1986-09-30 M/A Com, Inc. Microwave sterilizer
CA1226036A (en) 1983-05-05 1987-08-25 Irving J. Higgins Analytical equipment and sensor electrodes therefor
US5682884A (en) 1983-05-05 1997-11-04 Medisense, Inc. Strip electrode with screen printing
CA1219040A (en) 1983-05-05 1987-03-10 Elliot V. Plotkin Measurement of enzyme-catalysed reactions
US4848348A (en) * 1983-11-14 1989-07-18 Minnesota Mining And Manufacturing Company Coated films
US6846654B1 (en) 1983-11-29 2005-01-25 Igen International, Inc. Catalytic antibodies as chemical sensors
CA1258496A (en) 1984-07-30 1989-08-15 Teruyoshi Uchida Insulated noble metal wire and porous membrane as po.sub.2 bioelectrode
NL8501146A (en) * 1985-04-19 1986-11-17 Philips Nv DEVICE FOR COATING OPTICAL FIBERS.
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4680268A (en) * 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
JPS62225513A (en) 1986-03-26 1987-10-03 Shin Etsu Chem Co Ltd Block-graft copolymer and production thereof
US4685463A (en) 1986-04-03 1987-08-11 Williams R Bruce Device for continuous in vivo measurement of blood glucose concentrations
WO1987006701A1 (en) * 1986-04-22 1987-11-05 Toray Industries, Inc. Microelectrode for electrochemical analysis
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4726381A (en) * 1986-06-04 1988-02-23 Solutech, Inc. Dialysis system and method
US5190040A (en) 1986-12-26 1993-03-02 Nihon Kohden Corporation Apparatus for measuring the change in the concentration of a pigment in blood
US4886562A (en) * 1987-03-31 1989-12-12 The Boeing Company Method of manufacturing reinforced optical fiber
US4832034A (en) * 1987-04-09 1989-05-23 Pizziconi Vincent B Method and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US5286364A (en) * 1987-06-08 1994-02-15 Rutgers University Surface-modified electochemical biosensor
US4777205A (en) * 1987-07-22 1988-10-11 Wacker Silicones Corporation Electrically conductive compositions
GB8725936D0 (en) 1987-11-05 1987-12-09 Genetics Int Inc Sensing system
ZA889546B (en) 1987-12-24 1990-08-29 Igen Inc Chemical sensors employing catalytic antibodies
US4890621A (en) * 1988-01-19 1990-01-02 Northstar Research Institute, Ltd. Continuous glucose monitoring and a system utilized therefor
US5362307A (en) * 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
DK409188D0 (en) 1988-07-21 1988-07-21 Radiometer As PROCEDURE FOR MEASURING A CHARACTERISTICS IN A FLUIDUM
US6306594B1 (en) 1988-11-14 2001-10-23 I-Stat Corporation Methods for microdispensing patterened layers
US5200051A (en) 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US4974592A (en) 1988-11-14 1990-12-04 American Sensor Systems Corporation Continuous on-line blood monitoring system
US5212050A (en) * 1988-11-14 1993-05-18 Mier Randall M Method of forming a permselective layer
AU4951690A (en) 1988-12-30 1990-08-01 David M. Anderson Stabilized microporous materials and hydrogel materials
AT392847B (en) 1989-01-27 1991-06-25 Avl Verbrennungskraft Messtech SENSOR ELECTRODE ARRANGEMENT
JPH02298855A (en) 1989-03-20 1990-12-11 Assoc Univ Inc Electrochemical biosensor using immobilized enzyme and redox polymer
US5312590A (en) * 1989-04-24 1994-05-17 National University Of Singapore Amperometric sensor for single and multicomponent analysis
GB8909613D0 (en) 1989-04-27 1989-06-14 Pickup John C Glucose-sensing electrode
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US5101814A (en) * 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
CA2024548C (en) 1989-09-05 2002-05-28 David Issachar Analyte specific chemical sensor
US5512246A (en) 1989-09-21 1996-04-30 Anthony P. Russell Method and means for detecting polyhydroxyl compounds
US5067491A (en) 1989-12-08 1991-11-26 Becton, Dickinson And Company Barrier coating on blood contacting devices
JP3105243B2 (en) 1989-12-14 2000-10-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア How to increase the useful life of an implantable sensor
US5985129A (en) 1989-12-14 1999-11-16 The Regents Of The University Of California Method for increasing the service life of an implantable sensor
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
NL9002764A (en) 1990-12-14 1992-07-01 Tno ELECTRODE, FITTED WITH A POLYMER COATING WITH A REDOX ENZYM BOND TO IT.
US5773270A (en) 1991-03-12 1998-06-30 Chiron Diagnostics Corporation Three-layered membrane for use in an electrochemical sensor system
CA2069537A1 (en) 1991-06-07 1992-12-08 Thomas A. Cook Multiple output referencing system for evanescent wave sensor
JP2740587B2 (en) * 1991-07-18 1998-04-15 工業技術院長 Micro composite electrode and method of manufacturing the same
US5322063A (en) 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
WO1993008464A1 (en) 1991-10-21 1993-04-29 Holm Kennedy James W Method and device for biochemical sensing
US5524338A (en) * 1991-10-22 1996-06-11 Pi Medical Corporation Method of making implantable microelectrode
US5310469A (en) * 1991-12-31 1994-05-10 Abbott Laboratories Biosensor with a membrane containing biologically active material
US5683366A (en) 1992-01-07 1997-11-04 Arthrocare Corporation System and method for electrosurgical tissue canalization
US5985693A (en) 1994-09-30 1999-11-16 Elm Technology Corporation High density three-dimensional IC interconnection
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5324328A (en) 1992-08-05 1994-06-28 Siemens Pacesetter, Inc. Conductor for a defibrillator patch lead
US5676651A (en) 1992-08-06 1997-10-14 Electric Boat Corporation Surgically implantable pump arrangement and method for pumping body fluids
US5311013A (en) 1992-10-15 1994-05-10 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor in a luminescent sensor system
EP0721360A1 (en) 1992-11-09 1996-07-17 SIPIN, Anatole J. Controlled fluid transfer system
US5288009A (en) * 1992-11-23 1994-02-22 Carrar Method for degolding or tinning conductive portions of a microelectronic device
US5683514A (en) * 1992-12-15 1997-11-04 Weirton Steel Corporation Coating control apparatus
US5270079A (en) * 1992-12-18 1993-12-14 Specialty Coatings Systems, Inc. Methods of meniscus coating
SE9301270D0 (en) 1993-04-19 1993-04-17 BIOSENSOR
JP3204980B2 (en) 1993-04-22 2001-09-04 アンドケア,インコーポレイテッド Peroxidase colloidal gold oxidase biosensor for mediator-free glucose measurement
WO1996005501A1 (en) 1993-05-14 1996-02-22 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
JP2704046B2 (en) 1993-06-08 1998-01-26 ベーリンガー マンハイム コーポレーション Biosensing meter that detects the appropriate electrode connection and distinguishes between sample and check pieces
US5352351A (en) 1993-06-08 1994-10-04 Boehringer Mannheim Corporation Biosensing meter with fail/safe procedures to prevent erroneous indications
US5366609A (en) 1993-06-08 1994-11-22 Boehringer Mannheim Corporation Biosensing meter with pluggable memory key
ES2196034T3 (en) 1993-10-21 2003-12-16 Abbott Lab DEVICE AND DETECTION PROCEDURE OF A WHITE BINDING.
US5494562A (en) * 1994-06-27 1996-02-27 Ciba Corning Diagnostics Corp. Electrochemical sensors
US6218624B1 (en) * 1994-07-05 2001-04-17 Belden Wire & Cable Company Coaxial cable
US5509888A (en) * 1994-07-26 1996-04-23 Conceptek Corporation Controller valve device and method
AT402452B (en) 1994-09-14 1997-05-26 Avl Verbrennungskraft Messtech PLANAR SENSOR FOR DETECTING A CHEMICAL PARAMETER OF A SAMPLE
US5624537A (en) * 1994-09-20 1997-04-29 The University Of British Columbia - University-Industry Liaison Office Biosensor and interface membrane
US5676820A (en) 1995-02-03 1997-10-14 New Mexico State University Technology Transfer Corp. Remote electrochemical sensor
US5517313A (en) 1995-02-21 1996-05-14 Colvin, Jr.; Arthur E. Fluorescent optical sensor
US5565143A (en) * 1995-05-05 1996-10-15 E. I. Du Pont De Nemours And Company Water-based silver-silver chloride compositions
EP0744779A3 (en) 1995-05-17 1998-10-21 Matsushita Battery Industrial Co Ltd A manufacturing method of compound semiconductor thinfilms and photoelectric device or solar cell using the same compound semiconductor thinfilms
US6060640A (en) 1995-05-19 2000-05-09 Baxter International Inc. Multiple-layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue
US5611900A (en) * 1995-07-20 1997-03-18 Michigan State University Microbiosensor used in-situ
US6689265B2 (en) * 1995-10-11 2004-02-10 Therasense, Inc. Electrochemical analyte sensors using thermostable soybean peroxidase
US5972199A (en) 1995-10-11 1999-10-26 E. Heller & Company Electrochemical analyte sensors using thermostable peroxidase
US6063637A (en) * 1995-12-13 2000-05-16 California Institute Of Technology Sensors for sugars and other metal binding analytes
ATE396644T1 (en) * 1995-12-19 2008-06-15 Abbott Lab DEVICE FOR DETECTING AN ANALYTE AND ADMINISTERING A THERAPEUTIC SUBSTANCE
US5863460A (en) * 1996-04-01 1999-01-26 Chiron Diagnostics Corporation Oxygen sensing membranes and methods of making same
US6407195B2 (en) 1996-04-25 2002-06-18 3M Innovative Properties Company Tackified polydiorganosiloxane oligourea segmented copolymers and a process for making same
US5707502A (en) * 1996-07-12 1998-01-13 Chiron Diagnostics Corporation Sensors for measuring analyte concentrations and methods of making same
WO1998003431A1 (en) * 1996-07-23 1998-01-29 Medisense, Inc. Silver chloride particles
US5772903A (en) * 1996-09-27 1998-06-30 Hirsch; Gregory Tapered capillary optics
WO1998024358A2 (en) 1996-12-04 1998-06-11 Enact Health Management Systems System for downloading and reporting medical information
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6558321B1 (en) * 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
GB9704737D0 (en) 1997-03-07 1997-04-23 Optel Instr Limited Biological measurement system
US6270455B1 (en) 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US6186765B1 (en) 1997-03-31 2001-02-13 Toshiba Kikai Kabushiki Kaisha Apparatus for forming a molded multilayer product
EP1015669B1 (en) 1997-04-04 2010-11-17 University Of Southern California Electroplating method for forming a multilayer structure
AT404992B (en) 1997-04-17 1999-04-26 Avl List Gmbh SENSOR FOR DETERMINING AN ENZYME SUBSTRATE
US7006871B1 (en) * 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US5851438A (en) * 1997-08-29 1998-12-22 E. I. Du Pont De Nemours And Company Thick film compositions for making medical electrodes
US5999848A (en) 1997-09-12 1999-12-07 Alfred E. Mann Foundation Daisy chainable sensors and stimulators for implantation in living tissue
US5917346A (en) 1997-09-12 1999-06-29 Alfred E. Mann Foundation Low power current to frequency converter circuit for use in implantable sensors
US6007775A (en) 1997-09-26 1999-12-28 University Of Washington Multiple analyte diffusion based chemical sensor
US5879828A (en) * 1997-10-10 1999-03-09 Minnesota Mining And Manufacturing Company Membrane electrode assembly
US5967986A (en) 1997-11-25 1999-10-19 Vascusense, Inc. Endoluminal implant with fluid flow sensing capability
US6081736A (en) * 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
US6070093A (en) 1997-12-02 2000-05-30 Abbott Laboratories Multiplex sensor and method of use
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6106486A (en) * 1997-12-22 2000-08-22 Radi Medical Systems Ab Guide wire
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6134461A (en) * 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
GB9809918D0 (en) * 1998-05-08 1998-07-08 Isis Innovation Microelectrode biosensor and method therefor
CA2329411C (en) * 1998-05-13 2004-01-27 Cygnus, Inc. Collection assemblies for transdermal sampling system
US6662030B2 (en) 1998-05-18 2003-12-09 Abbott Laboratories Non-invasive sensor having controllable temperature feature
US6214115B1 (en) * 1998-07-21 2001-04-10 Biocompatibles Limited Coating
US6558320B1 (en) * 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
ATE394662T1 (en) 1998-08-26 2008-05-15 Sensors For Med & Science Inc OPTICALLY BASED SENSOR DEVICES
US6254586B1 (en) 1998-09-25 2001-07-03 Minimed Inc. Method and kit for supplying a fluid to a subcutaneous placement site
US6187378B1 (en) * 1998-10-01 2001-02-13 Lucent Technologies Inc. Automated system and method for electroless plating of optical fibers
US6201980B1 (en) * 1998-10-05 2001-03-13 The Regents Of The University Of California Implantable medical sensor system
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
AU6255699A (en) 1998-10-08 2000-04-26 Minimed, Inc. Telemetered characteristic monitor system
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6164921A (en) 1998-11-09 2000-12-26 Moubayed; Ahmad Maher Curvilinear peristaltic pump having insertable tubing assembly
US6353226B1 (en) 1998-11-23 2002-03-05 Abbott Laboratories Non-invasive sensor capable of determining optical parameters in a sample having multiple layers
KR20010102951A (en) 1998-12-02 2001-11-17 추후제출 In vivo biosensor apparatus and method of use
US7405149B1 (en) 1998-12-21 2008-07-29 Megica Corporation Post passivation method for semiconductor chip or wafer
IT1307750B1 (en) 1999-02-04 2001-11-19 Saicom S R L PH REACTIVE AMPEROMETRIC BIOSENSOR
CA2365609A1 (en) * 1999-02-12 2000-08-17 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6424847B1 (en) 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US6360888B1 (en) * 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6400992B1 (en) 1999-03-18 2002-06-04 Medtronic, Inc. Co-extruded, multi-lumen medical lead
US6585876B2 (en) 1999-04-08 2003-07-01 Applied Materials Inc. Flow diffuser to be used in electro-chemical plating system and method
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6465066B1 (en) 1999-05-11 2002-10-15 The Coca-Cola Company Packaged potable liquid and packaging for potable liquid
WO2000078992A2 (en) 1999-06-18 2000-12-28 Therasense, Inc. Mass transport limited in vivo analyte sensor
US6413393B1 (en) * 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
CA2382113A1 (en) 1999-08-31 2001-03-08 Cme Telemetrix Inc. Method of calibrating a spectroscopic device
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US7257328B2 (en) * 1999-12-13 2007-08-14 Finisar Corporation System and method for transmitting data on return path of a cable television system
WO2003008014A2 (en) 2000-01-21 2003-01-30 Medical Research Group Ambulatory medical apparatus with hand held communication device
US6733446B2 (en) 2000-01-21 2004-05-11 Medtronic Minimed, Inc. Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods
JP4703083B2 (en) 2000-01-21 2011-06-15 メドトロニック ミニメド インコーポレイテッド Medical system
US7003336B2 (en) * 2000-02-10 2006-02-21 Medtronic Minimed, Inc. Analyte sensor method of making the same
CA2395868C (en) 2000-02-10 2009-07-14 Medtronic Minimed, Inc. Improved analyte sensor and method of making the same
US6895263B2 (en) * 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6528318B1 (en) 2000-03-06 2003-03-04 The Johns Hopkins University Scatter controlled emission for optical taggants and chemical sensors
AU2001263022A1 (en) 2000-05-12 2001-11-26 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
WO2001088534A2 (en) 2000-05-16 2001-11-22 Cygnus, Inc. Methods for improving performance and reliability of biosensors
WO2001091218A2 (en) 2000-05-22 2001-11-29 Acumentrics Corporation Electrode-supported solid state electrochemical cell
DE60045740D1 (en) 2000-12-12 2011-04-28 Sony Deutschland Gmbh Selective chemical sensors based on chained nanoparticle accumulations
US6642015B2 (en) 2000-12-29 2003-11-04 Minimed Inc. Hydrophilic polymeric material for coating biosensors
US6560471B1 (en) * 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
WO2002058551A2 (en) 2001-01-22 2002-08-01 Integrated Sensing Systems, Inc. Wireless mems capacitive sensor for physiologic parameter measurement
US7268562B2 (en) 2001-02-15 2007-09-11 Integral Technologies, Inc. Low cost detectible pipe and electric fencing manufactured from conductive loaded resin-based materials
WO2002090948A1 (en) 2001-05-03 2002-11-14 Delta Dansk Elektronik, Lys & Akustik Apparatus and sensing devices for measuring fluorescence lifetimes of fluorescence sensors
BR0209357A (en) 2001-05-04 2004-06-08 Sensors For Med & Science Inc Electro-reading device with reference channel
US6613379B2 (en) * 2001-05-08 2003-09-02 Isense Corp. Implantable analyte sensor
US20020179457A1 (en) 2001-05-18 2002-12-05 Adam Heller Electrochemical method for high-throughput screening of minute quantities of candidate compounds
US6872297B2 (en) 2001-05-31 2005-03-29 Instrumentation Laboratory Company Analytical instruments, biosensors and methods thereof
US6960466B2 (en) 2001-05-31 2005-11-01 Instrumentation Laboratory Company Composite membrane containing a cross-linked enzyme matrix for a biosensor
US6501976B1 (en) 2001-06-12 2002-12-31 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
WO2003017745A2 (en) 2001-08-23 2003-03-06 Sciperio, Inc. Architecture tool and methods of use
EP1288308A1 (en) 2001-08-28 2003-03-05 Roche Diagnostics GmbH A method for the determination of multiple analytes
US7166208B2 (en) 2004-03-03 2007-01-23 Stephen Eliot Zweig Apoenzyme reactivation electrochemical detection method and assay
US6915147B2 (en) 2001-09-07 2005-07-05 Medtronic Minimed, Inc. Sensing apparatus and process
JP2003084101A (en) * 2001-09-17 2003-03-19 Dainippon Printing Co Ltd Resin composition for optical device, optical device and projection screen
US7425877B2 (en) 2001-09-21 2008-09-16 Ultrasource, Inc. Lange coupler system and method
US6989891B2 (en) * 2001-11-08 2006-01-24 Optiscan Biomedical Corporation Device and method for in vitro determination of analyte concentrations within body fluids
US7061593B2 (en) 2001-11-08 2006-06-13 Optiscan Biomedical Corp. Device and method for in vitro determination of analyte concentrations within body fluids
US6814845B2 (en) 2001-11-21 2004-11-09 University Of Kansas Method for depositing an enzyme on an electrically conductive substrate
US20050101841A9 (en) * 2001-12-04 2005-05-12 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
US20030113573A1 (en) 2001-12-19 2003-06-19 Pepin John Graeme Thick film composition yielding magnetic properties
DE10163972B4 (en) 2001-12-22 2005-10-27 Roche Diagnostics Gmbh Method and device for determining a light transport parameter and an analyte in a biological matrix
US7022072B2 (en) 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US9247901B2 (en) * 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US6998247B2 (en) * 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
EP1702561B1 (en) 2002-03-22 2011-05-04 Animas Technologies LLC Improving performance for an analyte monitoring device
JP2003297163A (en) * 2002-04-03 2003-10-17 Hitachi Cable Ltd Method for manufacturing enameled wire
US6991717B2 (en) * 2002-04-05 2006-01-31 3M Innovative Properties Company Web processing method and apparatus
US20070227907A1 (en) 2006-04-04 2007-10-04 Rajiv Shah Methods and materials for controlling the electrochemistry of analyte sensors
US7069078B2 (en) 2002-04-22 2006-06-27 Medtronic, Inc. Insulin-mediated glucose uptake monitor
US7813780B2 (en) 2005-12-13 2010-10-12 Medtronic Minimed, Inc. Biosensors and methods for making and using them
US6743635B2 (en) 2002-04-25 2004-06-01 Home Diagnostics, Inc. System and methods for blood glucose sensing
US7368190B2 (en) 2002-05-02 2008-05-06 Abbott Diabetes Care Inc. Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods
US20060258761A1 (en) 2002-05-22 2006-11-16 Robert Boock Silicone based membranes for use in implantable glucose sensors
WO2003102218A2 (en) 2002-06-03 2003-12-11 Arizona Board Of Regents Hybrid microcantilever sensors
US7288368B2 (en) 2002-06-17 2007-10-30 Stephen Eliot Zweig Membrane receptor reagent and assay
US20040010207A1 (en) * 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
US7171312B2 (en) 2002-07-19 2007-01-30 Smiths Detection, Inc. Chemical and biological agent sensor array detectors
US8512276B2 (en) * 2002-07-24 2013-08-20 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US7312040B2 (en) 2002-09-20 2007-12-25 Agilent Technologies, Inc. Microcapsule biosensors and methods of using the same
US8303511B2 (en) 2002-09-26 2012-11-06 Pacesetter, Inc. Implantable pressure transducer system optimized for reduced thrombosis effect
AU2003282548A1 (en) 2002-10-10 2004-05-04 Nanosys, Inc. Nano-chem-fet based biosensors
US9237865B2 (en) 2002-10-18 2016-01-19 Medtronic Minimed, Inc. Analyte sensors and methods for making and using them
US20050272989A1 (en) 2004-06-04 2005-12-08 Medtronic Minimed, Inc. Analyte sensors and methods for making and using them
US20040074785A1 (en) * 2002-10-18 2004-04-22 Holker James D. Analyte sensors and methods for making them
US7062385B2 (en) 2002-11-25 2006-06-13 Tufts University Intelligent electro-optical nucleic acid-based sensor array and method for detecting volatile compounds in ambient air
US6918982B2 (en) 2002-12-09 2005-07-19 International Business Machines Corporation System and method of transfer printing an organic semiconductor
US7120483B2 (en) * 2003-01-13 2006-10-10 Isense Corporation Methods for analyte sensing and measurement
US8003374B2 (en) 2003-03-25 2011-08-23 The Regents Of The University Of California Reagentless, reusable, bioelectronic detectors
US6965791B1 (en) 2003-03-26 2005-11-15 Sorenson Medical, Inc. Implantable biosensor system, apparatus and method
US7291496B2 (en) 2003-05-22 2007-11-06 University Of Hawaii Ultrasensitive biochemical sensor
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7146202B2 (en) 2003-06-16 2006-12-05 Isense Corporation Compound material analyte sensor
JP3939679B2 (en) * 2003-06-18 2007-07-04 黒沢建設株式会社 PC steel strand anticorrosive coating double bond structure forming method and PC steel strand
US7108733B2 (en) * 2003-06-20 2006-09-19 Massachusetts Institute Of Technology Metal slurry for electrode formation and production method of the same
ES2681398T3 (en) 2003-06-20 2018-09-12 F. Hoffmann-La Roche Ag Test strip with widened sample reception chamber
MXPA05013747A (en) 2003-06-20 2006-03-08 Hoffmann La Roche Devices and methods relating to electrochemical biosensors.
WO2005010518A1 (en) * 2003-07-23 2005-02-03 Dexcom, Inc. Rolled electrode array and its method for manufacture
WO2005012873A2 (en) 2003-07-25 2005-02-10 Dexcom, Inc. Electrode systems for electrochemical sensors
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
US7460898B2 (en) * 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7424318B2 (en) * 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20050176136A1 (en) 2003-11-19 2005-08-11 Dexcom, Inc. Afinity domain for analyte sensor
US7467003B2 (en) 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US8060173B2 (en) 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US7494465B2 (en) * 2004-07-13 2009-02-24 Dexcom, Inc. Transcutaneous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US20070208245A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US6958096B2 (en) * 2003-08-04 2005-10-25 Furukawa Electric North America, Inc. Systems and methods for coating optical fiber
US7529574B2 (en) 2003-08-14 2009-05-05 Isense Corporation Method of constructing a biosensor
US7632234B2 (en) 2003-08-29 2009-12-15 Medtronic, Inc. Implantable biosensor devices for monitoring cardiac marker molecules
US7214190B1 (en) 2003-09-09 2007-05-08 Kitchener Clark Wilson Apparatus and method for noninvasive monitoring of analytes in body fluids
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7970466B2 (en) 2003-10-07 2011-06-28 Medtronic, Inc. Method and apparatus for optimization and assessment of response to extra-systolic stimulation (ESS) therapy
US20050090607A1 (en) 2003-10-28 2005-04-28 Dexcom, Inc. Silicone composition for biocompatible membrane
DE602004028649D1 (en) 2003-11-13 2010-09-23 Medtronic Minimed Inc LONG-TERM ARRANGEMENT ANALYTENSENSOR
US8414489B2 (en) 2003-11-13 2013-04-09 Medtronic Minimed, Inc. Fabrication of multi-sensor arrays
WO2005051170A2 (en) * 2003-11-19 2005-06-09 Dexcom, Inc. Integrated receiver for continuous analyte sensor
CA2536188A1 (en) 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US20080197024A1 (en) 2003-12-05 2008-08-21 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP2329763B1 (en) 2003-12-09 2017-06-21 DexCom, Inc. Signal processing for continuous analyte sensor
US20050136500A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide; Inc. Flow-through assay devices
EP1557717B1 (en) 2003-12-22 2007-08-15 STMicroelectronics Limited Method of forming sensors comprising barriers of photoresist material
US7553625B2 (en) * 2003-12-22 2009-06-30 John Wayne Cancer Institute Method and apparatus for in vivo collection of circulating biological components
US8948836B2 (en) 2003-12-26 2015-02-03 Medtronic Minimed, Inc. Implantable apparatus for sensing multiple parameters
FR2864449A1 (en) * 2003-12-29 2005-07-01 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A CARDIAC STIMULATOR, WITH IMPROVED MANAGEMENT OF AUTOMATIC AAI / DDD MODE SWITCHING IN THE PRESENCE OF PAROXYSTIC BAV
US20050182451A1 (en) 2004-01-12 2005-08-18 Adam Griffin Implantable device with improved radio frequency capabilities
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
US20070027284A1 (en) 2004-01-13 2007-02-01 Kuang-Hwa Wei Covalently bonded polyhedral oligomeric silsesquioxane/polyimide nanocomposites and process for synthesizing the same
US7364592B2 (en) * 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
WO2005089103A2 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US20050196974A1 (en) * 2004-03-02 2005-09-08 Weigel Scott J. Compositions for preparing low dielectric materials containing solvents
WO2005089409A2 (en) 2004-03-17 2005-09-29 University Of Hawaii Sensor constructs and detection methods
US20050245799A1 (en) * 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US8277713B2 (en) * 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US7280879B2 (en) 2004-05-20 2007-10-09 Sap Ag Interfaces from external systems to time dependent process parameters in integrated process and product engineering
US20060015020A1 (en) 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20080242961A1 (en) 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7310544B2 (en) 2004-07-13 2007-12-18 Dexcom, Inc. Methods and systems for inserting a transcutaneous analyte sensor
US20060270922A1 (en) * 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
JP2008510154A (en) 2004-08-16 2008-04-03 ノボ ノルディスク アクティーゼルスカブ Multiphase biocompatible semipermeable membrane for biosensors
EP1782062A4 (en) 2004-08-24 2010-09-08 Univ South Florida Epoxy enhanced polymer membrane to increase durability of biosensors
US7519433B2 (en) * 2004-08-25 2009-04-14 Medtronic Transneuronix, Inc. Gastrointestinal stimulation lead
US7468033B2 (en) 2004-09-08 2008-12-23 Medtronic Minimed, Inc. Blood contacting sensor
US7387811B2 (en) 2004-09-21 2008-06-17 Superpower, Inc. Method for manufacturing high temperature superconducting conductors using chemical vapor deposition (CVD)
US7384532B2 (en) 2004-11-16 2008-06-10 Lacks Enterprises, Inc. Platable coating and plating process
US20060122864A1 (en) 2004-12-02 2006-06-08 Gottesman Janell M Patient management network
CN100367906C (en) * 2004-12-08 2008-02-13 圣美迪诺医疗科技(湖州)有限公司 Endermic implantating biological sensors
US7625596B2 (en) * 2004-12-15 2009-12-01 General Electric Company Adhesion promoter, electroactive layer and electroactive device comprising same, and method
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US20060163744A1 (en) * 2005-01-14 2006-07-27 Cabot Corporation Printable electrical conductors
US20090076360A1 (en) * 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US8244371B2 (en) 2005-03-18 2012-08-14 Metacure Limited Pancreas lead
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US20060252027A1 (en) 2005-05-05 2006-11-09 Petisce James R Cellulosic-based resistance domain for an analyte sensor
WO2006110193A2 (en) 2005-04-08 2006-10-19 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US8060174B2 (en) 2005-04-15 2011-11-15 Dexcom, Inc. Analyte sensing biointerface
US20060263763A1 (en) 2005-04-15 2006-11-23 Simpson Peter C Analyte sensing biointerface
US7308292B2 (en) 2005-04-15 2007-12-11 Sensors For Medicine And Science, Inc. Optical-based sensing devices
US20060263839A1 (en) 2005-05-17 2006-11-23 Isense Corporation Combined drug delivery and analyte sensor apparatus
JP4690115B2 (en) 2005-05-31 2011-06-01 株式会社リコー Control apparatus and image processing apparatus
US8021299B2 (en) 2005-06-01 2011-09-20 Medtronic, Inc. Correlating a non-polysomnographic physiological parameter set with sleep states
US7905999B2 (en) 2005-06-08 2011-03-15 Abbott Laboratories Biosensor strips and methods of preparing same
US7918978B2 (en) 2005-07-14 2011-04-05 I-Stat Corporation Photoformed silicone sensor membrane
EP1746454A1 (en) * 2005-07-18 2007-01-24 Barco, naamloze vennootschap. Device for coupling the light of multiple light sources
US20070032865A1 (en) * 2005-08-05 2007-02-08 Otis David R Prosthesis having a coating and systems and methods of making the same
US7725148B2 (en) 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US20080112853A1 (en) * 2006-08-15 2008-05-15 Hall W Dale Method and apparatus for analyte measurements in the presence of interferents
US20080072663A1 (en) * 2006-08-15 2008-03-27 Optiscan Biomedical Corporation Accurate and timely body fluid analysis
EP1954190A4 (en) 2005-11-15 2010-10-13 Luminous Medical Inc Blood analyte determinations
US20070135699A1 (en) 2005-12-12 2007-06-14 Isense Corporation Biosensor with antimicrobial agent
US20070141245A1 (en) * 2005-12-20 2007-06-21 Steve Tsai System and method for coating filaments
US20070173712A1 (en) 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Method of and system for stabilization of sensors
US7774038B2 (en) 2005-12-30 2010-08-10 Medtronic Minimed, Inc. Real-time self-calibrating sensor system and method
US9044179B2 (en) 2006-01-04 2015-06-02 The Trustees Of The University Of Pennslyvania Oxygen sensor for internal monitoring of tissue oxygen in vivo
EP2004796B1 (en) 2006-01-18 2015-04-08 DexCom, Inc. Membranes for an analyte sensor
WO2007097754A1 (en) 2006-02-22 2007-08-30 Dexcom, Inc. Analyte sensor
CN101360450A (en) 2006-02-27 2009-02-04 爱德华兹生命科学公司 Flux limiting membrane for intravenous amperometric biosensor
US7885698B2 (en) * 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20070227633A1 (en) * 2006-04-04 2007-10-04 Basol Bulent M Composition control for roll-to-roll processed photovoltaic films
WO2007120381A2 (en) 2006-04-14 2007-10-25 Dexcom, Inc. Analyte sensor
US7684872B2 (en) 2006-04-26 2010-03-23 Medtronic, Inc. Contactless interconnect for transducers
US7855653B2 (en) 2006-04-28 2010-12-21 Medtronic, Inc. External voiding sensor system
US20070255126A1 (en) 2006-04-28 2007-11-01 Moberg Sheldon B Data communication in networked fluid infusion systems
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
US20080033260A1 (en) * 2006-08-03 2008-02-07 Microchips, Inc. Cardiac Biosensor Devices and Methods
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
WO2008048709A1 (en) 2006-10-15 2008-04-24 Roche Diagnostic Gmbh Diagnostic test element and process for its production
DK2073939T3 (en) * 2006-10-16 2012-10-22 Materials And Technologies Corp Wet processing device using a fluid meniscus
CA2667639A1 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
WO2008051762A2 (en) 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
ES2405364T3 (en) 2006-12-29 2013-05-30 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US10154804B2 (en) 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US20080269723A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
EP1987761B1 (en) 2007-05-03 2019-10-23 F. Hoffmann-La Roche AG Tube-like sensor for proving an analyte
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
US20090247856A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
WO2010144790A1 (en) * 2009-06-12 2010-12-16 E. I. Du Pont De Nemours And Company Ink jettable silver/silver chloride compositions
US9237864B2 (en) 2009-07-02 2016-01-19 Dexcom, Inc. Analyte sensors and methods of manufacturing same

Patent Citations (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206755A (en) * 1977-04-21 1980-06-10 Association Pour La Recherche Et Le Developpement Des Methodes Et Processus Industriels A.R.M.I.N.E.S. Method and apparatus for the control and regulation of glycemia
US4225410A (en) * 1978-12-04 1980-09-30 Technicon Instruments Corporation Integrated array of electrochemical sensors
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4739380A (en) * 1984-01-19 1988-04-19 Integrated Ionics, Inc. Integrated ambient sensing devices and methods of manufacture
US4568444A (en) * 1984-04-30 1986-02-04 Kuraray Co., Ltd. Chemical substance measuring apparatus
US4736748A (en) * 1986-04-05 1988-04-12 Kuraray Co., Ltd. Blood component monitoring system
US4837049A (en) * 1986-06-17 1989-06-06 Alfred E. Mann Foundation For Scientific Research Method of making an electrode array
US4935345A (en) * 1987-04-07 1990-06-19 Arizona Board Of Regents Implantable microelectronic biochemical sensor incorporating thin film thermopile
US4925444A (en) * 1987-08-07 1990-05-15 Baxter Travenol Laboratories, Inc. Closed multi-fluid delivery system and method
US5002055A (en) * 1988-04-13 1991-03-26 Mic Medical Instruments Corporation Apparatus for the biofeedback control of body functions
US20030134347A1 (en) * 1991-03-04 2003-07-17 Therasense, Inc. Subcutaneous glucose electrode
US6514718B2 (en) * 1991-03-04 2003-02-04 Therasense, Inc. Subcutaneous glucose electrode
US6881551B2 (en) * 1991-03-04 2005-04-19 Therasense, Inc. Subcutaneous glucose electrode
US20020042090A1 (en) * 1991-03-04 2002-04-11 Therasense, Inc. Subcutaneous glucose electrode
US20060003398A1 (en) * 1991-03-04 2006-01-05 Therasense, Inc. Subcutaneous glucose electrode
US20070151869A1 (en) * 1991-03-04 2007-07-05 Abbott Diabetes Care, Inc. Subcutaneous Glucose Electrode
US5957854A (en) * 1993-09-04 1999-09-28 Besson; Marcus Wireless medical diagnosis and monitoring equipment
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US6121009A (en) * 1993-12-02 2000-09-19 E. Heller & Company Electrochemical analyte measurement system
US6083710A (en) * 1993-12-02 2000-07-04 E. Heller & Company Electrochemical analyte measurement system
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US6284478B1 (en) * 1993-12-02 2001-09-04 E. Heller & Company Subcutaneous glucose electrode
US5513636A (en) * 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
US6066448A (en) * 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US5959191A (en) * 1995-03-27 1999-09-28 California Institute Of Technology Sensor arrays for detecting analytes in fluids
US6122536A (en) * 1995-07-06 2000-09-19 Animas Corporation Implantable sensor and system for measurement and control of blood constituent levels
US5711861A (en) * 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US6212416B1 (en) * 1995-11-22 2001-04-03 Good Samaritan Hospital And Medical Center Device for monitoring changes in analyte concentration
US20040039298A1 (en) * 1996-09-04 2004-02-26 Abreu Marcio Marc Noninvasive measurement of chemical substances
US7402153B2 (en) * 1997-06-09 2008-07-22 Medtronic Minimed, Inc. Closed-loop method for controlling insulin infusion
US5904666A (en) * 1997-08-18 1999-05-18 L.Vad Technology, Inc. Method and apparatus for measuring flow rate and controlling delivered volume of fluid through a valve aperture
US6117290A (en) * 1997-09-26 2000-09-12 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US20020042561A1 (en) * 1997-10-20 2002-04-11 Schulman Joseph H. Implantable sensor and integrity tests therefor
US6088608A (en) * 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6032667A (en) * 1997-10-30 2000-03-07 Instrumentarium Corporation Variable orifice pulse valve
US6432050B1 (en) * 1997-12-30 2002-08-13 Remon Medical Technologies Ltd. Implantable acoustic bio-sensing system and method
US5904708A (en) * 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US6175767B1 (en) * 1998-04-01 2001-01-16 James H. Doyle, Sr. Multichannel implantable inner ear stimulator
US6091975A (en) * 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US6223080B1 (en) * 1998-04-29 2001-04-24 Medtronic, Inc. Power consumption reduction in medical devices employing multiple digital signal processors and different supply voltages
US20090099435A1 (en) * 1998-04-30 2009-04-16 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US6016448A (en) * 1998-10-27 2000-01-18 Medtronic, Inc. Multilevel ERI for implantable medical devices
US6447448B1 (en) * 1998-12-31 2002-09-10 Ball Semiconductor, Inc. Miniature implanted orthopedic sensors
US6230059B1 (en) * 1999-03-17 2001-05-08 Medtronic, Inc. Implantable monitor
US6223083B1 (en) * 1999-04-16 2001-04-24 Medtronic, Inc. Receiver employing digital filtering for use with an implantable medical device
US6546268B1 (en) * 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US7354420B2 (en) * 1999-06-03 2008-04-08 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US20030130616A1 (en) * 1999-06-03 2003-07-10 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US20020128546A1 (en) * 2000-05-15 2002-09-12 Silver James H. Implantable sensor
US20040176672A1 (en) * 2000-05-15 2004-09-09 Silver James H. Implantable, retrievable, thrombus minimizing sensors
US7033322B2 (en) * 2000-05-15 2006-04-25 Silver James H Implantable sensor
US20060079740A1 (en) * 2000-05-15 2006-04-13 Silver James H Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction
US6400974B1 (en) * 2000-06-29 2002-06-04 Sensors For Medicine And Science, Inc. Implanted sensor processing system and method for processing implanted sensor output
US6609071B2 (en) * 2000-12-06 2003-08-19 Project Cd System for monitoring and controlling pressure and concentration values in a fluid conduit
US6749587B2 (en) * 2001-02-22 2004-06-15 Insulet Corporation Modular infusion device and method
US20030050546A1 (en) * 2001-06-22 2003-03-13 Desai Shashi P. Methods for improving the performance of an analyte monitoring system
US20030076082A1 (en) * 2001-10-23 2003-04-24 Morgan Wayne A. Implantable sensor electrodes and electronic circuitry
US20050027182A1 (en) * 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US7399277B2 (en) * 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7226978B2 (en) * 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US7169289B2 (en) * 2002-06-28 2007-01-30 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Electrochemical detection method and device
US20040180391A1 (en) * 2002-10-11 2004-09-16 Miklos Gratzl Sliver type autonomous biosensors
US20040152187A1 (en) * 2002-11-13 2004-08-05 Haight Levoy Golden System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors
US20090143659A1 (en) * 2003-08-01 2009-06-04 Dexcom, Inc. Analyte sensor
US20070066873A1 (en) * 2003-08-22 2007-03-22 Apurv Kamath Systems and methods for processing analyte sensor data
US20070016381A1 (en) * 2003-08-22 2007-01-18 Apurv Kamath Systems and methods for processing analyte sensor data
US20050107677A1 (en) * 2003-09-24 2005-05-19 W. Kenneth Ward Implantable biosensor
US20050112358A1 (en) * 2003-11-24 2005-05-26 Potyrailo Radislav A. Methods for deposition of sensor regions onto optical storage media substrates and resulting devices
US20090124964A1 (en) * 2003-12-05 2009-05-14 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US7366556B2 (en) * 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7081195B2 (en) * 2003-12-08 2006-07-25 Dexcom, Inc. Systems and methods for improving electrochemical analyte sensors
US20060155180A1 (en) * 2004-07-13 2006-07-13 Mark Brister Analyte sensor
US20070163880A1 (en) * 2004-07-13 2007-07-19 Dexcom, Inc. Analyte sensor
US20070038044A1 (en) * 2004-07-13 2007-02-15 Dobbles J M Analyte sensor
US20060142651A1 (en) * 2004-07-13 2006-06-29 Mark Brister Analyte sensor
US20060183985A1 (en) * 2004-07-13 2006-08-17 Mark Brister Analyte sensor
US20070059196A1 (en) * 2004-07-13 2007-03-15 Mark Brister Analyte sensor
US20060258929A1 (en) * 2005-03-10 2006-11-16 Goode Paul V Jr System and methods for processing analyte sensor data for sensor calibration
US20070151868A1 (en) * 2005-11-12 2007-07-05 Arnulf Staib Implantable electrode system, method and apparatus for measuring an analyte concentration in a human or animal body
US20070131549A1 (en) * 2005-12-14 2007-06-14 Nova Biomedical Corporation Glucose biosensor and method
US20070197889A1 (en) * 2006-02-22 2007-08-23 Mark Brister Analyte sensor
US20070203407A1 (en) * 2006-02-28 2007-08-30 Abbott Diabetes Care, Inc. Analyte sensors and methods of use
US20080027301A1 (en) * 2006-07-28 2008-01-31 Ward W Kenneth Analyte sensing and response system
US20080154101A1 (en) * 2006-09-27 2008-06-26 Faquir Jain Implantable Biosensor and Methods of Use Thereof
US20080108942A1 (en) * 2006-10-04 2008-05-08 Dexcom, Inc. Analyte sensor
US20080119704A1 (en) * 2006-10-04 2008-05-22 Mark Brister Analyte sensor
US20080200788A1 (en) * 2006-10-04 2008-08-21 Dexcorn, Inc. Analyte sensor
US20080200791A1 (en) * 2006-10-04 2008-08-21 Dexcom, Inc. Analyte sensor
US20080200789A1 (en) * 2006-10-04 2008-08-21 Dexcom, Inc. Analyte sensor
US20090018424A1 (en) * 2006-10-04 2009-01-15 Dexcom, Inc. Analyte sensor
US20080119706A1 (en) * 2006-10-04 2008-05-22 Mark Brister Analyte sensor
US20080086042A1 (en) * 2006-10-04 2008-04-10 Dexcom, Inc. Analyte sensor
US20090131768A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090131769A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090131776A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090131777A1 (en) * 2006-10-04 2009-05-21 Dexcom, Inc. Analyte sensor
US20090137887A1 (en) * 2006-10-04 2009-05-28 Dexcom, Inc. Analyte sensor
US20090137886A1 (en) * 2006-10-04 2009-05-28 Dexcom, Inc. Analyte sensor
US20080086044A1 (en) * 2006-10-04 2008-04-10 Dexcom, Inc. Analyte sensor
US20090156924A1 (en) * 2007-12-17 2009-06-18 Dexcom, Inc. Systems and methods for processing sensor data
US20100030045A1 (en) * 2008-07-31 2010-02-04 Medtronic Minimed, Inc. Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them

Cited By (517)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20100274111A1 (en) * 1998-04-30 2010-10-28 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US20070203410A1 (en) * 1998-04-30 2007-08-30 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20070203411A1 (en) * 1998-04-30 2007-08-30 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20070244380A1 (en) * 1998-04-30 2007-10-18 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US20070249919A1 (en) * 1998-04-30 2007-10-25 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US20080033271A1 (en) * 1998-04-30 2008-02-07 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US8738109B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20080091096A1 (en) * 1998-04-30 2008-04-17 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US8672844B2 (en) 1998-04-30 2014-03-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8357091B2 (en) 1998-04-30 2013-01-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8670815B2 (en) 1998-04-30 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8666469B2 (en) 1998-04-30 2014-03-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20090171179A1 (en) * 1998-04-30 2009-07-02 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20090177064A1 (en) * 1998-04-30 2009-07-09 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20090187088A1 (en) * 1998-04-30 2009-07-23 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US8660627B2 (en) 1998-04-30 2014-02-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20040171921A1 (en) * 1998-04-30 2004-09-02 James Say Analyte monitoring device and methods of use
US8649841B2 (en) 1998-04-30 2014-02-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10478108B2 (en) 1998-04-30 2019-11-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8641619B2 (en) 1998-04-30 2014-02-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20100268047A1 (en) * 1998-04-30 2010-10-21 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US8353829B2 (en) 1998-04-30 2013-01-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734348B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734346B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8162829B2 (en) 1998-04-30 2012-04-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8622906B2 (en) 1998-04-30 2014-01-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8175673B2 (en) 1998-04-30 2012-05-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8177716B2 (en) 1998-04-30 2012-05-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8224413B2 (en) 1998-04-30 2012-07-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226558B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226557B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226555B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8231532B2 (en) 1998-04-30 2012-07-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8235896B2 (en) 1998-04-30 2012-08-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8255031B2 (en) 1998-04-30 2012-08-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8260392B2 (en) 1998-04-30 2012-09-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8265726B2 (en) 1998-04-30 2012-09-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8275439B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8273022B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8306598B2 (en) 1998-04-30 2012-11-06 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346336B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20070208247A1 (en) * 1998-04-30 2007-09-06 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20060189863A1 (en) * 1998-04-30 2006-08-24 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US8744545B2 (en) 1998-04-30 2014-06-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8366614B2 (en) 1998-04-30 2013-02-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8372005B2 (en) 1998-04-30 2013-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8380273B2 (en) 1998-04-30 2013-02-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8774887B2 (en) 1998-04-30 2014-07-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8391945B2 (en) 1998-04-30 2013-03-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8409131B2 (en) 1998-04-30 2013-04-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8473021B2 (en) 1998-04-30 2013-06-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8840553B2 (en) 1998-04-30 2014-09-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8880137B2 (en) 1998-04-30 2014-11-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8617071B2 (en) 1998-04-30 2013-12-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9326714B2 (en) 1998-04-30 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9072477B2 (en) 1998-04-30 2015-07-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066694B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066697B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9042953B2 (en) 1998-04-30 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8597189B2 (en) 1998-04-30 2013-12-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9014773B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011331B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011332B2 (en) 2001-01-02 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20080086039A1 (en) * 2001-01-02 2008-04-10 Abbott Diabetes Care, Inc. Analyte Monitoring Device And Methods Of Use
US8668645B2 (en) 2001-01-02 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9610034B2 (en) 2001-01-02 2017-04-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9498159B2 (en) 2001-01-02 2016-11-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9980670B2 (en) 2002-11-05 2018-05-29 Abbott Diabetes Care Inc. Sensor inserter assembly
US11141084B2 (en) 2002-11-05 2021-10-12 Abbott Diabetes Care Inc. Sensor inserter assembly
US11116430B2 (en) 2002-11-05 2021-09-14 Abbott Diabetes Care Inc. Sensor inserter assembly
US10973443B2 (en) 2002-11-05 2021-04-13 Abbott Diabetes Care Inc. Sensor inserter assembly
USD902408S1 (en) 2003-11-05 2020-11-17 Abbott Diabetes Care Inc. Analyte sensor control unit
USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11627900B2 (en) 2003-12-05 2023-04-18 Dexcom, Inc. Analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US11160475B2 (en) 2004-12-29 2021-11-02 Abbott Diabetes Care Inc. Sensor inserter having introducer
US20180153456A1 (en) * 2005-02-14 2018-06-07 Optiscan Biomedical Corporation Analyte detection systems and methods using multiple measurements
US8602991B2 (en) 2005-08-30 2013-12-10 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US10194850B2 (en) 2005-08-31 2019-02-05 Abbott Diabetes Care Inc. Accuracy of continuous glucose sensors
US9480421B2 (en) 2005-09-30 2016-11-01 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US20090054746A1 (en) * 2005-09-30 2009-02-26 Abbott Diabetes Care, Inc. Device for channeling fluid and methods of use
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US9775563B2 (en) 2005-09-30 2017-10-03 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US10342489B2 (en) 2005-09-30 2019-07-09 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US10194863B2 (en) 2005-09-30 2019-02-05 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
USD979766S1 (en) 2005-09-30 2023-02-28 Abbott Diabetes Care Inc. Analyte sensor device
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US11457869B2 (en) 2005-09-30 2022-10-04 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US11272867B2 (en) 2005-11-01 2022-03-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11399748B2 (en) 2005-11-01 2022-08-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9078607B2 (en) 2005-11-01 2015-07-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11363975B2 (en) 2005-11-01 2022-06-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11103165B2 (en) * 2005-11-01 2021-08-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10231654B2 (en) 2005-11-01 2019-03-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8920319B2 (en) 2005-11-01 2014-12-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8915850B2 (en) 2005-11-01 2014-12-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10201301B2 (en) 2005-11-01 2019-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11911151B1 (en) 2005-11-01 2024-02-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9326716B2 (en) 2005-11-01 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10952652B2 (en) 2005-11-01 2021-03-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8852101B2 (en) 2005-12-28 2014-10-07 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9332933B2 (en) 2005-12-28 2016-05-10 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US10307091B2 (en) 2005-12-28 2019-06-04 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9795331B2 (en) 2005-12-28 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US8545403B2 (en) 2005-12-28 2013-10-01 Abbott Diabetes Care Inc. Medical device insertion
US9326727B2 (en) 2006-01-30 2016-05-03 Abbott Diabetes Care Inc. On-body medical device securement
US11872039B2 (en) 2006-02-28 2024-01-16 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9844329B2 (en) 2006-02-28 2017-12-19 Abbott Diabetes Care Inc. Analyte sensors and methods of use
USD961778S1 (en) 2006-02-28 2022-08-23 Abbott Diabetes Care Inc. Analyte sensor device
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9031630B2 (en) 2006-02-28 2015-05-12 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US10028680B2 (en) 2006-04-28 2018-07-24 Abbott Diabetes Care Inc. Introducer assembly and methods of use
US10736547B2 (en) 2006-04-28 2020-08-11 Abbott Diabetes Care Inc. Introducer assembly and methods of use
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US11864894B2 (en) 2006-08-09 2024-01-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9833181B2 (en) 2006-08-09 2017-12-05 Abbot Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US10278630B2 (en) 2006-08-09 2019-05-07 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US10362972B2 (en) 2006-09-10 2019-07-30 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US9808186B2 (en) 2006-09-10 2017-11-07 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US8862198B2 (en) 2006-09-10 2014-10-14 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US9629578B2 (en) 2006-10-02 2017-04-25 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9839383B2 (en) 2006-10-02 2017-12-12 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US10342469B2 (en) 2006-10-02 2019-07-09 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9357959B2 (en) 2006-10-02 2016-06-07 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US11724029B2 (en) 2006-10-23 2023-08-15 Abbott Diabetes Care Inc. Flexible patch for fluid delivery and monitoring body analytes
US10070810B2 (en) 2006-10-23 2018-09-11 Abbott Diabetes Care Inc. Sensor insertion devices and methods of use
US10363363B2 (en) 2006-10-23 2019-07-30 Abbott Diabetes Care Inc. Flexible patch for fluid delivery and monitoring body analytes
US11234621B2 (en) 2006-10-23 2022-02-01 Abbott Diabetes Care Inc. Sensor insertion devices and methods of use
US10194868B2 (en) 2006-10-25 2019-02-05 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9113828B2 (en) 2006-10-25 2015-08-25 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US11282603B2 (en) 2006-10-25 2022-03-22 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9814428B2 (en) 2006-10-25 2017-11-14 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9882660B2 (en) 2006-10-26 2018-01-30 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US10903914B2 (en) 2006-10-26 2021-01-26 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US11722229B2 (en) 2006-10-26 2023-08-08 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US20100204557A1 (en) * 2007-02-18 2010-08-12 Abbott Diabetes Care Inc. Multi-Function Analyte Test Device and Methods Therefor
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US20080200897A1 (en) * 2007-02-19 2008-08-21 Abbott Diabetes Care, Inc. Modular combination of medication infusion and analyte monitoring
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US11039767B2 (en) 2007-04-14 2021-06-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10349877B2 (en) 2007-04-14 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10261069B2 (en) 2007-05-14 2019-04-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9558325B2 (en) 2007-05-14 2017-01-31 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US10143409B2 (en) 2007-05-14 2018-12-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10119956B2 (en) 2007-05-14 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9797880B2 (en) 2007-05-14 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8682615B2 (en) 2007-05-14 2014-03-25 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10653344B2 (en) 2007-05-14 2020-05-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9060719B2 (en) 2007-05-14 2015-06-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11828748B2 (en) 2007-05-14 2023-11-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10634662B2 (en) 2007-05-14 2020-04-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11076785B2 (en) 2007-05-14 2021-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10045720B2 (en) 2007-05-14 2018-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10031002B2 (en) 2007-05-14 2018-07-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10463310B2 (en) 2007-05-14 2019-11-05 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10820841B2 (en) 2007-05-14 2020-11-03 Abbot Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11300561B2 (en) 2007-05-14 2022-04-12 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US10991456B2 (en) 2007-05-14 2021-04-27 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9804150B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9737249B2 (en) 2007-05-14 2017-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8612163B2 (en) 2007-05-14 2013-12-17 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11125592B2 (en) 2007-05-14 2021-09-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9801571B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US11119090B2 (en) 2007-05-14 2021-09-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10976304B2 (en) 2007-05-14 2021-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8613703B2 (en) 2007-05-31 2013-12-24 Abbott Diabetes Care Inc. Insertion devices and methods
US20080300476A1 (en) * 2007-05-31 2008-12-04 Abbott Diabetes Care, Inc. Insertion devices and methods
US10856785B2 (en) 2007-06-29 2020-12-08 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US11678821B2 (en) 2007-06-29 2023-06-20 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9913600B2 (en) 2007-06-29 2018-03-13 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9398872B2 (en) 2007-07-31 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US20090063402A1 (en) * 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US11083843B2 (en) 2007-10-23 2021-08-10 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US9743865B2 (en) 2007-10-23 2017-08-29 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9804148B2 (en) 2007-10-23 2017-10-31 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US9332934B2 (en) 2007-10-23 2016-05-10 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US9439586B2 (en) 2007-10-23 2016-09-13 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US10173007B2 (en) 2007-10-23 2019-01-08 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US10685749B2 (en) 2007-12-19 2020-06-16 Abbott Diabetes Care Inc. Insulin delivery apparatuses capable of bluetooth data transmission
US9320468B2 (en) 2008-01-31 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9770211B2 (en) 2008-01-31 2017-09-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US11147483B2 (en) 2008-03-28 2021-10-19 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US10143410B2 (en) * 2008-03-28 2018-12-04 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9320462B2 (en) 2008-03-28 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor calibration management
US20170265795A1 (en) * 2008-03-28 2017-09-21 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8718739B2 (en) 2008-03-28 2014-05-06 Abbott Diabetes Care Inc. Analyte sensor calibration management
US20100234710A1 (en) * 2008-03-28 2010-09-16 Abbott Diabetes Care Inc. Analyte Sensor Calibration Management
US10463288B2 (en) 2008-03-28 2019-11-05 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US11779248B2 (en) 2008-03-28 2023-10-10 Abbott Diabetes Care Inc. Analyte sensor calibration management
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9730623B2 (en) 2008-03-28 2017-08-15 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9795328B2 (en) 2008-05-30 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9541556B2 (en) 2008-05-30 2017-01-10 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10327682B2 (en) 2008-05-30 2019-06-25 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9931075B2 (en) 2008-05-30 2018-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US11735295B2 (en) 2008-05-30 2023-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10328201B2 (en) 2008-07-14 2019-06-25 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US11621073B2 (en) 2008-07-14 2023-04-04 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
US10188794B2 (en) 2008-08-31 2019-01-29 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US20100056992A1 (en) * 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Variable Rate Closed Loop Control And Methods
US11679200B2 (en) 2008-08-31 2023-06-20 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US20100057042A1 (en) * 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Closed Loop Control With Improved Alarm Functions
US9572934B2 (en) 2008-08-31 2017-02-21 Abbott DiabetesCare Inc. Robust closed loop control and methods
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9610046B2 (en) 2008-08-31 2017-04-04 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US11202592B2 (en) 2008-09-30 2021-12-21 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US20100081906A1 (en) * 2008-09-30 2010-04-01 Abbott Diabetes Care, Inc. Analyte Sensor Sensitivity Attenuation Mitigation
US11464434B2 (en) 2008-09-30 2022-10-11 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US10045739B2 (en) 2008-09-30 2018-08-14 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9662056B2 (en) 2008-09-30 2017-05-30 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US11484234B2 (en) 2008-09-30 2022-11-01 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11013439B2 (en) 2008-09-30 2021-05-25 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9730650B2 (en) 2008-11-10 2017-08-15 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US11272890B2 (en) 2008-11-10 2022-03-15 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US11678848B2 (en) 2008-11-10 2023-06-20 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US8532935B2 (en) 2009-01-29 2013-09-10 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US11464430B2 (en) 2009-01-29 2022-10-11 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8676513B2 (en) 2009-01-29 2014-03-18 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9066709B2 (en) 2009-01-29 2015-06-30 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US10089446B2 (en) 2009-01-29 2018-10-02 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US10786190B2 (en) 2009-02-03 2020-09-29 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11006871B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US9993188B2 (en) 2009-02-03 2018-06-12 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11202591B2 (en) 2009-02-03 2021-12-21 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11213229B2 (en) 2009-02-03 2022-01-04 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
USD882432S1 (en) 2009-02-03 2020-04-28 Abbott Diabetes Care Inc. Analyte sensor on body unit
US9636068B2 (en) 2009-02-03 2017-05-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11006870B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
USD957642S1 (en) 2009-02-03 2022-07-12 Abbott Diabetes Care Inc. Analyte sensor inserter
USD957643S1 (en) 2009-02-03 2022-07-12 Abbott Diabetes Care Inc. Analyte sensor device
USD955599S1 (en) 2009-02-03 2022-06-21 Abbott Diabetes Care Inc. Analyte sensor inserter
US11006872B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11166656B2 (en) 2009-02-03 2021-11-09 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US10009244B2 (en) 2009-04-15 2018-06-26 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8730058B2 (en) 2009-04-15 2014-05-20 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US9178752B2 (en) 2009-04-15 2015-11-03 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US9310230B2 (en) 2009-04-29 2016-04-12 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US10820842B2 (en) 2009-04-29 2020-11-03 Abbott Diabetes Care Inc. Methods and systems for early signal attenuation detection and processing
US11013431B2 (en) 2009-04-29 2021-05-25 Abbott Diabetes Care Inc. Methods and systems for early signal attenuation detection and processing
US10952653B2 (en) 2009-04-29 2021-03-23 Abbott Diabetes Care Inc. Methods and systems for early signal attenuation detection and processing
US11116431B1 (en) 2009-04-29 2021-09-14 Abbott Diabetes Care Inc. Methods and systems for early signal attenuation detection and processing
US10194844B2 (en) 2009-04-29 2019-02-05 Abbott Diabetes Care Inc. Methods and systems for early signal attenuation detection and processing
US11298056B2 (en) 2009-04-29 2022-04-12 Abbott Diabetes Care Inc. Methods and systems for early signal attenuation detection and processing
US11559229B2 (en) 2009-07-02 2023-01-24 Dexcom, Inc. Analyte sensor
US9907497B2 (en) 2009-07-02 2018-03-06 Dexcom, Inc. Analyte sensor
US10420494B2 (en) 2009-07-02 2019-09-24 Dexcom, Inc. Analyte sensor
US9320466B2 (en) 2009-07-02 2016-04-26 Dexcom, Inc. Analyte sensor
US20110021889A1 (en) * 2009-07-23 2011-01-27 Abbott Diabetes Care Inc. Continuous Analyte Measurement Systems and Systems and Methods for Implanting Them
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US10872102B2 (en) 2009-07-23 2020-12-22 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US10827954B2 (en) 2009-07-23 2020-11-10 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9936910B2 (en) 2009-07-31 2018-04-10 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US10660554B2 (en) 2009-07-31 2020-05-26 Abbott Diabetes Care Inc. Methods and devices for analyte monitoring calibration
US11234625B2 (en) 2009-07-31 2022-02-01 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US8718965B2 (en) 2009-07-31 2014-05-06 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
USD962446S1 (en) 2009-08-31 2022-08-30 Abbott Diabetes Care, Inc. Analyte sensor device
US9226714B2 (en) 2009-08-31 2016-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US10881355B2 (en) 2009-08-31 2021-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US11241175B2 (en) 2009-08-31 2022-02-08 Abbott Diabetes Care Inc. Displays for a medical device
US10918342B1 (en) 2009-08-31 2021-02-16 Abbott Diabetes Care Inc. Displays for a medical device
US10456091B2 (en) 2009-08-31 2019-10-29 Abbott Diabetes Care Inc. Displays for a medical device
US10123752B2 (en) 2009-08-31 2018-11-13 Abbott Diabetes Care Inc. Displays for a medical device
US10772572B2 (en) 2009-08-31 2020-09-15 Abbott Diabetes Care Inc. Displays for a medical device
US11730429B2 (en) 2009-08-31 2023-08-22 Abbott Diabetes Care Inc. Displays for a medical device
USRE47315E1 (en) 2009-08-31 2019-03-26 Abbott Diabetes Care Inc. Displays for a medical device
US9186113B2 (en) 2009-08-31 2015-11-17 Abbott Diabetes Care Inc. Displays for a medical device
US8816862B2 (en) 2009-08-31 2014-08-26 Abbott Diabetes Care Inc. Displays for a medical device
US11202586B2 (en) 2009-08-31 2021-12-21 Abbott Diabetes Care Inc. Displays for a medical device
US9549694B2 (en) 2009-08-31 2017-01-24 Abbott Diabetes Care Inc. Displays for a medical device
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US20110054275A1 (en) * 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Mounting Unit Having a Sensor and Associated Circuitry
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US9750439B2 (en) 2009-09-29 2017-09-05 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US10349874B2 (en) 2009-09-29 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US11259725B2 (en) 2009-09-30 2022-03-01 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US10765351B2 (en) 2009-09-30 2020-09-08 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US9750444B2 (en) 2009-09-30 2017-09-05 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US10117606B2 (en) 2009-10-30 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US11207005B2 (en) 2009-10-30 2021-12-28 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
US11061491B2 (en) 2010-03-10 2021-07-13 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US10078380B2 (en) 2010-03-10 2018-09-18 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US10881340B2 (en) 2010-03-24 2021-01-05 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US8764657B2 (en) 2010-03-24 2014-07-01 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
USD987830S1 (en) 2010-03-24 2023-05-30 Abbott Diabetes Care Inc. Analyte sensor inserter
US9186098B2 (en) 2010-03-24 2015-11-17 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US9215992B2 (en) 2010-03-24 2015-12-22 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US9265453B2 (en) 2010-03-24 2016-02-23 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10772547B1 (en) 2010-03-24 2020-09-15 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10292632B2 (en) 2010-03-24 2019-05-21 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US11064922B1 (en) 2010-03-24 2021-07-20 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
USD997362S1 (en) 2010-03-24 2023-08-29 Abbott Diabetes Care Inc. Analyte sensor inserter
US11000216B2 (en) 2010-03-24 2021-05-11 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10959654B2 (en) 2010-03-24 2021-03-30 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10952657B2 (en) 2010-03-24 2021-03-23 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US11013440B2 (en) 2010-03-24 2021-05-25 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US11058334B1 (en) 2010-03-24 2021-07-13 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10010280B2 (en) 2010-03-24 2018-07-03 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US9687183B2 (en) 2010-03-24 2017-06-27 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10881341B1 (en) 2010-03-24 2021-01-05 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US10945649B2 (en) 2010-03-24 2021-03-16 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10973449B2 (en) 2010-06-29 2021-04-13 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10959653B2 (en) 2010-06-29 2021-03-30 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10874338B2 (en) 2010-06-29 2020-12-29 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10966644B2 (en) 2010-06-29 2021-04-06 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US11478173B2 (en) 2010-06-29 2022-10-25 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US20130211219A1 (en) * 2010-08-24 2013-08-15 Micro CHIPS ,Inc. Implantable Biosensor Device and Methods of Use Thereof
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US20120097554A1 (en) * 2010-10-18 2012-04-26 Medtronic Minimed, Inc. Analyte sensors comprising electrodes having selected electrochemical and mechanical properties
US11534089B2 (en) 2011-02-28 2022-12-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US11627898B2 (en) 2011-02-28 2023-04-18 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US10722162B2 (en) 2011-04-15 2020-07-28 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10561354B2 (en) 2011-04-15 2020-02-18 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10610141B2 (en) 2011-04-15 2020-04-07 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US20190380627A1 (en) * 2011-04-15 2019-12-19 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10624568B2 (en) 2011-04-15 2020-04-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US20190350499A1 (en) * 2011-04-15 2019-11-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10682084B2 (en) 2011-04-15 2020-06-16 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10835162B2 (en) 2011-04-15 2020-11-17 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9549692B2 (en) * 2011-08-26 2017-01-24 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US20130053665A1 (en) * 2011-08-26 2013-02-28 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11406331B2 (en) 2011-10-31 2022-08-09 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9913619B2 (en) 2011-10-31 2018-03-13 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9743872B2 (en) 2011-11-23 2017-08-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10136847B2 (en) 2011-11-23 2018-11-27 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10939859B2 (en) 2011-11-23 2021-03-09 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9721063B2 (en) 2011-11-23 2017-08-01 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US9289179B2 (en) 2011-11-23 2016-03-22 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US11783941B2 (en) 2011-11-23 2023-10-10 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11391723B2 (en) 2011-11-25 2022-07-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11051725B2 (en) 2011-12-11 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
US9402570B2 (en) 2011-12-11 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
US11051724B2 (en) 2011-12-11 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
US9931066B2 (en) 2011-12-11 2018-04-03 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
US9693713B2 (en) 2011-12-11 2017-07-04 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
USD903877S1 (en) 2011-12-11 2020-12-01 Abbott Diabetes Care Inc. Analyte sensor device
USD915601S1 (en) 2011-12-11 2021-04-06 Abbott Diabetes Care Inc. Analyte sensor device
US11179068B2 (en) 2011-12-11 2021-11-23 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
USD915602S1 (en) 2011-12-11 2021-04-06 Abbott Diabetes Care Inc. Analyte sensor device
US20210251526A1 (en) * 2012-03-16 2021-08-19 Dexcom, Inc. Systems and methods for processing analyte sensor data
WO2013152090A2 (en) 2012-04-04 2013-10-10 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP4275598A2 (en) 2012-04-04 2023-11-15 DexCom, Inc. Applicator and method for applying a transcutaneous analyte sensor
WO2013184566A2 (en) 2012-06-05 2013-12-12 Dexcom, Inc. Systems and methods for processing analyte data and generating reports
EP3975192A1 (en) 2012-06-05 2022-03-30 Dexcom, Inc. Systems and methods for processing analyte data and generating reports
US11145410B2 (en) 2012-06-05 2021-10-12 Dexcom, Inc. Dynamic report building
US10908114B2 (en) * 2012-06-29 2021-02-02 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
WO2014004460A1 (en) 2012-06-29 2014-01-03 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
WO2014004450A1 (en) * 2012-06-29 2014-01-03 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
EP4018929A1 (en) 2012-06-29 2022-06-29 Dexcom, Inc. Method and system for processing data from a continuous glucose sensor
US10881339B2 (en) * 2012-06-29 2021-01-05 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US11892426B2 (en) 2012-06-29 2024-02-06 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
US10722161B2 (en) 2012-06-29 2020-07-28 Dexcom, Inc. Implantable sensor devices, systems, and methods
EP3915465A2 (en) 2012-06-29 2021-12-01 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US10598627B2 (en) 2012-06-29 2020-03-24 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
US20150090589A1 (en) * 2012-06-29 2015-04-02 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
US11737692B2 (en) 2012-06-29 2023-08-29 Dexcom, Inc. Implantable sensor devices, systems, and methods
EP3915465A3 (en) * 2012-06-29 2022-01-19 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US20140005505A1 (en) * 2012-06-29 2014-01-02 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
WO2014011488A2 (en) 2012-07-09 2014-01-16 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP3767633A1 (en) 2012-07-09 2021-01-20 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP4080517A1 (en) 2012-07-09 2022-10-26 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP4075441A1 (en) 2012-07-09 2022-10-19 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
US10656139B2 (en) 2012-08-30 2020-05-19 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10942164B2 (en) 2012-08-30 2021-03-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10345291B2 (en) 2012-08-30 2019-07-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US9743871B2 (en) * 2012-09-24 2017-08-29 Dexcom, Inc. Multiple electrode system for a continuous analyte sensor, and related methods
US20170319111A1 (en) * 2012-09-24 2017-11-09 Dexcom, Inc. Multiple electrode system for a continuous analyte sensor, and related methods
US20140088389A1 (en) * 2012-09-24 2014-03-27 Dexcom, Inc. Multiple electrode system for a continuous analyte sensor, and related methods
US10842420B2 (en) 2012-09-26 2020-11-24 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US11179079B2 (en) 2012-09-28 2021-11-23 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
EP3782550A1 (en) 2012-09-28 2021-02-24 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US11864891B2 (en) 2012-09-28 2024-01-09 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
WO2014052080A1 (en) 2012-09-28 2014-04-03 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US10188334B2 (en) 2012-10-30 2019-01-29 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9801577B2 (en) 2012-10-30 2017-10-31 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
EP3654348A1 (en) 2012-11-07 2020-05-20 Dexcom, Inc. Systems and methods for managing glycemic variability
EP4231309A2 (en) 2012-11-07 2023-08-23 DexCom, Inc. Systems and methods for managing glycemic variability
US11744463B2 (en) 2012-12-31 2023-09-05 Dexcom, Inc. Remote monitoring of analyte measurements
US11160452B2 (en) 2012-12-31 2021-11-02 Dexcom, Inc. Remote monitoring of analyte measurements
US11850020B2 (en) 2012-12-31 2023-12-26 Dexcom, Inc. Remote monitoring of analyte measurements
US11213204B2 (en) 2012-12-31 2022-01-04 Dexcom, Inc. Remote monitoring of analyte measurements
US10869599B2 (en) 2012-12-31 2020-12-22 Dexcom, Inc. Remote monitoring of analyte measurements
US10860687B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US11109757B2 (en) 2012-12-31 2021-09-07 Dexcom, Inc. Remote monitoring of analyte measurements
US10856736B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US11382508B2 (en) 2012-12-31 2022-07-12 Dexcom, Inc. Remote monitoring of analyte measurements
US10993617B2 (en) 2012-12-31 2021-05-04 Dexcom, Inc. Remote monitoring of analyte measurements
US11193924B2 (en) * 2013-01-03 2021-12-07 Dexcom, Inc. End of life detection for analyte sensors
US11879887B2 (en) 2013-01-03 2024-01-23 Dexcom, Inc. End of life detection for analyte sensors
EP3401818A1 (en) 2013-03-14 2018-11-14 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP4235684A1 (en) 2013-03-14 2023-08-30 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP4220654A1 (en) 2013-03-14 2023-08-02 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
WO2014158327A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Advanced calibration for analyte sensors
WO2014158405A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US11677443B1 (en) 2013-03-14 2023-06-13 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP3806103A1 (en) 2013-03-14 2021-04-14 Dexcom, Inc. Advanced calibration for analyte sensors
US10985804B2 (en) 2013-03-14 2021-04-20 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US10874336B2 (en) 2013-03-15 2020-12-29 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US11229382B2 (en) 2013-12-31 2022-01-25 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
EP4257044A2 (en) 2014-04-10 2023-10-11 DexCom, Inc. Sensor for continuous analyte monitoring
WO2015156966A1 (en) 2014-04-10 2015-10-15 Dexcom, Inc. Sensors for continuous analyte monitoring, and related methods
US10424219B2 (en) 2015-05-07 2019-09-24 Dexcom, Inc. System and method for educating users, including responding to patterns
US10410538B2 (en) 2015-05-07 2019-09-10 Dexcom, Inc. System and method for educating users, including responding to patterns
EP4108170A1 (en) 2015-05-07 2022-12-28 DexCom, Inc. Sensor array calibration
USD980986S1 (en) 2015-05-14 2023-03-14 Abbott Diabetes Care Inc. Analyte sensor inserter
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
US10674944B2 (en) 2015-05-14 2020-06-09 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11883126B2 (en) 2015-09-10 2024-01-30 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
WO2017044654A1 (en) 2015-09-10 2017-03-16 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
US11504004B2 (en) 2015-09-10 2022-11-22 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
US9903755B2 (en) * 2015-10-05 2018-02-27 Microsoft Technology Licensing, Llc Indoors / outdoors detection
EP4046571A1 (en) 2015-10-21 2022-08-24 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US10932672B2 (en) 2015-12-28 2021-03-02 Dexcom, Inc. Systems and methods for remote and host monitoring communications
US11399721B2 (en) 2015-12-28 2022-08-02 Dexcom, Inc. Systems and methods for remote and host monitoring communications
EP4253536A2 (en) 2015-12-30 2023-10-04 DexCom, Inc. Diffusion resistance layer for analyte sensors
EP4292528A1 (en) 2015-12-30 2023-12-20 Dexcom, Inc. Membrane layers for analyte sensors
US11112377B2 (en) 2015-12-30 2021-09-07 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
EP3895614A1 (en) 2015-12-30 2021-10-20 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
EP4324921A2 (en) 2015-12-30 2024-02-21 Dexcom, Inc. Biointerface layer for analyte sensors
US10980451B2 (en) 2016-03-31 2021-04-20 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10568552B2 (en) 2016-03-31 2020-02-25 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10980453B2 (en) 2016-03-31 2021-04-20 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10980450B2 (en) 2016-03-31 2021-04-20 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10881335B2 (en) 2016-03-31 2021-01-05 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10561349B2 (en) 2016-03-31 2020-02-18 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10799157B2 (en) 2016-03-31 2020-10-13 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10152947B2 (en) 2016-04-06 2018-12-11 Microsoft Technology Licensing, Llc Display brightness updating
US20200072827A1 (en) * 2016-12-09 2020-03-05 Abbott Point Of Care Inc. Dual range cardiac troponin immunoassay devices and methods using immunosensor and magnetic immunosensor
US11071478B2 (en) 2017-01-23 2021-07-27 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11129557B2 (en) 2017-05-31 2021-09-28 Cardiac Pacemakers, Inc. Implantable medical device with chemical sensor
EP3925522A1 (en) 2017-06-23 2021-12-22 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP3928688A1 (en) 2017-06-23 2021-12-29 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP4111949A1 (en) 2017-06-23 2023-01-04 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature
US11510625B2 (en) 2017-06-23 2022-11-29 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11504063B2 (en) 2017-06-23 2022-11-22 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP4008240A1 (en) 2017-06-23 2022-06-08 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11311241B2 (en) 2017-06-23 2022-04-26 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11395631B2 (en) 2017-06-23 2022-07-26 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11439304B2 (en) 2017-08-10 2022-09-13 Cardiac Pacemakers, Inc. Systems and methods including electrolyte sensor fusion
EP3669175A4 (en) * 2017-08-14 2021-08-11 Senseonics, Incorporated Methods and systems for calculating analyte levels
US11406298B2 (en) 2017-08-14 2022-08-09 Senseonics, Incorporated Methods and systems for calculating analyte levels
US11571151B2 (en) 2017-08-23 2023-02-07 Cardiac Pacemakers, Inc. Implantable chemical sensor with staged activation
WO2019046853A1 (en) * 2017-09-02 2019-03-07 Biocrede Inc. Medical device with integrated biosensor
US10709360B2 (en) 2017-09-02 2020-07-14 Biocrede Inc. Medical device with integrated biosensor
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US11089983B2 (en) 2017-12-01 2021-08-17 Cardiac Pacemakers, Inc. Multimodal analyte sensors for medical devices
US10952621B2 (en) 2017-12-05 2021-03-23 Cardiac Pacemakers, Inc. Multimodal analyte sensor optoelectronic interface
WO2020140017A1 (en) * 2018-12-28 2020-07-02 Dexcom, Inc. Analyte sensor break-in mitigation
USD1002852S1 (en) 2019-06-06 2023-10-24 Abbott Diabetes Care Inc. Analyte sensor device
USD982762S1 (en) 2020-12-21 2023-04-04 Abbott Diabetes Care Inc. Analyte sensor inserter
USD999913S1 (en) 2020-12-21 2023-09-26 Abbott Diabetes Care Inc Analyte sensor inserter
WO2022136712A1 (en) * 2020-12-21 2022-06-30 Bioquochem S.L. Method for selectively measuring a concentration of a compound in a complex sample
USD1006235S1 (en) 2020-12-21 2023-11-28 Abbott Diabetes Care Inc. Analyte sensor inserter

Also Published As

Publication number Publication date
US20190167163A1 (en) 2019-06-06
US20230301563A1 (en) 2023-09-28
US20110028816A1 (en) 2011-02-03
US20180000388A1 (en) 2018-01-04
US9320466B2 (en) 2016-04-26
WO2011003039A2 (en) 2011-01-06
EP3970610A2 (en) 2022-03-23
US9763608B2 (en) 2017-09-19
US9131885B2 (en) 2015-09-15
WO2011003036A3 (en) 2011-04-14
US20110027127A1 (en) 2011-02-03
US20110027453A1 (en) 2011-02-03
EP2448485B1 (en) 2021-08-25
US20180146896A1 (en) 2018-05-31
EP2448486A4 (en) 2014-07-09
EP2448485A2 (en) 2012-05-09
US20210353185A1 (en) 2021-11-18
US20110024043A1 (en) 2011-02-03
US20140123893A1 (en) 2014-05-08
US9907497B2 (en) 2018-03-06
WO2011003035A3 (en) 2011-04-14
US10420494B2 (en) 2019-09-24
US20110028815A1 (en) 2011-02-03
EP3970610A3 (en) 2022-05-18
WO2011003036A2 (en) 2011-01-06
US20230129853A1 (en) 2023-04-27
EP2448486B1 (en) 2021-08-25
US20190307371A1 (en) 2019-10-10
EP4029444A1 (en) 2022-07-20
US20140343386A1 (en) 2014-11-20
US20160081600A1 (en) 2016-03-24
WO2011003035A2 (en) 2011-01-06
US20220346674A1 (en) 2022-11-03
EP2448486A2 (en) 2012-05-09
US20140046148A1 (en) 2014-02-13
US11559229B2 (en) 2023-01-24
US20190357815A1 (en) 2019-11-28
US8828201B2 (en) 2014-09-09
US20110027458A1 (en) 2011-02-03
US9237864B2 (en) 2016-01-19
US20140046149A1 (en) 2014-02-13
WO2011003039A3 (en) 2011-04-14
EP2448485A4 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
US11559229B2 (en) Analyte sensor
US20220125357A1 (en) Calibration techniques for a continuous analyte sensor
US11737692B2 (en) Implantable sensor devices, systems, and methods
AU2007303239A1 (en) Dual electrode system for a continuous analyte sensor
AU2006348994A1 (en) Dual electrode system for a continuous analyte sensor

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEXCOM, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMPSON, PETER C.;BOOCK, ROBERT;KAMATH, APURV ULLAS;AND OTHERS;SIGNING DATES FROM 20100915 TO 20101014;REEL/FRAME:025167/0924

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION